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Abstract 
Activation of the androgen receptor (AR) results in a phenotypic change in androgen-responsive 
cells; for example, in the human prostate carcinoma cell line LNCaP, androgens mediate 
proliferation.  MicroRNAs (miRNA) are a class of short non-coding RNA that act as post-
transcriptional regulators of gene expression; their role in the androgenic phenotype is yet to be 
fully explored.  
In the present study, I examined the hypothesis that androgen-mediated effects on gene 
expression and cellular proliferation are in part mediated through miRNAs.  Therefore, exposure 
to a synthetic AR agonist (mibolerone), a physiological AR agonist (dihydrotestosterone) and a 
therapeutic AR antagonist (bicalutamide) was studied in LNCaP at four, eight, 24 and 120 hours.  
The cellular response to these compounds was assessed in terms of proliferation, prostate-
specific antigen (PSA) expression and alteration of the miRNA profile.   
Microarray analysis revealed that a number of miRNAs were altered in a compound-specific and 
temporal manner.  Of note, androgen-induced proliferation and PSA secretion were associated 
with repression of miR-221 and induction of miR-210. 
In silico methods identified putative targets of miR-221, such as the transcription factor IRX5.   
Immunoblotting and a luciferase reporter construct provided preliminary evidence that IRX5 is 
indeed a novel target of miR-221.  Down-regulation of IRX5 is anti-proliferative and pro-
apoptotic therefore androgen-mediated repression of miR-221 may contribute to growth. 
miR-210, a hypoxia-inducible miRNA, was induced under androgenic stimuli with concomitant 
repression of the Myc-inhibitor Mnt.  Efforts were made to elucidate the mechanism of miR-210 
induction outside the context of classical HIF1 activation, but further research is required.  
miR-720 had the highest expression of any individual miRNA in LNCaP cells.  DNMT3A was 
identified as a potential target implicating miR-720 in androgen insensitivity.  However, analysis 
of androgen-insensitive cell lines did not reveal differential expression and its role in prostate 
epithelial biology remains to be discovered.  
In summary, the research confirms the hypothesis that androgens can mediate phenotypic 
change through mechanisms that include miRNA-mediated responses.  The data offers insights 
into androgen-induced processes and identifies new avenues for future research. 
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FIH:  Factor inhibiting HIF 
FRET:  Fluorescent resonance energy transfer 
FU:  Fluorescence unit 
G:  Guanine 
G0:  Gap 0 phase 
G1:  Gap 1 phase 
G2:  Gap 2 phase 
GTPase: Guanosine triphosphatase 
H:  Hinge domain 
HDAC3: Histone deacetylase 3 
HIF:  Hypoxia inducible factor 
hK2:  Human glandular kallikrein 2 
hLuc:  Firefly luciferase 
HmiR:  miR-221 expression vector   
HmiT:  IRX5 3'UTR expression vector 
hnRNP A1: Heterogenous nuclear ribonucleoprotein A1 
HRE:  Hypoxia response element 
HRP:  Horseradish peroxidase 
Hrs:  Hours 
HSD:  Hydroxysteroid dehydrogenase 
HSP90:  Heat shock protein 90 
HuR:  Hu antigen R 
iASPP:  Inhibitor of apoptosis stimulating protein of p53 
IC50:  Inhibitory concentration 50 
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IGF:  Insulin-like growth factor 
IGF-1R:  Insulin-like growth factor 1 receptor 
KEGG:  Kyoto encyclopaedia of genes and genomes 
LBD:  Ligand-binding domain 
LIMK2:  LIM domain kinase 2 
LNCaP-FGC: Lymph node metastasis of prostate cancer fast growing colony 
LHRH:  Luteinizing hormone-releasing hormone 
mAb:  Monoclonal antibody 
MAPK:   Mitogen activated protein kinase 
mAR:  Membrane androgen receptor 
mTOR:  Mechanistic target of rapamycin (serine/threonine kinase) 
M7G:  7-methyl guanine 
MEM:  Minimum Essential Media 
MGB:  Minor-groove-binder 
MIB:  Mibolerone 
miRISC: miRNA-induced silencing complex 
miRNA: MicroRNA 
M-phase: Mitosis phase 
mRNA:  Messenger RNA 
N:  Any nucleotide 
NCoR:  Nuclear receptor co-repressor 
NEAA:  Non-essential amino acids 
NLS:  Nuclear localisation sequence 
No-RT:  No reverse transcriptase control (negative control)  
NOT1:  Negative on TATA-less 
No-TC:  No template control (negative control) 
NOX:  NADPH oxidase 
nm:  Nanometres 
NTD:  Nuclear trans-activation domain 
OD:  Optical density 
P450:  Cytochrome P450 
p63:   protein 63, also known as cytoskeleton-associated protein 4 
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PABP:  Poly(A) binding protein 
PACT:  Protein activator of PKR 
PAPD4:  PAP associated domain containing 4 
PARP:  Poly(ADP-ribose) polymerase 
PBS:  Phosphate buffered saline 
PCa:  Prostate adenocarcinoma 
PCA:  Principal component analysis 
PHD:  Prolyl hydroxylase 
PI3K:  Phosphoinositol 3 kinase 
PMA:   Phorbol 12-myristate 13-actetate 
PolyG:  Poly-glycine 
PolyP:   Poly-proline 
PolyQ:  Poly-glutamine 
PREG:  Pregnenolone 
Pre-miRNA: Precursor miRNA 
Pri-miRNA: Primary microRNA 
PROG:  Progesterone 
PSA:  Prostate specific antigen 
qRT-PCR: Quantitative real-time reverse transcriptase polymerase chain reaction  
QA:  Quality assessment 
QC:  Quality control 
Rac:  Ras-related C3 botulinum toxin substrate 1 
RB:  Retinoblastoma 
Red:  Reductase 
RhoA/B: Ras homolog family member A/B 
RIN:  RNA integrity number 
RIPA:  Radio Immunoprecipitation Assay  
RLuc:  Renilla luciferase 
RLU:  Relative light units 
RMA:  Robust multi-array average 
Rn:  Normalised reporter 
RNA:  Ribonucleic acid 
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RNase:  Ribonuclease 
ROCK:  Rho-associated, coiled-coil containing protein kinase 1 
ROS:  Reactive oxygen species 
rpm:  Revolutions per minute 
rRNA:  Ribosomal RNA 
SD:  Standard deviation 
SHBG:  Sex hormone binding globulin 
SMO:  Smoothened  
SMRT:  Silencing mediator of retinoid and thyroid receptors 
S-phase: Synthesis phase 
SRC:  Steroid hormone receptor co-activator 
SSAT:  Spermidine/spermine N1-acetyltransferase 
StAR:  Steroidogenic acute regulatory protein 
Sult:  Sulphatase 
T-BSA:  Testosterone-bovine serum albumin 
TE:  Tris-EDTA 
TEMED:  Tetramethylethylenediamide 
TESTO: Testosterone 
TF:  Transcription factor 
TFBS:  Transcription factor binding site 
TGS:  Total gene signal 
TNM:  Tumour size lymph node status distant metastasis 
TNRC6A: Trinucleotide repeat containing 6A 
TRAP220: Thyroid hormone receptor-associated protein 220 
TRBP:  Tar RNA binding protein 
tRNA:  Transfer RNA 
TURP:  Transurethral resection of the prostate 
UTR:  Untranslated region 
VC:  Vehicle control 
VEGF:  Vascular endothelial growth factor 
VIN:  Vinclozolin 
XRN2:  5'-3' exoribonuclease 2 
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1. Introduction to androgens and microRNA 
1.1 Androgens and the androgen receptor 
Androgens are important in the normal physiological setting, influencing the male reproductive 
system throughout life: from development in utero, through puberty and into adulthood.  Key 
roles of androgens include male sexual differentiation, pubertal sexual maturation, maintenance 
of spermatogenesis, and male gonadotrophin regulation (Heinlein and Chang, 2002a). 
1.1.1 Synthesis of testosterone 
 
Testosterone and dihydrotestosterone (DHT) are the two major circulating endogenous 
androgens.  Testosterone, produced by testicular Leydig cells, is the precursor to the more 
potent androgen DHT, conversion of which happens locally in the prostate via 5α-reductase 
type I (Luu-The, Bélanger and Labrie, 2008). The biosynthetic pathway of androgens is detailed 
in Figure 1. 1.   
 
 
Figure 1. 1 - General steroidogenic pathway 
Abbreviations: 3α-DIOL = 5α-androstane-3α,17β-diol; 4-DIONE = 4-androstenedione; 5-DIL = 5-androstenediol; 
11-DEOXYC.L = 11-deoxycorticosterone; A-DIONE = 5α-androstanedione; ALDO = aldosterone; ANDRO = 
androsterone; CORTICO = corticosterone; DHEA = dehydroepiandrosterone; DHEA-S = dehydroepi-
androsterone sulphate; DHT = dihydrotestosterone; HSD = hydroxysteroid dehydrogenase; P450 = cytochrome 
P450; PREG = pregnenolone; PROG = progesterone; red = reductase; Sult = sulphatase; TESTO = testosterone.  
Reproduced from Luu-The, Bélanger and Labrie (2008).   
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1.1.2 Protein structure of the AR 
The androgen receptor (AR) is a transcription factor (TF) of the nuclear steroid hormone family.  
With a molecular weight of 114 kiloDaltons (kDa), the AR consists of an average 918 amino acids 
(Lee and Chang 2003).  It contains four functional domains, as indicated in Figure 1. 2, that 
confer ligand as well as DNA (deoxyribonucleic acid) binding ability.  
 
Figure 1. 2 - The protein structure of the androgen receptor (AR)  
As a nuclear steroid hormone receptor, the AR contains four functional domains: a variable NH2-terminal 
domain containing the poly-glutamine repeats (Poly-Q), activation function 1 area (AF1) important for 
transcriptional activity, poly-proline (Poly-P) repeats and poly-glycine repeats (Poly-G); a DNA-binding domain 
(DBD) with the zinc finger structure typical of steroid hormone receptors; a hinge domain (H) containing the 
proline, glutamate, serine and threonine-rich sequence degradation motif which targets the AR for ubiquitin-
mediated proteasome degradation; and a ligand-binding domain (LBD) containing activation function 2 (AF2) 
(Agoulnik and Weigel, 2006; Lee and Chang, 2003).  Reproduced from Agoulnik and Weigel (2006). 
 
1.1.3 Mechanisms of the AR 
Androgens are known to elicit cellular effects that can be categorised into ‘classical’, binding to 
DNA, and ‘non-classical’/’non-genomic’, which do not involve DNA binding but rather 2nd 
messenger signalling cascades (Pang et al., 2012).  
1.1.3.1 Genomic actions of androgens 
Classically, in the DNA binding-dependent model of androgen action, the AR acts as a TF: this is 
via interaction with androgen response elements (AREs) in promoter regions of target genes 
(Lee and Chang, 2003). 
The mechanism of AR activation is illustrated in Figure 1. 3.  In the absence of ligand, the AR is 
held in an inactive conformation by heat shock protein 90 (HSP90).  In the presence of a ligand, 
such as DHT, the receptor translocates to the nucleus and homo-dimerises with another AR on 
an ARE.  Ultimately this results in transcription of target genes; these genes are involved in 
processes such as proliferation, differentiation, apoptosis and secretion (Nieto et al., 2007).   
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Figure 1. 3 - Potentiation of AR transcriptional activity by DHT and bicalutamide    
In the absence of ligand, AR is associated with heat shock protein 90 (HSP90), which maintains the receptor in 
a conformation capable of binding hormone (Agoulnik and Weigel 2006).  Ligand binding causes loss of HSP90 
and a conformational change, allowing helix 12 of the ligand binding domain (LBD) and the AF2 domain to fold 
back forming a pocket which binds the FQNLF peptide sequence of the nuclear trans-activation domain (NTD) 
(Lee and Chang, 2003, Shen and Balk, 2009).  This exposes the nuclear localisation sequence (NLS) allowing 
Importin to transport the complex into the nucleus to bind to the androgen response elements via the DNA 
binding domain (DBD). After phosphorylation and homo-dimerisation, the LBD and NTD co-operate to recruit 
co-activators: the LxxLL motif present in co-activators, such as steroid receptor co-activator (SRC), displaces 
the FQNLF and recruits more co-activators such as CARM (co-activator-associated arginine methyltransferase 
1), CBP/p300 (CREB-binding protein) and TRAP220 (thyroid hormone receptor-associated protein). 
Recruitment of all the various complexes leads to modification of the chromatin structure (facilitating binding 
and activation of the polymerase complex by making the DNA binding sites more accessible), recruitment of 
RNA polymerase II  (to begin transcription) and expression of target genes (Agoulnik and Weigel, 2006; 
Heinlein and Chang, 2002a).  Genes involved in the proliferative response may be expressed leading to 
changes in cell cycle proteins (Nieto et al., 2007).  In the case of the antagonist bicalutamide, after 
translocation to the nucleus there is ineffective co-activator recruitment and enhanced recruitment of co-
repressors such as NCoR (nuclear receptor co-repressor), SMRT (silencing mediator of retinoid and thyroid 
receptors) and HDAC3 (histone deacetylase) (by binding at the CoRNR box).  Abbreviations: AR = androgen 
receptor; BIC = bicalutamide; DHT = dihydrotestosterone; P = phosphate.  Taken from Shen and Balk (2009). 
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The activity of the AR is not just dependent on hormone/receptor levels but also on the levels 
and activities of co-regulators.  Co-regulators are proteins that interact with the ligand-bound 
receptor, either acting to enhance transcriptional activities (co-activator) or decrease activity 
(co-repressors) (Agoulnik and Weigel, 2006).  Examples of co-regulators are the steroid receptor 
co-activator (SRC) that has intrinsic histone acetyltransferase activity, and androgen-receptor-
associated 70 (ARA70) that acts as a co-repressor by influencing sub-cellular distribution of AR 
(Heinlein and Chang, 2002a). 
There are more than 100 AR-regulated genes (Koivisto et al., 1998; Shen and Balk, 2009; Xu et 
al., 2009); of particular interest is the kallikrein-related peptidase 3 gene, KLK3, which encodes 
prostate specific antigen (PSA).  See Chapter 2, page 47, for further details. 
 
1.1.3.2 Non-genomic actions of androgens 
Rapid effects of androgens, i.e. those effects occurring within minutes rather than hours of 
androgenic stimulation, are typically defined as non-genomic; the process of messenger 
ribonucleic acid (mRNA) transcription and protein synthesis takes considerably longer than a 
few minutes.   
Non-genomic effects of androgens can be mediated by multiple mechanisms: binding at the sex 
hormone binding globulin (SHBG) receptor; stimulation of the non-receptor tyrosine kinase c-
src; and binding at a membrane-bound AR (Heinlein and Chang, 2002b). 
The first report to identify an androgen-binding membrane-bound receptor (mAR) was by 
Kampa and colleagues in 2002.  Using non-permeable bovine serum albumin (BSA)-conjugated 
testosterone, they were able to show that activation of the mAR leads to actin polymerization 
and cytoskeletal changes in addition to early PSA release (Kampa et al., 2002).  Furthermore 
activation of mAR lead to phosphorylation of FAK (focal adhesion kinase), subsequent 
association and activation of PI3K (phosphatidylinositol-3 kinase) and activation of cdc42 (cell 
division cycle 42)/Rac 1 (ras-related C3 botulinum toxin substrate 1) (Papakonstanti et al., 2003).  
Subsequently, it was shown that RhoA and RhoB were up-regulated and the Rho/ROCK1 
signalling cascade (including LIM domain kinase 2 (LIMK2)) has a functional role in the 
cytoskeletal reorganisation and, in addition to inducing release of stocked PSA, induces 
apoptotic regression in LNCaP (Papadopoulou et al., 2008).  The pathway of mAR activation is 
summarised in Figure 1. 4. 
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Figure 1. 4 - Non-genomic membrane AR signalling in LNCaP   
Binding at the mAR leads to FAK (focal adhesion kinase) phosphorylation and association with the catalytic p85 
subunit of PI3K (phosphatidylinositol-3 kinase), downstream up-regulation of cdc42 (cell division cycle 42), 
Rac1, RhoA, RhoB and re-organisation of the actin cytoskeleton.  Rho/ROCK/actin signalling also induces 
apoptosis.  The solid lines indicate experimentally proven pathways, dashed lines possible links.  Abbreviations: 
Rac1 = ras-related C3 botulinum toxin substrate 1; rhoA/B = ras homolog family member A/B; ROCK = rho-
associated, coiled-coil containing protein kinase 1; T-BSA = testosterone-bovine serum albumin.  Reproduced 
from Papadopolou et al. (2009).   
 
 
1.1.4 The role of androgens in normal and malignant prostate 
 
The prostate is a male exocrine organ; the primary function in the adult male is to produce 
prostatic fluid, which comprises approximately 30% of the whole ejaculate, providing essential 
components such as PSA, zinc and citrate (Jonsson, Lundwall and Malm, 2006; Veveris-Lowe et 
al., 2007).   
The prostate has two major compartments: the epithelial cell compartment; and the supporting 
stromal compartment, comprising smooth muscle cells, fibroblasts, neuronal, lymphatic and 
vascular cell types (Marker et al., 2003).  Two types of histologically distinct epithelial cells form 
the glandular acini: the tall columnar secretory luminal cells with apical-basal polarity and the 
basal cells upon which the luminal cells are sited.  In addition to the basal and luminal cells are 
the intermediate cells that possess properties of both the luminal and basal cells (Figure 1.5). 
1 
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Figure 1. 5 - Cell types of the prostate   
The two main cell types are the luminal secretory epithelial cells and the basal cells.  The presence and 
absence of specific proteins and markers are indicated in the diagram.  Abbreviations: AR = androgen receptor; 
BCL-2 = B-cell lymphoma 2; CK = cytokeratin; ITGA6 = integrin, alpha 6; Nkx3.1 = NK3 homeobox 1; PSA = 
prostate specific antigen, PSAP = prostate specific acid phosphatase; p63 = protein 63, also known as 
cytoskeleton-associated protein 4.  Reproduced from de Marzo et al. (2010).    
 
In the normal prostate, androgens are responsible for growth and maintenance of prostate cells, 
controlling cell proliferation via a paracrine-mediated pathway.   Stromal cells express low levels 
of the AR that, when activated by androgens, produce epithelial growth factors termed 
‘andromedins’.  Andromedins diffuse from the stromal compartment into the epithelial 
compartment where they bind to their respective receptors on the basal cells (AR-negative) 
resulting in proliferation and terminal differentiation into proliferatively dormant AR-positive 
secretory-luminal epithelial cells (Marker et al., 2003; Vander Griend, Litvinov and Isaacs, 2007).  
Once terminally differentiated, the secretory luminal epithelial cells require stromal 
andromedins for their continued survival. In the absence of circulating androgens, apoptotic cell 
death of the AR-positive luminal epithelial cells and inhibition of growth of the AR-negative 
basal cells (which require AR-induced andromedins for their survival) occurs. 
One of the major diseases of the aging male is prostate adenocarcinoma (PCa).  PCa is a 
malignant tumour of glandular epithelium.  Early during prostatic carcinogenesis, genetic 
damage to epithelial cells can lead to a malignant conversion so that ligand binding in the 
nucleus of the affected epithelial cells induces cell autonomous regulation of proliferation and 
Luminal 
High: AR, PSA, PSAP, Nkx3.1, CK8, CK18 
Absent: p63, CK5, CK14, BCL-2 
Basal 
High: p63, 
CK5, CK14, 
BCL-2, ITGA6 
Low/Absent: 
AR, CK8, CK18, 
PSA, PSAP, 
Nkx3.1 
Intermediate 
Low/variable: AR, PSA, NKx3.1, PSAP 
Moderate/high: CK5, CK8, CK18, BCL-2 
Absent: p63 
, CK14 
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survival independent of the expression of AR in the supporting stromal cells (Vander Griend, 
Litvinov and Isaacs, 2007).  In this manner, there is a molecular switch from paracrine to 
autocrine control of proliferation, which enables the prostate to respond abnormally to 
endogenous levels of circulating androgens.  
Histologically, PCa is characterised by having a luminal cell phenotype: there is loss of basal cells 
and ‘expansion’ of the luminal population.  In the normal and pre-neoplastic prostatic tissue, 
p63 is almost uniformly observed in basal cells (the outer layer of the two-layer glandular lining).  
However in PCa specimens, the expression of p63 is lost, indicating that the cells are of a luminal 
phenotype.  Whether this is due to expansion of the luminal population or whether it is loss of 
the basal characteristics and rapid differentiation into luminal cells (with loss of the associated 
markers) is not yet known – evidence thus far is contradictory (De Marzo et al., 2010).  It is 
reasonable to state that both cell types, or indeed intermediate cells, could be targets for 
neoplastic transformation and that tumours resultant from transformation of different cells 
could produce tumours with differing biological properties.    
The most recent statistics available show that prostate cancer was the most commonly 
registered type of malignancy for males (followed by lung and colorectal).  In the year 2008, in 
England alone, 30,893 patients were diagnosed with prostate cancer accounting for 24.1% of 
the total number of male malignancies (Office for National Statistics, 2010). 
Since 1941, when PCa was reported to be responsive to androgen withdrawal (Huggins, Stevens 
and Hodges, 1941), many treatments have been developed to either suppress secretion of 
testicular androgens or to inhibit androgen action at the receptor level.  The basis of androgen 
deprivation treatment (ADT) is that as PCa is initially dependent on circulating levels of 
androgen, removal of endogenous androgens, either by surgical or chemical castration, will 
result in tumour reduction.  PSA is routinely used as a proxy of therapy effectiveness.  However, 
it has been observed that even those with PSA between 4 and 10ng/mL will develop metastatic 
PCa even when it appears that their tumour is confined to the organ at surgery (Balk, Ko and 
Bubley, 2003).   
The outcome of PCa very much depends on the Gleason score (grade), tumour size lymph node 
status distant metastasis (TNM) classification, the PSA level, volume of metastatic disease and 
the presence of bone related symptoms at diagnosis (Heidenreich et al., 2011).  For those 
patients whose PCa progresses despite ADT, there is poor overall survival - for example, for 
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those who are grouped in the most favourable category, classed as ‘asymptomatic PSA and with 
no metastases’, the estimated mean survival is just over 2 years (24 - 27 months).  For those at 
the other end of the spectrum, classed as ‘symptomatic PSA with extensive metastases’, sadly 
the estimated mean survival is between 9 and 12 months (Heidenreich et al., 2011). 
1.1.5 Mechanisms of progression to castration-resistant prostate cancer 
Commonly after hormonal treatment, there is progression of the disease to a castration-
resistant state (CRPC).  Historically this was termed ‘hormone refractory’ prostate cancer 
although this terminology has changed recently to reflect the knowledge that the cancer is not 
resistant but rather exquisitely sensitive to low levels of androgens (Chen et al., 2004).   
Activation of AR signalling despite ADT can result from: 
 AR gene amplification or mutation; 
 alterations in AR co-activators/co-repressors; 
 activation of AR function due to crosstalk with other signalling pathways; and 
 increased local production of androgens (Feldman and Feldman, 2001).  
These alterations could lead to enhancement of the ligand response or induction of a ligand-
independent response. Possible mechanisms that have been implicated in development of CRPC 
are detailed in Figure 1. 6.  
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Figure 1. 6 - Mechanisms of AR signalling that may drive progressive prostate cancer   
Mechanisms that may contribute to disease progression in CRPC can be divided in pre-receptor ligand binding 
events that occur prior to ligand-receptor interactions, receptor events which are to do with the activity of the 
receptor itself and post-receptor-ligand binding events which involve binding of the ligand to the receptor. 
Abbreviations: AR = androgen receptor; ARE = androgen response element; ARsv= mutant AR; ARwt = wild-
type AR; DHEA = dehydroepiandrosterone; DHT = dihydrotestosterone; PSA = prostate specific antigen. 
Adapted from Ryan and Tindall (2011). 
 
Due to the limitations of current treatment options and incomplete knowledge regarding 
resistance to therapy, there still remains much insight that can be garnered using in vitro models 
to elucidate the molecular mechanisms behind proliferation and PSA secretion, one of the 
diagnostic indicators of PCa. 
1.2 MicroRNA 
MicroRNAs (miRNA) are a species of short non-coding RNA (approximately 22 nucleotides) that 
are effectors of post-transcriptional gene regulation.  Since their discovery in the nematode 
Caenorhabditis elegans (Lee, Feinbaum and Ambros, 1993), the number of miRNAs identified, 
knowledge of their biogenesis and mechanisms of action has increased rapidly.  To date, 1527 
human miRNAs have been discovered (miRBase Registry v18, release November 2011, 
www.mirbase.org); they have been implicated in natural processes, such as imprinting and 
chromatin modifications (Dinger, Mercer and Mattick, 2008), exhibiting distinct, and stage-
specific, expression patterns (Bartel, 2004).   
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One of the first expression profiling studies of miRNA in PCa was lead by Lu and others in 2005. 
They profiled 16,000 mRNAs and 217 mammalian miRNAs from 334 samples including eight 
normal and six PCa samples.  They identified that the miRNA expression was more accurate than 
the mRNA profile in classifying tumours, and that distinct patterns of expression for different 
cancer types could be observed highlighting the utility of miRNA as classifiers for cancers of 
unknown origin (Lu et al., 2005).   
miRNAs have been implicated in a number of pathological conditions, especially cancer, where 
studies have shown abnormally expressed miRNA levels in both model cell-based systems and 
tumours.   
1.2.1 Biogenesis 
The biogenesis of miRNAs involves the processing of a double-stranded primary miRNA (pri-
miRNA) into a single-stranded effecter moiety (mature miRNA) capable of targeting mRNA.  The 
process is represented in Figure 1. 7. 
miRNAs are either intronic, that is found within a protein coding gene (termed ‘mirtron’), or 
exonic, found outside a known gene in their own locus.  Approximately 30% of miRNAs are 
located within the introns of annotated mRNA (Baskerville and Bartel, 2005).  The authors found 
strong correlation between miRNA and their host genes, suggesting that they are generally co-
expressed with their host gene, spliced out during mRNA processing, and are under the control 
of the promoter which controls transcription of the primary mRNA.   
miRNA genes are found either as single genes, encoding one specific miRNA, or are found 
clustered together in which case many miRNAs may be transcribed as one polycistronic unit 
(Lagos-Quintana et al., 2001).  It is thought that clustered miRNA are under the control of a 
single promoter and are transcribed together although it is possible that a single member of a 
cluster may be independently transcribed (Baskerville and Bartel, 2005). 
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Figure 1. 7 - Canonical miRNA biogenesis 
The biogenesis of miRNA involves the processing of double-stranded primary miRNA (pri-miRNA) transcripts 
into shorter, functional, single-stranded mature miRNA.   miRNA are transcribed as pri-miRNA stemloop 
transcripts by RNA polymerase II (or sometimes III).  The pri-miRNA is processed by the microprocessor 
complex Drosha and DGCR8 (DiGeorge syndrome critical region 8) into the shorter hairpin precursor miRNA 
(pre-miRNA).  Exported from the nucleus into the cytoplasm by Exportin-5 and Ran-GTP, the pre-miRNA is 
cleaved to its mature length by Dicer in complex with the double-stranded RNA-binding protein TRBP (Tar RNA 
binding protein). The resultant miRNA duplex consists of the passenger (designated by *) and guide strand. 
The strand that is generally labelled as miRNA* is found at lower levels and is considered to be non-functional. 
It is generally thought that the miRNA strand with the least stable base pair at its 5’ end is loaded into miRISC 
(miRNA-induced silencing complex) whilst the other strand (* strand) is degraded. However, recent studies 
have found that the star form can itself have activity (Biasiolo et al., 2011).  Additionally, which strand is 
dominant may differ between cell types: with this in mind the naming convention has been recently changed 
(in miRBase versions 13 and above) and miRNA are designated as the 3’ or 5’ versions.  Incorporation of the 
mature miRNA and its mRNA target into miRISC results in either mRNA degradation or translational repression 
based on the degree of complementarity.  This is mediated primarily by miRNA binding to the 3’UTR of target 
mRNA.   Abbreviations: AGO2: argonaute 2.  Reproduced from Winter et al. (2009).   
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1.2.2 Mechanism of action 
miRNAs silence their target mRNA by translational repression or induction of mRNA degradation 
(Nilsen 2007; Zaratiegui, Irvine and Martienssen, 2007).  Generally, the mechanism of action 
depends on the degree of complementarity; those miRNA that have limited complementarity to 
the mRNA (i.e. just the seed region) induce translational repression whilst those with extensive 
complementarity over their entire length induce degradation (Bartel, 2009).  The level of 
suppression mediated by miRNAs is often modest, e.g. 2-fold (Baek et al., 2008) and an 
estimated 60% of human genes are putative targets of one or more miRNA (Friedman et al., 
2009).  Baccarini et al. (2011) found that each miRNA was able to regulate at least two target 
transcripts providing evidence that miRNAs are not irreversibly sequestered with their targets. 
Krek et al. (2005) provided evidence that transcripts can be targeted co-operatively by miRNA: 
they identified myotrophin regulation by miR-375, miR-124 and let-7b. 
1.2.2.1 Translational repression 
During the process of translation, the presence of the 5’ cap on the mRNA facilitates ribosomal 
recruitment whilst the 3’ poly(A) tail (which binds poly(A) binding protein (PABP)) acts as a 
translational enhancer (Fabian, Sonenberg and Filipowicz, 2010).  At least 13 eukaryotic 
initiation factors (eIF) are required for cap-dependent translation: current evidence suggests 
miRNA alter eIF4E function or recruitment to the 5’ Cap (Fabian, Sonenberg and Filipowicz, 
2010).  Other mechanisms have been put forward such as inhibition of the 60S subunit joining, 
and poly(A)tail-dependent and -independent mechanisms.  Figure 1. 8 depicts the current 
models of translational repression by miRNA. 
Post-initiation translational events are proposed to be repression of elongation, premature 
termination and recruitment of proteolytic enzymes (Fabian, Sonenberg and Filipowicz, 2010).  
However, limited evidence exists for the post-initiation models of translational repression. 
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Figure 1. 8 - Mechanisms of mRNA translational repression 
(A) Initiation repression: miRISC represses translational initiation via repression of cap recognition by eIF4E or 
by repression of 60S subunit joining. 
(B) Post-initiation repression: this may depend on repression of elongation or premature termination leading 
to ribosome drop-off or induction of proteolysis.  The nascent polypeptide is represented by the hashed line.  
Abbreviations: AGO = argonaute; A(n) = poly(A) tail; eIF4E = eukaryotic initiation factor 4E; m
7
G = 7-methyl 
guanine cap; miRISC = miRNA-induced silencing complex; ORF = open reading frame; PABP = poly(A) binding 
protein; TNRC6A = trinucleotide repeat containing 6A.  Reproduced from Fabian, Sonenberg and Filipowicz 
(2010).  
 
The strength of translational repression has been reported to be dependent on the binding 
between the miRNA and its target: the efficacy of repression is generally of the order 8mer > 
>7mer-m8 > 7mer-A1 >> 6mer > no site (Figure 1. 9, Bartel (2009)).  Repression was also shown 
to be affected by the location of the site – i.e. in the 3’ untranslated region (UTR), the protein 
coding region or indeed the 5’ UTR.  The strength of repression also depends on the number of 
B – Post-initiation block 
A – Post-initiation block 
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such sites, so that repression by a site of low efficacy (such as an atypical site) is increased by 
the presence of multiple sites.  
 
Figure 1. 9 - Types of miRNA target site   
The miRNA seed region (nucleotides 2-7) is coloured blue, whilst the corresponding matching nucleotide in the 
mRNA is coloured purple.  Base pairing between nucleotides is represented by a vertical line between the 
pairs.  Supplementary sites (F) require at least 3-4 base pairs for increased efficacy.  Compensatory sites (G) 
require at least 4-5 pairs to compensate for a mismatched seed region.  Abbreviations: 6mer = exact match to 
the mature miRNA seed; 7mer-A1 = exact match to the mature miRNA seed followed by an ‘A’; 7mer-m8 = 
exact match to the mature miRNA seed and position 8; 8mer = exact match to the mature miRNA seed plus 
position 8 followed by an ‘A’; N = any nucleotide; ORF = open reading frame; poly(A) = poly adenine. 
Reproduced from Bartel (2009).  
 
1.2.2.2 mRNA degradation 
Figure 1. 10 depicts the current model of miRNA-induced mRNA degradation involving 
deadenylation and decapping.  Interaction of miRISC’s TNRC6A (trinucleotide repeat containing 
6A) with PABP (poly(A) binding protein) at the poly(A) tail and interaction of TNRC6A with 
CAF1/CCR4/NOT1 (CCR4-associated factor/carbon catabolite repression 4 protein/negative on 
TATA-less) complex results in deadenylation of mRNA  (Fabian, Sonenberg and Filipowicz, 2010).  
Subsequent decapping at the 5’ end of the mRNA, by the decapping enzymes DCP1 and DCP2, 
results in a 5’ to 3’ directed digestion. 
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Figure 1. 10 - Possible mechanism of mRNA degradation 
Targeting of an mRNA by a complementary miRNA may result in degradation either by decapping (A) or by 
deadenylation (B).  Abbreviations: AGO = argonaute; A(n) = poly(A) tail; CAF1 = CCR4-associated factor; CCR4 = 
carbon catabolite repression 4 protein; DCP1 = decapping enzyme homolog B; DCP2 = decapping enzyme 
homolog; m
7
G = 7-methyl guanine cap; miRISC = miRNA-induced silencing complex; NOT1 = negative on TATA-
less; ORF = open reading frame; PABP = poly(A) binding protein; TNRC6A = trinucleotide repeat containing 6A.  
Reproduced from Fabian, Sonenberg and Filipowicz (2010). 
 
1.3 Regulation of miRNA expression 
The levels of any given miRNA are dependent on the rates of transcription, processing and 
decay.  
1.3.1 Transcriptional control 
Transcriptional mechanisms include: targeting of the miRNA promoter region by TFs; changes in 
DNA methylation status; mutations in the genomic promoter region or the miRNA itself altering 
TF binding; amplification/loss of the genomic region of the miRNA. 
For example, Lujambio et al. (2007) identified that DNA methylation down-regulated the 
expression of miR-127, -124 and -34.  In another study by Zhou et al. (2007) of 109 human 
miRNAs, 30 (27.5%) had CpG (Cytosine-phosphate-Guanine) islands in their upstream region 
(19.3% within the 500 base pairs upstream) suggesting that methylation could be a significant 
mode of regulation.  
1.3.2 Processing 
miRNAs are generally thought to be stable although there are some notable exceptions that are 
heavily influenced by specific processing and decay. 
Processing can be broadly affected by three groups of regulatory proteins: Drosha-
binding/associated proteins; Dicer-binding proteins; and terminal loop-binding proteins (Slezak-
Prochazka et al., 2010).   
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For example, Yamagata et al. (2009) reported that ERα stimulation lead to obstructed Drosha 
processing of miR-16, -125a, -143, -145 and -195 via a p68/p72-dependant mechanism.  
Additionally, proteins that interact with p68/p72 might alter the processing of specific miRNAs 
(Slezak-Prochazka et al., 2010). 
Dicer binding proteins are those such as TRBP (Tar RNA binding protein), PACT (protein activator 
of PKR) and the Ago proteins (mostly Ago2).  Paroo et al. (2009) identified that phosphorylated 
TRBP lead to increased levels of miR-17, -20a and -92.   
Terminal loop binding proteins can alter the processing efficiency of the primary and pre-cursor 
miRNAs. For example, RNA binding hnRNP A1 (heterogeneous nuclear ribonucleoprotein A1) has 
been shown to facilitate the specific processing of one of the members of the miR-17-92 cluster, 
miR-18a, suggesting that specific factors may be required for the processing of particular 
miRNAs (Guil and Caceres, 2007). 
1.3.3 Decay 
After mature miRNAs are generated, the rate of decay is dependent on their stability which is 
controlled by cis-acting modifications, protein complex formation and exposure to nucleases 
(Kai and Pasquinelli, 2010).  The implication of altered miRNA stability is that those miRNAs that 
are less stable are likely to have less sustained regulatory effects. 
Baccarini et al. (2011) found some miRNAs, such as miR-223, had a half-life of 23 hours in the 
presence of moderate levels of target.  Interestingly, the decay rate was faster with over-
expression of the perfect target of the order perfect target > bulge target > moderate level.  
From these experiments they deduced that target regulation can increase the miRNA’s rate of 
decay and that this is dependent on target concentration and complementarity.   
Chatterjee and Groshans (2009) study in C.elegans found targets could stabilise miRNA by 
protecting it from 5’ to 3’ exonuclease activity however others (Baccarini et al., 2011) found no 
evidence of this postulating that this could be due to species-specific effects.   
Post-transcriptional addition of non-templated uridines to the cognate miRNA could be a 
mechanism of accelerating decay (Baccarini et al., 2011).  However, others have found over-
expression of uridyltransferases did not alter the level of miRNAs (Jones et al., 2009).  This decay 
mechanism could be miRNA-specific, cellular context specific, or due to transcript-specific 
factors.   
42 
 
A recent study of miRNA turnover identified an average half-life of approximately 5 days (based 
on a panel of six miRNAs).  The half-life was also found to differ dependent upon cell type 
(Gantier et al., 2011).   
Another study found that miR-382, a miRNA that contributes to HIV-1 provirus latency, is 
unstable in cells primarily due to the seven nucleotides at the 3’ terminal end and the action of 
the nuclease exosome 3′–5′ exoribonuclease complex (Bail et al., 2010).   
Kai and Pasquinelli (2010) identified that XRN2 (5’ to 3’ exonuclease 2) is able to catalyse the 
degradation of those mature miRNAs that are not incorporated into miRISC, or have been 
released from the complex.  In vitro, this mechanism is influenced by target availability where 
the Ago protein seems to act to protect the miRNA from decay.  This adds another layer of 
complexity to miRNA regulation, as not only events that alter miRNA levels lead to gene 
regulatory effects, but changes in protein levels themselves lead to altered miRNA levels.   
Recently, the first report of a mechanism that selectively stabilises a specific mammalian miRNA 
was published: in mice, the cytoplasmic poly(A) polymerase PAPD4 (PAP associated domain 
containing 4, also known as GLD-2) adds a non-templated adenine to the 3’ end of the mature 
liver-specific miR-122 after unwinding of the miRNA duplex, resulting in stabilisation (Katoh et 
al., 2009).  Loss of PAPD4 did not affect the abundance of other miRNAs indicating the miR-122 
was specifically affected or that only a fraction were altered.  They hypothesised that the 
steady-state level of miR-122 might be the result of competition between two pathways, either 
adding or removing nucleotides at the 3’ end, leading to elongation and stabilisation or 
shortening and degradation. 
In summary, various factors influence miRNA levels, covering transcriptional and post-
transcriptional levels.   
1.4 miRNA and PCa 
To date over ten profiling studies have been published analysing the miRNA expression levels in 
PCa; the results have been inconsistent, often with specific miRNAs being up-regulated in one 
study whilst down or not detected in another.  For example Lu et al. (2005) reported a global 
down-regulation of miRNA in cancer, whereas Volinia et al. (2006) did not. 
Technical factors such as the miRNA isolation method, measurement technology sensitivity and 
specificity, differing number of miRNAs, variable cut-offs (does a 1.5-fold have more biological 
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significance that a 1.3-fold?) and hypothesis testing significance levels all conspire to introduce 
uncertainty in identifying truly differentially expressed miRNAs in PCa.  The proportion of 
cancer:non-cancer in the tissues, choice of control (i.e. matched normal adjacent area or 
different non-diseased individual) and varying levels of stroma in the tissue preparations are 
likely to impact on the identification of differentially expressed miRNAs.  Even studies from the 
same group contain completely conflicting results: Waltering et al. (2010) reported that 
expression of miR-141 was increased in clinical PCa and CRPC samples compared with benign 
prostatic hyperplasia (BPH) (samples obtained by transurethral resection of the prostate/TURP); 
previously the same group reported that miR-141 was reduced in CRPC compared with BPH 
(Porkka et al., 2007).  They put this finding down to the fact that different array platforms were 
used in the two studies and that, in the previous study, they compared the CRPC specimens 
obtained from TURPs with BPH specimens from cystoprostatectomies.  The Waltering study 
noted that TURP specimens often show lower expression of miRNAs than prostatectomy 
samples.  This highlights the importance of comparing appropriate tissues/samples; a point not 
lost on the authors.  They suggested that the lower levels of the miRNAs found in TURP 
compared with prostatectomy samples might be because these specimens represent different 
anatomical sites of the prostate gland. 
With heterogeneity in PCa, and stratification of disease into different grades and stages, it is 
perhaps surprising that there is any consensus at all.  Despite these issues, some miRNAs have 
been identified by several groups to be consistently altered.  The outcome of ten profiling 
experiments in prostate cancer samples versus normal is summarised in Appendix, Table 7. 1, 
page 217. 
In the future, it would be useful if more papers published what treatments, if any, the patients 
were taking, perhaps taking additional measurements such as local or circulating androgen 
levels with longer follow up periods and measurements of survival.  Studies of larger patient 
cohorts would be of great benefit, including more studies using normal adjacent tissue as the 
control, as would integration of miRNA data with genomic and proteomic data; this would aid in 
establishing potential reasons for the reported discrepancies.  
Due to the discordance between the PCa profiling studies, it is important to investigate how 
miRNA may affect, or be affected by, components of the androgen signalling axis to shed light 
on how the differences reported in the clinical samples may have arisen. 
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1.5 miRNA targeting the AR 
Ostling et al. (2011) identified 71 unique miRNAs that were able to influence the level of the AR 
in cell lines, 52 decreasing and 19 increasing AR protein.  Of these, 35 unique miRNAs were 
predicted to bind one or several sites of the AR 3’UTR.  
Using luciferase reporter assays, they validated 13 miRNAs as being able to regulate the AR 
3’UTR: miR-135b, -185, -297, -299-33p, -34a, -34c, -371-3p, -421, -449a, -449b, -634, -654-5p 
and -9.  Despite the decrease in AR protein, only 6 of the miRNAs decreased the mRNA 
significantly after 24 hours, suggesting that most target the AR by translational inhibition.  
A recent study by Sikand and others (2011) revealed  miR-488*  is able to target the 3’UTR of 
the AR, ultimately leading to decreased protein expression, subsequent down-regulation of PSA, 
inhibition of growth and enhanced apoptosis.  miR-488* itself is predominantly expressed in 
brain tissues from the host gene ASTN1 and was undetectable in the PCa lines tested (LNCaP, 
MDA, PCa 2b, C4-2B, PC-3 and DU-145); it may offer an avenue for therapeutic intervention 
(Sikand et al., 2011).   
1.6 In vitro studies of androgen sensitive and insensitive cell lines 
A number of papers have been published that compare miRNA expression profiles between 
androgen sensitive and insensitive cell lines with the aim of identifying miRNA involved in the 
switch from androgen sensitive to insensitive PCa.  The results of Lin et al. (2008), Mattie et al. 
(2006), deVere White et al., (2009) and Xu et al. (2010) can be found in Appendix, Table 7. 2, 
page 221.   
Xu and colleagues (2010) found the majority of the miRNAs were equally expressed between 
the androgen sensitive cell line LNCaP to a sub-line of LNCaP that was androgen insensitive 
(LNCaP-AI) although 83 were expressed differently with fold changes greater than 2 (p-value 
<0.001).  Amongst the predicted targets of the differentially expressed miRNAs, AKT3 (v-akt 
murine thymoma viral oncogene homolog 3) was targeted by 11 of the miRNAs, suggesting that 
de-repression of AKT3 in the androgen-independent line may contribute to the aggressiveness 
of androgen-independent PCa:  in accordance with this hypothesis androgen-insensitive cell 
lines have previously been reported to contain increased AKT3 mRNA and protein (Nakatani et 
al., 1999). 
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Of the Mattie, Lin and Xu studies, only miR-222 was dys-regulated (down-regulated) in all three 
studies. It is perhaps of interest to note that the miRNA microarray profiling in the Mattie study 
was conducted in cells maintained in normal media whilst both the Lin and Xu studies were 
conducted in charcoal stripped media; this may, in part, explain the lack of overlap in identified 
miRNAs. 
1.7 Aims and hypothesis 
The overall hypothesis of this project was that androgens can induce alterations in miRNA 
expression in LNCaP prostate epithelial cells and that these changes may be associated with 
proliferation and PSA secretion.  To address this hypothesis, the aims were to: 
 Characterise the androgenic response to treatment with AR agonists and antagonists in 
terms of proliferation and PSA secretion 
 Determine whether androgenic chemicals can elicit a miRNA response 
 To investigate the temporal and concentration-dependent aspects of the miRNA 
response  
 Establish whether AR agonists or antagonists differentially affect miRNA expression 
 Explore potential and proven biochemical targets of those differentially expressed 
miRNA 
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2. Establishment of the phenotypic anchor 
2.1 Introduction 
As previously described in Chapter 1, androgens suppress proliferation and drive differentiation 
in the normal prostate (Balk and Knudsen, 2008).  The foundation of ADT is built on the 
hypothesis that in the context of PCa, androgens stimulate growth.   
2.1.1 Androgenic control of the cell cycle in PCa 
The cell cycle consists of four sequential steps through which the production of an identical 
daughter cell is enabled.  The steps are briefly summarised: the gap 1 phase (G1-phase) 
regulatory period where cells either commit to continued division or exit into G0 (reversible 
resting state); the synthesis phase (S-phase) where DNA is replicated and chromosomes are 
duplicated; the gap 2 phase (G2-phase) where the cell prepares for mitosis; and the mitosis 
phase (M-phase) which comprises nuclear division (mitosis) and cell division (cytokinesis) 
(O'Morgan 2007). 
Between certain phases are the so-called ‘restriction points’ which prevent the cell progressing 
further through the cycle if the preceding phase has not been completed appropriately: the 
G1/S checkpoint, which initiates DNA replication, and the G2/M checkpoint, which controls 
entry into mitosis.  A further regulatory checkpoint is that of the metaphase-to-anaphase 
transition.    
Sequential progression through the cycle is complex and is managed by ordered expression and 
activation of cyclins and cyclin-dependent kinases (CDKs): CDKs are activated by binding to 
cyclins, the production of which changes at different stages in the cell cycle (O'Morgan, 2007). 
Figure 2.1 illustrates how androgens are able to induce proliferation: currently, the data suggest 
that androgens induce proliferation through at least three complementary mechanisms: cyclin D 
accumulation via mTOR (mechanistic target of rapamycin serine/threonine kinase) which 
increases the rate of protein translation of cyclin D1; p21 induction leading to promotion of 
CDK4/cyclin D1 assembly; and degradation of p27 leading to facilitation of CDK2 activation (Balk 
and Knudsen, 2008).   
In its hypo-phosphorylated state, the retinoblastoma tumour suppressor protein (RB) is bound 
to members of the E2F family: consequently there is repression of transcriptionally-regulated 
E2F gene targets such as cyclin A. 
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Figure 2. 1 - Androgens and the cell cycle in PCa   
Elevated D1 acts as a modulator by a negative feedback loop.  Components outlined in red suppress AR 
function; those in green promote AR activity.  Cyclins are depicted as oval objects.  Abbreviations: A = cyclin A; 
AR = androgen receptor; B = cyclin B; cdc = cell division cycle; CDK = cyclin-dependent kinase; D1 = cyclin D1, E 
= cyclin E; mTOR = mechanistic target of rapamycin serine/threonine kinase; P = phosphate; p21/27 = protein 
21/27; RB = retinoblastoma.  Adapted from Balk and Knudsen (2008).     
 
In late G1, hyper-phosphorylation of RB by cyclin D plus CDK4 or CDK6 results in dissociation of 
Rb from E2F.  CDK4 or 6 initiates RB phosphorylation but only partly affects the transcriptional 
repressor function (Knudsen and Knudsen, 2006): CDK2 completes RB’s phosphorylation thus 
extinguishing its repressor function.   E2F is then able to stimulate expression of its target genes 
which encode proteins required for cycle progression, such as de-repression of cyclin A 
expression and S phase progression (Alberts et al., 2002).  In G2, CDK1 promotes 
phosphorylation and activation of AR whilst during mitosis (M-phase), the AR is degraded and 
acts as a licensing factor to enable further rounds of replication (Balk and Knudsen, 2008).   
2.1.2 PSA 
Prostatic fluid comprises approximately 30% of the whole ejaculate, providing essential 
components such as PSA, zinc and citrate which are required for sperm cell activation and 
capacitation (Jonsson, Lundwall and Malm, 2006; Veveris-Lowe et al., 2007).   
The glycoprotein PSA is the major protein in seminal fluid and is secreted by the secretory 
epithelial cells directly into the lumen of the prostate gland (Balk, Ko and Bubley, 2003). The 
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gene KLK3 encodes for PSA, a member of the family encoding the tissue kallikrein-like serine 
proteases; they are clustered in the kallikrein locus on chromosome 19q13.3-13.4 (Diamandis 
and Yousef 2001).  As previously mentioned, KLK3 is positively regulated by androgens 
(Montgomery et al., 1992).  
The function of PSA is to cleave the high molecular weight seminal vesicle proteins semenogelin 
I and II thus inhibiting coagulation in seminal fluid (Lilja et al., 1987).  It is released into the 
seminal fluid at between 0.5 – 3mg/mL (Wang et al., 1998), around 1 million times higher than 
measured in plasma.  Despite its name, PSA is detectable in breast and other tissues although it 
is at much lower levels (Lovgren et al., 1999). 
PSA is synthesised intra-cellularly as preproPSA and cleaved co-translationally to proPSA; in the 
prostatic lumen the propeptide is cleaved by hK2 (human glandular kallikrein 2) to generate 
active PSA (Balk, Ko and Bubley, 2003).  Additionally, active PSA can undergo proteolysis in the 
lumen to generate an inactive form.  In PCa there is reduced processing at two different steps 
resulting in increased levels of proPSA and also of the bound PSA (Balk, Ko and Bubley, 2003). 
As mentioned in Chapter 1, page 30, PSA is the most widely used biomarker of PCa, being used 
to aid detection, monitor disease progression and effectiveness of treatment, and finally to 
assess the re-emergence of the disease after therapy (biochemical recurrence) (Agoulnik and 
Weigel, 2006).  Its elevated presence in serum is due to abnormal glandular architecture 
resulting in greater than normal leakage into the extracellular fluid of the prostate (Kim and 
Coetzee, 2004).  Despite its widespread usage, its utilisation as a biomarker is controversial as 
any disease state that disrupts the prostatic architecture, such benign prostatic hyperplasia and 
inflammation, can elevate serum PSA levels (Balk, Ko and Bubley, 2003). 
PSA may also play a role in the microinvasion of LNCaP as it has the capacity to cleave 
extracellular matrix glycoproteins such as laminin (Webber, Waghray and Bello, 1995). 
2.1.3 Rationale for compounds 
DHT was chosen for study as it is the most potent endogenous androgenic compound (Chapter 
1, section 1.1.1). 
Bicalutamide (BIC), also known as Casodex®, is a therapeutic non-steroidal androgen antagonist, 
used as part of a regimen in the treatment of androgen-sensitive prostate cancer: it is used in 
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combination with a luteinizing hormone-releasing hormone (LHRH) analogue for stage D2 
metastatic PCa (AstraZeneca, 2009). 
Mibolerone (MIB) is a potent non-metabolisable synthetic androgen agonist, originally used by 
veterinarians to prevent oestrus in female dogs (Sokolowski and Geng, 1977).  It has been used 
extensively in cell culture assays to study effects of the AR.  It is also reported to have been 
abused by body builders, who use it illegally to induce aggression (Roberts, 2008).   
Vinclozolin (VIN) is an agricultural dicarboximide fungicide widely used in Europe for the control 
of diseases caused by several species of the fungi Botrytis, Sclerotinia, and Monilinia (Spencer, 
1982).  VIN is a reported AR antagonist primarily by virtue of its degradation metabolites which 
show structural similarity to the anti-androgen flutamide (Kelce, Monosson and Gray, 1995).  In 
rats, VIN rapidly hydrolyses to its metabolites and studies provide evidence of inhibition of 
growth of androgen-dependent tissues (Kelce, Monosson and Gray, 1995) and Leydig cell 
hyperplasia via the altered hypothalamus-pituitary-gonadal feedback mechanism (Zober et al., 
1995).  Concern has arisen because in utero exposure to rats may result in trans-generational 
effects on offspring through epigenetic alteration (DNA methylation status) causing permanent 
perturbations, such as aging-associated prostatis observed in four generations (Prins et al., 
2007).  It has also been reported that exposure during embryogenesis results in epigenetic re-
programming of the male germ line in rodents (Anway, Rekow and Skinner, 2008).  These latter 
observations have generated much controversy. 
2.1.4 Aims 
The aims of the present study were to define the androgenic response to treatment with 
androgen agonists and antagonists.  Establishing the basal response to such compounds, the so-
called phenotypic anchor, would enable any alterations in miRNA expression to be correlated 
with these changes, allowing deductions to be made about the potential role of miRNA in 
androgen-induced phenotypic change.  Proliferation and PSA secretion are end-points of 
androgen administration in prostate cancer cells and are suitable to be used as surrogate 
measures of AR activation: these two measures are the phenotypic anchor.  
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2.2 Methods and Materials 
2.2.1 Characteristics of LNCaP 
LNCaP-FGC are an adherent fast growing colony of human prostate epithelial cells derived from 
a lymph node metastasis originally established by Horoszewicz et al. (1983).  LNCaP-FGC (herein 
termed ‘LNCaP’) exhibit a reduction in the doubling time (60 hours to 34 hours), as compared to 
the data in Horoszewicz et al. (1983), hence the ‘fast growing’ designation.  In terms of their 
culturing characteristics: they have low anchorage ability, tend to grow in clumps and do not 
form a confluent monolayer (Figure 2. 2).  Therefore, confluency was defined as an approximate 
coverage across the growing surface prior to the formation of large clumps.   
A – Low density B – High density 
 
 
 
C – Low density (in-house image) – 20x magnification  
 
 
 
 
 
 
 
 
 
Figure 2. 2 - Light microscopy images of LNCaP-FGC 
LNCaP have an average cell diameter of 14 micrometers and a single cell volume of 1.437fL (Sedelaar and 
Isaacs, 2009).  ATCC images obtained from http://www.lgcstandards-atcc.org/Attachments/1832.jpg.  
Accessed 02.08.11. 
LNCaP are used extensively to study the actions of androgens and prostate cancer: this is 
because they maintain the markers of PCa, maintaining secretion of prostatic acid phosphatase, 
PSA, are responsive to hormones and have retained the presence of the Y chromosome 
(Horoszewicz et al., 1983). 
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LNCaP express high levels of 5-α reductase I and modest levels of type II (Xu et al., 2006).   They 
also express various forms of the androgen metabolism enzyme hydroxysteroid dehydrogenase 
(HSD): 3α-HSD, 3β-HSD and 17β-HSD4 (Gingras and Simard, 1999; Castagnetta et al., 1997).  The 
key steroidogenic enzymes StAR (steroidogenic acute regulatory protein), cytochrome P450s 
11A1 or 17 (also known as aromatase) are not expressed at detectable levels (Sedelaar and 
Isaacs, 2009).   
LNCaP have a mutated AR (a single mutation of adenine to guanine at nucleotide 876) that 
results in the ability of the AR to bind non-canonical ligands, however it has the same affinity as 
the wild-type AR for mibolerone, DHT and testosterone (Montgomery et al., 1992).  This same 
mutation has been reported in 25% of a small cohort of clinically advanced PCa samples 
(Gaddipati et al., 1994).   
LNCaP were supplied from an in-house stock originally purchased from the ATCC (American 
Type Culture Collection), via LGC Standards (Teddington, UK), catalogue identification number 
CRL-1740. 
2.2.2 Cell culturing 
All cell culture reagents were supplied by Invitrogen, unless otherwise stated, and propagated in 
Corning® standard tissue culture treated plastic-ware. 
LNCaP were routinely cultured in complete media consisting of phenol red-free MEM (minimum 
essential medium) supplemented with 10% v/v FBS (foetal bovine serum), 1% v/v NEAA (non-
essential amino acids) and 2mM L-glutamine.  On occasion, the media was also supplemented 
with 1% Penicillin/Streptomycin (100U/mL, 100μg/mL respectively) to prevent the growth of 
gram-positive and gram-negative bacteria; the use of antibiotics was minimised to prevent the 
development of bacterial resistance. 
The purpose of FBS is to supply nutrients such as essential fatty acids, cholesterol, endocrine 
factors (androgen, triiodothyronine), serum growth factors (insulin, insulin-like growth factor 
(IGF) and epidermal growth factor (EGF)) and cell attachment proteins such as fetuin (Hedlund 
and Miller, 1994).   
2.2.3 Cell resuscitation 
To resuscitate, a vial of cells was removed from storage in the liquid phase of liquid N2, allowed 
to stand at room temperature for one minute, warmed gently in a water bath until partially 
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thawed and brought to room temperature by addition of pre-warmed complete media. The 
mixture was transferred to a T25 flask for culturing at standard conditions of 37°C, 5% CO2, 95% 
air.  Once established and confluent, the cells were transferred into T75 flasks for routine 
culturing. 
2.2.4 Cell maintenance and passaging 
Cells were maintained in T75 flasks containing approximately 15mL of the media and sub-
cultured when the cells reached approximately 80% confluency.  To passage the cells, the cell 
monolayer was rinsed in sterile phosphate-buffered saline (PBS) and incubated at 37°C with 
0.05% trypsin-EDTA (ethylenediaminetetraacetic acid) until in suspension.  Trypsinisation was 
terminated when an equal volume of complete media, containing intrinsic trypsin-inhibitor 
activity, was added.  Replicate flasks were pooled and the cell mixture centrifuged at 1000 rpm 
(revolutions per minute; ~900 xg) for five minutes to pellet the cells.  After centrifugation, the 
supernatant was discarded, the pellet re-suspended in fresh media and seeded into new flasks 
at ratios between 1:3 and 1:6. 
Media was refreshed two to three times per week by removal of the aged media, washing of the 
adhered cells with PBS and addition of fresh media.    
Cells were manually counted using an advanced Neuberger Haemocytometer and the Trypan 
Blue exclusion method whereby cell viability is determined by uptake of the blue dye by dead 
cells, due to permeabilisation of the cell membrane, and exclusion of the dye by live cells.  
Briefly an aliquot of the cell suspension was added to an equal volume of 0.4% Trypan Blue 
(dilution factor of two) and incubated at room temperature for two to three minutes.  After 
which, approximately 8µL of the mixture was loaded onto each side of the haemocytometer.  
Non-blue cells (live population) were counted in 10 squares, averaged, and the total number of 
live cells determined by: 
      c = t(xdz)       
where:  c = total number of live cells 
t = total volume of cell suspension (mL) 
x = average number of counted cells 
d = dilution factor 
z = 104 cells/mL 
Cells were then seeded into new culturing vessels at the required number. 
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2.2.5 Preparation of frozen stocks 
To prepare stocks of cells of early passage number for future use, cells were harvested with trypsin 
and pelleted, as mentioned previously, and re-suspended in 95% FBS and 5% of the cryoprotectant 
dimethylsulphoxide (DMSO).  The cells were frozen at -80°C for 24 hours before transferral to 
permanent storage in liquid N2.  
2.2.6 Preparation of triple dextran-coated charcoal-stripped FBS (dccFBS) 
The majority of testosterone found in serum is complexed to proteins such as SHBG and 
albumin; a small proportion is ‘free’.  The purpose of the stripping is to reduce the amount of 
endogenous steroids and growth factors, thus potentially lowering the total testosterone by as 
much as 80% (Sedelaar and Isaacs, 2009).  The actions of exogenous steroids can then be 
assessed without influence from endogenous steroids.   
Serum was stripped using an in-house method that utilises dextran-coated charcoal (Lauber 
2003).  A volume (10mL) of dextran-coated charcoal was added to 500mL FBS and stirred 
overnight at 4°C (step 1).  The FBS mixture was decanted to remove any sediments and a further 
10mL dextran-coated charcoal added (step 2).  The mixture was heated in a water bath at 50°C 
for 45 minutes (step 3) after which it was cooled to 4°C (step 4), and centrifuged at 1000 rpm for 
20 minutes (step 5).  Steps 2 through to 5 were repeated a further two times.  Finally, the 
mixture was decanted once more and centrifuged at 3000 rpm (~2700 xg) for 30 minutes before 
being sterile filtered through a 0.2µM filter.  The prepared dccFBS was stored at -20°C until 
required.  
2.2.7 Definition of experimental media 
The experimental media was an adaptation of the normal culturing media whereby 10% FBS was 
substituted for 5% dccFBS.  
2.2.8 Cell proliferation - AlamarBlue® 
AlamarBlue® is an indicator dye that changes colour and fluoresces in response to the chemical 
reduction of resazurin to fluorescent resorufin by metabolically competent cells (AbD Serotec, 
2009); the amount of reduction is directly proportional to the number of cells present in the 
sample and is used to determine cell number.     
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Calibration curves (Figure 2. 3) were performed for different cell ranges to allow accurate 
determination of cell number in different growth environments.  
A - 24-well plate with 2 hours incubation B - T25 with 1 hour incubation 
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C – T75 flask with 1 hour incubation 
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Figure 2. 3 - Cell number calibration curves   
LNCaP were plated out in appropriate vessels and incubated for 1 or 2 hours with 10% v/v alamarBlue®.  The 
calibration curve was used to ensure linearity of response across the range of cell number expected in the 
proliferation assays allowing accurate cell number determination where required.  Data for (A) and (B) are 
mean with S.E.M error (n=3), (C) is of a single culture.  Abbreviations: AU = arbitrary units; ex/em: 
excitation/emission. 
 
To generate the calibration curves, cells were manually counted using the haemocytometer, as 
previously described, and plated into 24-well plates, T25 flasks or T75 flasks at defined cell 
numbers in an appropriate volume of complete media (Table 2.2).  The cells were left to settle 
for one hour and the dye was added directly (at 10% the culture volume).  After one or two 
hours (hrs) incubation, the plate was read on the FLUOStar microplate reader, pre-heated to 
37°C, at 560 nanometres (nm) excitation and 590nm emission (ex/em).  Where the cells were 
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grown in flasks, an aliquot (0.55mL) of the media with AlamarBlue® was removed and placed 
into 24-well plates prior to reading with the plate reader.  In all cases, the inclusion of a blank 
well or flask, consisting of media and the dye but lacking cells, allowed removal of background 
fluorescence. 
2.2.9 PSA expression 
PSA expression was measured using Calbiotech’s PSA enzyme-linked immunosorbent assay 
(ELISA) kit PS07T as per the manufacturer’s protocol.  All required reagents were supplied in the 
kit.  The amount of PSA was determined by comparison to the standard curve which was run 
concurrently with each set of samples.  Prior to PSA determination, the cellular supernatant 
containing the secreted PSA was diluted with distilled water to ensure that the expected PSA 
concentration fell within the range of the calibration curve – dilution factors were between 1:10 
and 1:40.   
The kit utilised a 96-well plate format: each well was provided pre-coated with anti-PSA 
monoclonal antibody (mAb).  All incubations were at room temperature.  The diluted samples 
(50µL) plus 50µL of assay buffer were added to each well and incubated for 30 minutes to allow 
the PSA in the samples/standards to bind to the mAb.  Unbound proteins were rinsed off by 3 
cycles of wash buffer (300µL/cycle).  Enzyme conjugate (anti-PSA horseradish peroxidase-
labelled (HRP-labelled) secondary antibody; 100µL) was added and incubated for a further 30 
minutes to allow binding.  After which, the unbound proteins were again washed off as 
previously described.  The substrate (100µL) was added, the plate incubated for 15 minutes, and 
50µL of Stop Solution added.  Addition of the Stop Solution causes a change in colour, the 
intensity of which is proportional to PSA concentration.  PSA levels were read on the Tecan 
Sunrise™ microplate absorbance reader at 450nm within 10 minutes of adding Stop Solution.  
2.2.10 Test compounds 
Table 2. 1 and Figure 2. 4 provide details and structures of the chemical compounds used in this 
study.  Stock concentrations of the compounds were prepared concentrated and serially diluted 
to give the required final working concentrations.  
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Table 2. 1 – Details of test compounds 
Compound CAS number Acronym Purity Vehicle concentration Supplier 
Bicalutamide (CDX) 90357-06-5 BIC ≥98% 0.1% Sigma 
Dihydrotestosterone 521-18-6 DHT ≥97.5% 0.1% Sigma 
Mibolerone 3704-09-4 MIB >95% 0.1% Perkin Elmer 
Vinclozolin 50471-44-8 VIN 99.5% 0.1% Sigma 
All compounds were prepared in ethanol.  Where CAS is Chemical Abstract Service registry number. 
 
A – Dihydrotestosterone B – Bicalutamide 
  
(5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-10,13-dimethyl-
1,2,4,5,6,7,8,9,11,12,14,15,16,17-
tetradecahydrocyclopenta[a]phenanthren-3-one 
N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-
hydroxy-2-methylpropanamide 
C – Mibolerone D – Vinclozolin 
 
 
(7R,8R,9S,10R,13S,14S,17S)-17-hydroxy-7,13,17-trimethyl-
1,2,6,7,8,9,10, 
11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-
one 
3-(3,5-dichlorophenyl)-5-ethenyl-5-methyl-1,3-oxazolidine-2,4-dione 
Figure 2. 4 - Chemical structures of test compounds 
With International Union of Pure and Applied Chemistry names. 
 
2.2.11 Experimental conditions 
The experimental conditions employed were an adaptation of the E-SCREEN assay which is used 
to screen compounds for estrogenic activity (Soto et al., 2006).  The equivalent assay used to 
screen androgens, the A-SCREEN, employs a specific transfected cell type (MCF7-AR1) which 
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was not available in our laboratory.   Therefore the general method of the E-SCREEN was 
developed for use with LNCaP cells.  Exposure time (96 hours or 120 hours) and cell number (up 
to maximum 13,000cm2) were optimised: the protocol described below is the final protocol.  
Experiments were completed within ten passages of resuscitation. Cells were seeded into the 
appropriate culture vessel, as indicated in Table 2. 2, and given 24 hours to attach to the plastic 
substrate.  After which, the media was aspirated, cells washed with PBS and an equivalent 
volume of experimental media added. 
Table 2. 2 - Cell density and media volume 
Culture vessel Growing surface (cm
2
) Cell number Volume of complete media (mL)   
24-well plate 1.9 24,700 0.55   
12-well plate 3.8 50,000 1   
T25 25 330,000 6.6   
T75 75 990,000 19.8   
All culture vessels provide the same ratio of cells to media (50,000 cells/mL) or ratio of cells to growing surface 
(13,000 cells/cm
2
).  Where large amounts of protein were required for immunoblot, the cells were grown in 
flasks rather than well plates.   
 
After 48 hours, the cells were dosed with the relevant compounds (delivered in the 
experimental media).  The negative control consisted of cells cultured with the compound 
solvent (vehicle control; VC). 
At the end of the experiment, 120 hrs post-dosing, proliferation was measured using 
alamarBlue®, the supernatant collected and frozen at -20°C for future PSA analysis and the cell 
pellet frozen for future immunoblotting.     
2.2.12 Total cellular protein 
Total cellular protein was measured using the bicinchoninic (BCA) assay and pre-diluted protein 
standards (Thermo Scientific).  The cell pellet was re-suspended in 99:1 lysis buffer (0.1% v/v 
Igepal, 150mM sodium chloride, 1mM tris pH 7.4, 1mM ethylenediaminetetraacetic acid) to 
Halt™ Protease Inhibitor Cocktail (Pierce) and lysed on ice for 5 minutes to release cellular 
content. After lysing, the mixture was centrifuged at 10,000rpm (10,621 xg) for 5 minutes (at 
2°C) to pellet the cellular debris and the supernatant collected into fresh tubes. 
Protein was determined as per the manufacturer’s protocol with minimal modification.  Briefly, 
2.5µL of sample and 22.5µL of distilled water was placed into the wells to which 200µL working 
reagent was added.  After 30 minutes incubation at 37°C, protein content was determined by 
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measurement of absorbance at 560nm on the FLUOStar microplate reader.  Total protein levels 
were obtained by comparison to a standard curve run concurrently with the samples taking into 
account any dilution factors. 
2.2.13 Immunoblotting 
Using the total protein measurements determined by the BCA assay, the amount of protein was 
normalised to approximately 10μg protein per gel lane.  For stacking and resolving gel recipes, 
and details of the transfer, blocking and wash buffers refer to Appendix, page 223.  
To each sample loading buffer (50mM Tris-Cl pH 6.8, 2% w/v sodium dodecyl sulphate, 0.1% v/v 
bromophenol blue, 10% v/v glycerol, 100mM dithiothreitol) was added. The samples were 
heated at 95°C for 5 minutes followed by centrifugation at 10,000rpm (10,621 xg) for 5 minutes, 
after which they were loaded into the gel wells.  A pre-stained molecular weight marker ladder 
(Novex® Sharp Pre-Stained Protein Standard, Invitrogen) was used to identify the proteins.  
Samples were electrophoresed at 100v in 8% acrylamide:bisacrylamide resolving gel until 
sufficient separation was attained.  Proteins were electro-blotted onto a nitrocellulose 
membrane (1.5 hour transfer time) and transfer was confirmed by ponceau red staining (0.1% 
Ponceau S w/v in 5% v/v acetic acid, Sigma Aldrich).   
Antibodies are described in Table 2. 3.  Incubation with primary anti-AR antibody was conducted 
overnight at 4°C followed by incubation with secondary antibody for 1 hour at room temp.  
Chemiluminescent methods were used to visualise the HRP-conjugated secondary antibody 
(SuperSignal West Pico Chemiluminescent Substrate, Thermo Scientific).   
Table 2. 3 - Details of antibodies 
Antibody Species Band appearance Catalogue number Dilution  
Anti-AR Mouse 110kDa sc-7305 1:600  
Anti-β-actin Mouse 42kDa A5441 1:20,000  
Anti-mouse IgG-HRP Goat - sc-2031 1:2,000  
All antibodies were supplied by Santa Cruz except for anti-β-actin (Sigma-Aldrich).  Antibody is diluted in 
blocking buffer. The anti-AR antibody was raised against amino acids 299-315 of human AR. 
 
The relative density of each band was calculated using the Kodak Imaging Station 4000MM. The 
absolute value is estimated by the optimal density of the band multiplied by the surface area of 
the band.   
β-actin was used as the normalising loading control protein; all blocking/washing/incubations 
were performed at room temperature.  After visualisation and quantitation of the protein of 
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interest (the AR), the blot was washed three times in wash buffer for 15 minutes, blocked for 1 
hour, incubated with anti-β-actin primary for 1hr, washed three times as before, incubated with 
goat anti-mouse secondary and finally washed three times.  AR protein values were normalised 
against the values for β-actin for each sample. 
2.2.14 Data analysis 
Proliferation dose-response curves are presented as percentage fluorescence of vehicle control 
and are representative of cell number.  The fluorescence of the vehicle control is given as 100%.   
The curve fitting models applied to the data were log(agonist) versus response or log(inhibitor) 
versus response – the data and 95% confidence intervals (CI) were derived from the best fit 
values.  Where the shape of the response was obviously not agonistic or antagonistic, a 
comparison of models was undertaken and the preferred model chosen based on the goodness 
of fit. 
The EC50 (effective concentration) is the concentration at which the measured response is half of 
the maximal – use of the EC50 enables comparisons of potency to be made.  The IC50 is the 
concentration at which the inhibitory response is half of the maximal.   
When determining the response of antagonists, the inclusion of a positive control (2nM of DHT) 
confirmed that any lack of response was not due to the assay failing but was rather a 
characteristic of the compound under investigation.  
For experiments consisting of an agonist and potential antagonists, the data is presented as 
percentage fluorescence of the positive control.  Inclusion of a positive control (2nM DHT) and a 
negative control (50nM BIC) ensured the assay was working as expected. 
All analyses have been performed using GraphPad Prism Version 5.00 by GraphPad Software Inc.  
Statistical significance was determined by one-way analysis of variance (ANOVA) followed by 
Dunnett’s post-hoc test. 
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2.3 Results 
2.3.1 Proliferative dose-response curves 
The effect of five days (120 hours) of exposure to each compound on the proliferative ability of 
LNCaP was assessed.   The potency values for the AR agonists are detailed in Table 2. 4, page 60. 
DHT 
The DHT concentrations included, and exceeded, the normal physiological range of DHT (0.8 to 
4.1nM) (Saroff et al., 1980).  The effect of DHT was assessed in LNCaP cells exposed to different 
media: one media containing FBS (normal media), the other media containing serum that had 
been stripped of charcoal-adsorbable steroids and serum components (experimental media). 
Figure 2. 5A presents the results of when LNCaP were cultured in steroid-depleted dccFBS 
(experimental media).  DHT induced cellular proliferation at concentrations above 100pM (10-
10M) in a dose-dependent manner reaching an optimum level above the control of 73.5% (95% 
C.I. 68 to 79.1).  Maximal proliferation was achieved by concentrations equal to and above 
approximately 10nM (10-8M) although there was no increase in proliferation at higher 
concentrations.  
When cultured in media containing normal serum components (Figure 2. 5B), 10nM DHT caused 
a decrease in proliferation down to 36.7% of the control’s level (95% C.I. 34.5 to 38.9).  Higher 
concentrations had no effect on cell number.   
Mibolerone 
As mentioned previously, mibolerone is a synthetic androgen agonist.  The maximal response 
reached a plateau at 87% greater than control (95% C.I. 81.5 to 93.9) at approximately 100pM 
(Figure 2. 5C).   
Table 2. 4 - EC50 of DHT or MIB in dccFBS-media or IC50 of DHT in FBS-media with 95% confidence intervals 
(C.I.) 
 
 log EC50 or log IC50 EC50   or IC50 
DHT in dccFBs -9.36M (-9.55 to -9.16) 442pM (285pM to 689pM) 
DHT in FBS -8.83M ( -8.90 to -8.76) 1.46nM (1.25nM to 1.73nM) 
MIB in dccFBS -12.24 M (-12.49 to -11.99) 572fM (322fM to 1.02pM)   
LNCaP were seeded in 12-well plates at approximately 13,000 cells/cm
2 
using normal or experiment media and 
left to adhere to the well surface for 24 hours (37°, 5% CO2).  24-hours post-seeding, the media was changed to 
experimental media; 48 hours later the media was refreshed and the cells dosed.  Cell proliferation was 
assessed after 120 hours exposure using alamarBlue™. In the case of DHT in FBS, complete media was 
maintained throughout.  Values are from quadruplicate cultures with 95% confidence intervals (in brackets).     
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A- DHT (dccFBS) B – DHT (FBS) 
 
 
 
 
 
C – Mibolerone (dccFBS) 
 
Figure 2. 5 - Dose-response curves for LNCaP treated with DHT or MIB 
(A) and (C) - Cells cultured in media containing dccFBS. (B) – Cells cultured in media containing FBS. LNCaP 
were seeded in 12-well plates at approximately 13,000 cells/cm
2 
using complete media and left to adhere to 
the well surface for 24 hours (37°, 5% CO2).  24-hours post-seeding, the media was changed to experimental 
media; 48 hours later the media was refreshed and the cells dosed.  Cell proliferation was assessed after 120 
hours exposure using alamarBlue™.  In the case of (B), complete media was maintained throughout.  
Presented as mean with S.E.M. error bars for quadruplicate cultures.  Shaded area represents the 95% 
confidence interval for determination of the Log EC50 (dotted line).  Abbreviations: DHT = dihydrotestosterone; 
dccFBS = dextran-coated charcoal-stripped FBS; FBS = foetal bovine serum; MIB = mibolerone 
 
Bicalutamide 
Initially the effect of BIC at concentrations ranging from 5pM to 50nM (5x10-12M to 5x10-8M) 
was tested alone and in combination with 2nM DHT (2x10-9M).  DHT at 2nM is a sub-maximal 
concentration that is physiologically relevant (Labrie et al., 1997).  Subsequently, the 
experiments were repeated using a higher dose range up to a maximum of 10µM. 
BIC had no effect on proliferation at concentrations less than 50nM (log -7.30M) when cultured 
in isolation (Figure 2. 6A).   In the presence of 2nM DHT, there was a slight increase in 
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proliferation (18% greater than the control) with 1nM BIC (log -9M) but there was large 
variability between the biological replicates (Figure 2. 6B).  
 
A - Low concentration BIC B - Low concentration BIC + DHT 
 
 
 
 
C – High concentration BIC D – High concentration BIC + DHT 
 
 
 
Figure 2. 6 - Effect of BIC on LNCaP proliferation alone and in combination with DHT 
LNCaP were seeded in 12-well plates at approximately 13,000 cells/cm
2 
using complete media and left to 
adhere to the well surface for 24 hours (37°, 5% CO2).  Post-seeding (24 hours), the media was changed to 
dccFBS-containing media; 48 hours later the media was refreshed and the cells dosed.  Cell proliferation was 
assessed after 120 hours exposure using alamarBlue™.  Presented as percentage fluorescence of vehicle 
control (VC) or positive control (+ve; 2nM DHT) with S.E.M. error bars for quadruplicate cultures.  Negative 
control is 50nM BIC.  Shaded area represents the 95% confidence interval for determination of the Log EC50 
(dotted line).  Abbreviations: BIC = bicalutamide; DHT = dihydrotestosterone 
 
When BIC was cultured in isolation at concentrations greater than 1µM (log -6M), there seemed 
to be a mild agonistic effect – a maximum of 38% greater than control was achieved by 10µM 
(Figure 2. 6C).  The absence of a plateau effect meant that an accurate determination of the EC50 
was not possible although the shading and hashed lines on the graph indicate possible values. 
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However, when the cells were cultured with higher concentrations of BIC there was a clear 
attenuation of DHT-induced proliferation in a dose-dependent manner.   Any mild proliferative 
effect of BIC was lost and there was a steady decrease in fluorescence (cell number) resulting in 
10µM BIC inducing a reduction of 15% fluorescence compared to the positive control levels 
(Figure 2. 6D).  
Vinclozolin 
Like BIC, VIN was tested alone and in combination with 2nM DHT at low and then high 
concentrations. 
When LNCaP were cultured with VIN alone there was a mild agonistic response (10.8% greater 
than control; Figure 2. 7A).  However, the best model chosen to fit the data had poor goodness 
of fit (R2 0.14) although it was better than fitting a straight line.  Low concentrations of 
vinclozolin (between 5pM and 50nM) plus 2nM DHT had no effect on proliferation (Figure 2. 7B, 
mean maximal 105.7%, 95% C.I. 101.4 to 110).  Interestingly, 2nM DHT, which had previously 
caused an increase (Figure 2. 7A) was similar to the proliferation in the vehicle controls.   
It became clear when testing higher concentrations of VIN, 10nM to 100µM, that indeed there 
was a trend towards increasing proliferation: 60% greater proliferation than the vehicle control 
achieved by concentrations greater than 50µM (Figure 2. 7C).  The EC50 was determined to 
4.16µM (95% C.I. 1.3µM to 13.34µM).   
However, higher concentrations of VIN plus DHT induced proliferation: proliferation increased 
up to 15% greater than the DHT alone positive control (mean 115.6%, 95% C.I. 107.9 to 123.2; 
Figure 2. 7D).  The variability of the samples means that establishment of an EC50 is meaningless.   
Although VIN plus DHT was deemed to be proliferative, the maximal proliferation induced was 
less than VIN alone (60% induction) and also much less than both DHT alone and mibolerone 
alone (73% and 87%, respectively).  Additionally, the concentrations required to achieve these 
figures were much lower than the 100mM VIN used to induce this proliferative response.  To 
summarise, contrary to expectations, high doses of VIN acted as an agonist, although with less 
efficacy and potency than both DHT and MIB.   
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A - Low concentration VIN B - Low concentration VIN + DHT 
 
 
C – High concentration VIN D – High concentration VIN + DHT 
 
 
Figure 2. 7 - Effect of VIN on LNCaP proliferation alone and in combination with DHT 
LNCaP were seeded in 12-well plates at approximately 13,000 cells/cm
2 
using complete media and left to 
adhere to the well surface for 24 hours (37°, 5% CO2).   Post-seeding (24 hours), the media was changed to 
dccFBS-containing media; 48 hours later the media was refreshed and the cells dosed.  Cell proliferation was 
assessed after 120 hours exposure using alamarBlue™.  Presented as percentage fluorescence of vehicle 
control (VC) or positive control (+ve; 2nM DHT) with S.E.M. error bars for quadruplicate cultures.  Negative 
control is 10nM VIN (10
-8
M).  Shaded area represents the 95% confidence interval for determination of the Log 
EC50 (dotted line). Abbreviations: VIN = vinclozolin; DHT = dihydrotestosterone. 
 
2.3.2 PSA 
DHT 
Concentrations above 500pM DHT induced PSA secretion up to a maximal response of 332.6% 
(95% C.I.  319.8% to 345.4%) when compared to the vehicle control (Figure 2. 8A).  The log EC50 
was determined to be log -11.07M (95% C.I. -11.24 to -10.90): this is equivalent to 8.5pM 
(5.8pM to 12.6pM).   
Mibolerone 
Induction of PSA secretion was maximal at 10-12M, inducing a 3.5 fold increase (352.6%, C.I. 
331.1% to 374.3%) compared to the vehicle control (Figure 2. 8B).  Concentrations above this 
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did not increase PSA secretion.  The Log EC50 was -13.70M which equates to 51.5fM (95%C.I. 
19.5fM to 128fM).    
Bicalutamide 
The media from selected concentrations of the dose-response experiments were selected for 
PSA analysis.  As expected, bicalutamide alone had no effect on PSA secretion (Figure 2. 8C).  In 
combination with 2nM DHT, bicalutamide was able to attenuate the DHT induced secretion of 
PSA, showing a steady decline in expression down from 200ng/mL to 50ng/mL (4-fold reduction; 
Figure 2. 8D).   
A - DHT  B – MIB 
 
 
 
 
 
 
 
 
 
 
C – BIC D – BIC plus 2nM DHT 
 
 
 
 
 
Figure 2. 8 - PSA values 
LNCaP were seeded in 12-well plates at approximately 13,000 cells/cm
2 
using complete media and left to 
adhere to the well surface for 24 hours (37°, 5% CO2).   Post-seeding (24 hours), the media was changed to 
dccFBS-containing media; 48 hours later the media was refreshed and the cells dosed.  Conditioned media was 
collected after 120 hours exposure and stored at -80°c until required.  PSA was determined using the PSA Elisa 
kit and data are from single determinations. Abbreviations: PSA = prostate specific antigen; DHT = 
dihydrotestosterone; BIC = bicalutamide; VC = vehicle control. 
 
 
2.3.3 AR protein levels 
To support the proliferation and PSA data, immunoblotting of AR protein was undertaken and 
expression determined using densitometry and normalised to β-actin.  As this required 
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significantly more protein than can be extracted from cells grown in well plates, experiments 
were conducted in flasks and the proliferative and PSA-inducing effect of DHT reconfirmed.  As 
cell number was calculated, PSA is expressed as ng PSA per 106 cells. 
As previously observed, DHT induced proliferation and PSA secretion (Figure 2. 9A and B).   
Figure 2. 9 C/D shows the result of the immunoblot analysis in LNCaP cultured in experimental 
media: concomitant with the inductions of proliferation and PSA was an increase in AR protein 
level. 
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Figure 2. 9 - Effect of DHT on proliferation of LNCaP (A), PSA secretion (B) and AR expression (C and D)  
LNCaP were seeded into 25cm
2 
culture flasks at approximately 13,000 cells/cm
2 
using complete media and left 
to adhere to the well surface for 24 hours (37°, 5% CO2).  The following day (24-hours post-seeding), the media 
was changed to experimental media (dccFBS instead of FBS); a further 48 hours later the media was refreshed 
and the cells dosed.  Cell proliferation was assessed after 120 hours exposure using alamarBlue™.  The 
supernatant and cells, used for PSA analysis and protein level respectively, were obtained from the same 
experimental data set as for (A).  (C) At 120 hours post-androgen treatment, cells were lysed, electrophoresed 
and immuno-blotted using anti-AR monoclonal antibody, followed by an appropriate HRP-conjugated 
secondary antibody.  Three biological replicates were used for (A) (with SEM error bars) and two biological 
replicates for (B), (C) and (D).  Statistical analysis using 1-way ANOVA with Dunnett’s post hoc test, where *** 
indicates P<0.001, **P<0.01 and *P<0.05.  Abbreviations: AR = androgen receptor; DHT = dihydrotestosterone; 
PSA = prostate specific antigen. 
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2.4 Discussion 
This study assessed the mitogenic and PSA secretory effects of the test compounds as a 
surrogate measure of androgen receptor activity. 
2.4.1 Androgens induced proliferation, PSA and AR protein production  
Mibolerone was able to induce proliferation in LNCaP with a concomitant increase in PSA 
production.  It achieved a greater maximal response (efficacy) and exhibited a lower EC50 
(potency) than DHT.  Mibolerone is the more potent androgen, it is likely that it has a lower 
dissociation rate than DHT and perhaps the half-life of the DHT/AR complex is less than the 
MIB/AR complex as has been observed for testosterone whose half-life is 2.5 times less than the 
DHT/AR complex and is therefore less able to sustain efficient AR signalling (Askew et al., 2007). 
PSA production is under the control of the AR (Young et al., 1991).  The maximal PSA production 
that was observed by 120 hrs was 3.5-fold for mibolerone.  This is similar to what has been 
reported previously - a single concentration of mibolerone in LNCaP cells, 10nM, induced a 3 to 
4-fold increase in PSA (Kumar et al., 2000). 
LNCaP cellular proliferation was positively attenuated in a dose-dependent manner by the 
presence of DHT in the experimental medium.  PSA was also induced in accordance with 
previous studies (3.3-fold for DHT, Kumar et al., 2000).  This study confirmed that the optimal 
level of DHT required for proliferation in experimental media is 10nM, maximal proliferation of 
170%, in agreement with Horoszewicz et al. (1983).   
DHT induced a trend of increasing AR protein levels; this confirms the study by Arnold et al. 
(2007) who also reported an increase in AR protein level (using 10nM DHT, protein not 
quantified).  Lee and Chang (2003) have reported similar findings and have suggested this is due 
to the stabilisation of the AR protein rather than up-regulation of transcription as no changes in 
AR mRNA were reported.  
2.4.2 DHT induced opposing effects dependent on serum  
DHT-treated LNCaP exhibited a distinctive dose-responsive profile, with either a pro-
proliferative or anti-proliferative phenotype dependent upon the serum in which they were 
grown.    
In this study it was identified that when cultured in normal media, the addition of up to 100pM 
exogenous DHT elicited no effect on LNCaP proliferation compared to the control.  This was 
68 
 
followed by a dose-dependent decrease in cell number in agreement with other reports 
(Horoszewicz et al., 1983; Sedelaar and Isaacs, 2009).  Sedelaar and Isaacs (2009) determined 
that 10% FBS, used routinely to supplement media, contains castrate levels of testosterone 
(approximately 90pM) and LNCaP are able to auto-regulate their androgenic metabolism to 
generate intracellular levels of 10nM DHT (approximately physiological).  Therefore the addition 
of DHT <100pM has no additional effect on proliferation as LNCaP are able to maintain their 
growth by auto-regulation.  The mechanism for the decrease in cell number with increasing 
androgen supplementation has been elucidated by three groups (D'Antonio, Vander Griend and 
Isaacs, 2009; Litvinov et al., 2006; Vander Griend, Litvinov and Isaacs, 2007) who were able to 
show that the AR acts as a ‘licensing factor’ for DNA replication in PCa cells.  During mitosis, the 
AR is degraded (proteasomal degradation) for re-licensing in the next round of the cell cycle: 
high concentrations of DHT retard the required AR degradation so that relicensing can no longer 
occur resulting in S-phase growth arrest.   
Interestingly, PSA secretion continues to rise under conditions where DHT suppresses growth 
(Sedelaar and Isaacs, 2009).  The dichotomous effect observed, with increasing PSA despite 
stalled proliferation, is because PSA production does not require AR degradation and thus 
transcriptional activation is able to continue (Sedelaar and Isaacs, 2009).     
When in experimental media (dccFBS-containing), the contribution of steroids from dccFBS is so 
low that proliferation is sub-maximal: proliferation starts to increase from 100pM up to a 
maximal level reached by 10nM.  Androgens have been reported to have a bell-shaped dose-
response curve due to a proliferative ‘shut-off’ that occurs at high concentrations: in 
experimental media this occurs at concentrations greater than 100nM (Horoszewicz et al., 1983) 
and is due to ligand-induced AR stabilisation (D'Antonio, Vander Griend and Isaacs, 2009).  This 
response was not observed in this study as the maximum concentration tested was 100nM.   In 
addition, other authors have not seen this biphasic response even up to 10µM DHT (Arnold et 
al., 2005); they hypothesised that it may be due to differing cell culture conditions between the 
studies (growth substrate, basal media and percentage of dccFBS used). 
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2.4.3 The antagonist bicalutamide attenuated DHT’s effect on proliferation and PSA 
secretion 
It was expected that when treating cells with a fixed concentration of 2nM DHT the introduction 
of increasing concentrations of bicalutamide would lead to a decrease in proliferation due to 
competitive antagonism at the AR.  This anti-proliferative effect was observed at concentrations 
greater than 10-7M which is consistent with the knowledge that high concentrations are 
required in the treatment of PCa – the steady state concentration of the active isomer R-bic 
achieved after treatment with the recommended dosing regimen corresponds to approximately 
21µM (AstraZeneca, 2009).  The relatively mild proliferative antagonism is consistent with what 
has been reported by (Arnold et al., 2007). 
The PSA data supported the result that bicalutamide alone had no effect on AR activation, 
although a mild agonistic effect was seen in terms of proliferation at 10µM.  As bicalutamide has 
been shown to exert its antagonistic effects by ineffective co-activator recruitment (Chapter 1, 
page 27) as well as co-repressor recruitment, it could be that there was a mismatch between 
the availability of co-repressors and the amount required for full antagonism.  To further 
address the bicalutamide agonism in the castrate levels of hormones provided in the dccFBS-
supplemented serum, it would be interesting to analyse the complement of proteins attached to 
the DNA with the bicalutamide/AR complex. Hodgson et al. (2007) reported that bicalutamide 
can function as an agonist by removal of the NCoR from the AR complex.  Interestingly they also 
suggested that enhanced co-activator recruitment, rather than co-repressor loss, may be a 
contributing factor to bicalutamide resistance that has been observed in patients.   
As bicalutamide was able to attenuate DHT-induced proliferation, it is possible that proliferation 
induced by BIC alone was via non-genomic pathways resulting in an agonistic response – this 
could be determined by using inhibitors of translation or transcription (Bhat-Nakshatri et al., 
2009). 
2.4.4 Vinclozolin alone acted as an agonist 
In vitro studies have shown equivocal results of VIN’s AR antagonist activity.  Kelce et al. (1994) 
identified the metabolites of VIN, M1 and M2, as having potent binding ability at the AR whilst 
reporting that VIN itself had little activity.  Using LNCaP, Wong et al. (1995) found that M2 was 
able to act as an AR agonist at high concentrations (0.2 to 1µM) in the absence of DHT and that 
in cells expressing wild-type AR, it was also able to act as an agonist (at 10µM), apparently 
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inducing a conformation that was conducive to AR binding and transcriptional activation.  At 
lower concentrations, M2 was the most effective anti-androgen, compared to M1.  A more 
recent study found that vinclozolin, M1 and M2 were antagonists for the AR, whilst M2 was 
found to be a partial agonist (Molina-Molina et al., 2006).  
In vivo studies have been more definitive providing evidence for androgen antagonist effects, 
although they have been at artificially high concentrations.   Loutchanwoot, Wuttke and Jarry 
(2008) reported mixed AR antagonist/ER agonist effects in the brain, pituitary, seminal vesicles, 
epididymis and prostate.  This was achieved with a serum level of VIN of 54.65µM ± 3.46µM; 
they did not assess the levels of the metabolites. 
Few studies have looked at VIN in humans.  Zober et al. (1995) looked at the effects of VIN in 
men who worked in a factory synthesising and formulating the compound.  A large percentage 
of the study group, 66%, exceeded the acceptable daily intake amount of 25µg/kg body 
weight/day but yet there was no evidence of health effects (52 vinclozolin-exposed individuals).  
There was, however, an increase in the percentage of men with testicular abnormalities but the 
presence of the abnormalities was not related to average exposure or cumulative exposure.   
Indeed some of the abnormalities reported, such as an un-descended testis that was surgically 
corrected at age two, would have obviously occurred prior to the individual commencing work.  
Despite these results, much work has been done since this report and VIN is still considered a 
potentially endocrine-disrupting environmental chemical due to biological plausibility, its 
ubiquitous presence in the environment and potential interactions with other anti-androgens.  
In this study, VIN alone induced proliferation.  In the presence of DHT, it again acted as an 
agonist although the efficacy was less than when present in the culture medium alone.  This was 
the opposite of what was expected based on previously published studies.  However, 
determination of an accurate EC50 and correct analysis of VIN’s action on LNCaP was hampered 
by the large variability between biological replicates and across experiments. 
Further studies investigating the metabolism of VIN are clearly warranted to establish what 
proportion of antagonistic metabolites were produced after the five day exposure period.  
However, the reported antagonist effect of VIN on proliferation was not supported by this test 
system, there was a lack of discernible activity at physiologically realistic doses and therefore 
further work on VIN was halted. 
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2.4.1 Summary 
To summarise, the results indicated that proliferation and PSA secretion were robust and 
sensitive end-points that could be utilised to study androgenic effects. 
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3. Microarray analysis of miRNA expression 
3.1 Introduction – Androgen-responsive miRNAs 
miRNAs have been implicated in various diseases, especially cancer.  To date, over 150 studies 
have been published that have profiled miRNAs from clinical specimens at different stages of 
PCa or assessed miRNA in vitro.  As was previously mentioned in Chapter 1, there has been a 
large degree of discordance between the profiling studies in PCa and few studies have reached 
the same conclusions regarding up- or down-regulation of specific miRNA.   
Aside from clinical PCa specimens, miRNA profiling has also been conducted in vitro. Of note, 
the four studies mentioned below assessed miRNA expression in prostate epithelial cells 
including LNCaP: Table 3. 1 summarises the findings. 
Ambs et al. (2008) profiled miRNAs in PCa tissues and prostate epithelial cell lines.  They 
identified seven miRNAs that were significantly dys-regulated; all, except miR-338, were found 
to be down-regulated by treatment with R1881 at either 12, 24 or 48 hours.  They also identified 
putative AR binding sites in the flanking sequences of miRNA, indicating that these miRNA may 
be under the transcriptional control of the AR.   
The Ribas et al. (2009) study was conducted in LNCaP and LAPC-4 both of which are AR positive 
but LAPC-4 is castration resistant. Using microarray technology, they revealed that seven 
miRNAs were up-regulated by treatment with R1881 for 72 hours in both cell lines.  
Waltering et al. (2010) conducted a large study of miRNAs in various cell lines (including parent 
LNCaP and derivatives), xenografts and clinical samples of differing origins.  To assess androgen-
regulated miRNA, cells were treated with DHT for 4 or 24 hours, and measured by microarray: 
17 miRNAs were up- or down-regulated > 1.5 fold with DHT in LNCaP or VCaP.  Interestingly, the 
DHT-regulated miRNAs in the cell lines were quite different from the miRNAs altered by 
castration in xenografts: only four miRNAs (miR-10a, -141, -150* and -1255-5p) were regulated 
in both cell lines and at least two intact-castration xenograft pairs.  They suggested that perhaps 
the in vitro response was immediate whereas xenografts showed the long-term effect of 
androgen deprivation. 
Murata and colleague’s (2010) sequencing study revealed 431 androgen-regulated short RNAs 
(androgen R1881 for 24 or 48 hours): eleven miRNAs were identified as androgen inducible.  
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Table 3. 1 - miRNAs dys-regulated by androgen treatment in LNCaP prostate epithelial cells 
miRNA Waltering Ribas Murata Ambs 
let-7d  Up (1.7)   
let-7g  Up (1.8)   
miR-106a  Up (1.9)   
miR-106b   Up (>1.5) – 24 hrs  
miR-10a Down    
miR-1225-5p Down    
miR-125b   Up (>2.0) – 48 hrs  
miR-126-5p    Down (2.2) 
miR-141 Up  Up (>1.5) – 48 hrs  
miR-146b    Down (1.4) 
miR-148a  Up (3.3) Up (>1.5) – 24 hrs  
miR-150* Down    
miR-15b  Up (1.6)   
miR-16  Up (2.7)   
miR-17-5p  Up (1.7) Up (>2.0) – 24 hrs  
miR-181b-1    Down (1.9) 
miR-181c    Down (2.0) 
miR-193a-3p Up    
miR-19b  Up (1.5)   
miR-200a   Up (>2.5) – 24 hrs  
miR-20a  Up (1.7)   
miR-20b  Up (2.7)   
miR-21 Up Up (2.1)   
miR-219-5p    Down (2.3) 
miR-22 Up  Up (>2.0 at 24 hrs); Down (>1.5 at 48 hrs)  
miR-221 Down   Down (2.0) 
miR-27a   Up (>2.0) – 24 hrs  
miR-29a  Up Up (2.9)   
miR-29b Up Up (2.1) Up (>3.0 at 24 hrs): Down (>2.0 at 48 hrs)  
miR-29c  Up (3.6)   
miR-30a-5p   Up (>2.0) – 24 hrs  
miR-30b   Up (>1.5) – 28 hrs  
miR-32 Up    
miR-338    Up (3.1) 
miR-494 Up    
miR-594  Up (2.7)   
miR-630 Down    
miR-93  Up (2.1)   
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miRNA Waltering Ribas Murata Ambs 
miR-940 Down       
Where known, the degree of fold change is indicated in the table. 
Ribas et al., 2009:  miRNAs greater than 1.5-fold by R1881 treatment for 72 hours in LNCaP and LAPC-4.  
Actual concentration that causes the induction is unknown but could be 0.1, 1 or 10nM (not specified in the 
paper). 
Murata et al., 2010: Identified by RNA sequencing and confirmed by qRT-PCR.  All up-regulated by > 1.5-fold at 
respective exposure time.  
Waltering et al., 2010: Although Waltering reported 17 miRNAs dys-regulated > 1.5-fold, for some miRNA it 
was unclear which cell line they were referring to (and the necessary information could not be found even 
within the supplementary data).  Therefore they are excluded from the table.  However, for completeness, 
they are miR-194 (down) and miR-638 (down).  miR-375 was also dys-regulated in VCaP.  Treatment is in 
LNCaP-pcDNA3.1 with 10nM or 100nM DHT for 24hrs.   
Ambs et al., 2008: LNCaP were treated with 10nM R1881 for 24hrs. 
 
As shown in Figure 3. 1 overleaf, the reports of androgen-regulated miRNAs differ: this is likely 
to be due to factors such as the compound used, length of exposure, compound concentrations, 
culturing conditions and cell line sensitivity to androgens.  
Interestingly, the level of the AR might play a part in determining androgen-responsive miRNA: 
for example miR-141 has been reported to be induced by androgens but only in LNCaP-ARhi 
(LNCaP transfected with AR receptor to give 4-6 fold increase in AR): in the normal LNCaP miR-
141 was not altered by androgens (Waltering et al., 2010). 
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Figure 3. 1 - Androgen-regulated miRNAs identified from four different studies 
Data taken from Ambs et al. (2008), Murata et al. (2010), Ribas et al. (2009), Waltering et al. (2010). Venn 
diagram produced using Venny software (Oliveros, 2007).  
 
3.1.1 Aims and hypothesis 
Hypothesis: 
 Androgen induced phenotypic change is mediated via miRNA expression 
Aims: 
 To determine whether androgenic chemicals can elicit a miRNA response in prostate 
epithelial cells (compound specific) 
 To investigate the temporal aspects of the miRNA response 
 To investigate whether AR agonists and antagonists differentially affect miRNA 
expression 
 Explore potential biochemical targets of differentially expressed miRNA 
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3.2 Materials and methods 
3.2.1 Experimental design 
Temporal changes in miRNA expression in LNCaP were assessed after exposure to a single 
concentration of DHT (physiological androgen; 2nM; physiologically relevant concentration), 
mibolerone (synthetic androgen; 100pM; maximal response concentration) and bicalutamide 
(AR antagonist; 10µM; therapeutically relevant concentration), as compared with the vehicle 
control (ethanol; 0.1% v/v).   
To ensure that the miRNA results were as reliable as possible, new LNCaP were purchased from 
ATCC at passage number 17 and future experiments were conducted within 10 passages of the 
original number.  
The experiment was conducted using triplicate cultures in T25 flasks (Table 2. 2, page 57).  Data 
was collected at 4, 8, 24 and 120 hours of exposure: proliferation was assessed, media collected 
for future PSA analysis and the cells harvested for microarray analysis.  The procedure for 
harvesting cells is described below (Section 3.2.3.1). 
Validation of a number of miRNAs identified as differentially expressed by statistical analysis of 
the microarray data was achieved using qRT-PCR (quantitative real-time reverse transcriptase 
polymerase chain reaction).  
3.2.2 Proliferation and PSA analysis  
Measurement of proliferation and PSA secretion has already been described in Chapter 2, page 
53 (proliferation) and page 55 (PSA).  
3.2.3 Preparation for miRNA analyses 
Total RNA was extracted from the in vitro generated samples.  The success of the microarray, 
and real-time RT-PCR procedures, depends on the extraction of high quality and contaminant-
free RNA. 
3.2.3.1 TRIzol® RNA extraction  
Isolation of RNA using TRIzol® reagent (Invitrogen) is the most widely used extraction method,  
providing robust and reproducible isolation results (Mraz et al., 2009).  TRIzol® is a solution of 
phenol, guanidine isothiocyanate, red dye and other ingredients that can be used to extract 
RNA, DNA and protein from cells or tissues.  Isopropanol and chloroform were supplied by 
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Sigma-Aldrich and were of molecular biology grade.  Glycogen (5µg/µL) was supplied by 
Ambion.  DEPC-treated (diethylpyrocarbonate) water, designated 
ribonuclease/deoxyribonuclease (RNase/DNase) free, and tris-EDTA (TE) buffer (pH 8.0) were 
supplied by Invitrogen. 
In accordance with Invitrogen’s guidelines to prevent RNA degradation by RNAses, all 
consumables were certified RNase-free and RNaseZap (Ambion) was used to decontaminate 
surfaces and pipettes.  Gloves were also decontaminated by RNaseZap® and changed 
frequently.  In this manner, proper handling will ensure the samples do not exhibit appreciable 
degradation when stored over time at -80°C (Mraz et al., 2009). 
RNA was extracted as per the manufacturer’s protocol with a few modifications which are 
detailed in the relevant sections. 
Homogenisation 
At each time point, after collection of media for PSA assessment, the cells were rinsed in 5mL 
PBS.  A volume of TRIzol®, 2.5mL, was added to the flask which was gently agitated to aid 
cellular disruption and homogenisation.  After 5 minutes, the homogenate was collected and 
frozen at -80°C for future processing. 
Phase separation 
After thawing at room temperature, 0.5mL of chloroform was added to each sample, (0.2mL 
chloroform/1mL initial volume of TRIzol® use) and shaken vigorously for 15 seconds.  The 
samples were then incubated at room temperature for 3 minutes before centrifugation at 3,000 
xg for 1 hour at 4°C.  After centrifugation, the clear aqueous phase containing RNA was gently 
removed (top fraction; ~1.5mL), taking care not to disrupt the interphase (cloudy phase 
containing DNA).  
Agilent recommend an additional chloroform extraction for their microarray experiments 
(Agilent Technologies, 2009a).  Therefore, a further 0.5mL chloroform was added to the 
aqueous phase and the ensuing steps (mixing, incubation, centrifugation, removal of the top 
fraction) repeated.   
Precipitation 
To aid precipitation, 1µL of glycogen (co-precipitant) was added to the aqueous phase and 
mixed thoroughly.  The solution was divided into new tubes and 1.25mL of ice-cold isopropanol 
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was added to each tube.  The protocol suggests 10 minutes at room temperature is adequate to 
precipitate RNA but test extractions and previous reports (Mraz et al., 2009) determined that 
the yield was greatly increased by incubations performed at -20°C for longer time periods.  
Therefore the samples were incubated at -20°C for 1 hour 15 minutes and followed by 
centrifugation at 11,900 xg for 10 minutes at 4°C, to produce two RNA pellets per sample.  
RNA wash 
Washing of the pellet reduces salt or phenol contamination (present in the TRIzol® preparation).  
Test extractions showed that additional washing improved the quality assessment 
measurements, so the final protocol included washing the pellet in 9mL total washing solution 
(rather than the minimum suggested volume of 2.5mL).  After the first wash, the samples were 
recombined to produce one pellet per sample.  Samples were washed in wash solution (75% 
ethanol in DEPC-treated water), mixed thoroughly and centrifuged at 7,500 xg for 5 minutes at 
4°C.   
Re-dissolving the RNA 
After washing, excess wash solution was carefully removed and residual ethanol evaporated by 
10 minutes on the heat block (at 55°C) taking care not to over-dry the pellet.  Pellets were re-
suspended in 40µL of TE buffer pH 8.0 and assessed for concentration and quality (see below). 
3.2.3.2 Nanodrop 
The Nanodrop 1000 is a micro-volume ultraviolet-visible spectrophotometer which quantifies 
nucleic acids and generates an absorbance spectrum from 220nm to 350nm using as little 1µL of 
the sample.  TE buffer was used to provide the blank measurement – this was the same buffer 
that was used to suspend the RNA pellet.   
The optical density (OD) of the samples was measured at various wavelengths to assess the 
concentration of nucleic acids and the presence of any residual carryover from the TRIzol® 
(contaminants): nucleic acids absorb at 260nm, proteins at 280nm, TRIzol® contaminants at 
230nm and 270nm (Becker et al., 2010).  An example spectrum of a ‘clean’ sample is presented 
in Figure 3. 2. 
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Figure 3. 2 - Example Nanodrop spectrum 
The absorbance ratio 260/280 is 2.15 and the ratio of 260/230 is 1.93, concentration 51.0ng/µL.  The spectrum 
allows assessment of contamination – a downward shift of the 260/280 and 260/230 ratio indicate 
contamination with phenol and/or salts or protein. 
 
Absorbance at 230nm, 260nm and 280nm gives rise to two important ratios for quality 
assessment: the 260/280 and 260/230 ratio.  A sample generating a ratio of 260/280 > 1.7 and 
260/230 > 1.8 is considered to have minimal interference from contamination. 
3.2.3.3 Bioanalyser 
Assessment of the purity and integrity of the samples was achieved using the Agilent’s 
Bioanalyser and Eukaryote Total RNA Nano kit which generates the RNA integrity number (RIN): 
a sample’s RIN is indicative of the extent of RNA degradation and purity (Schroeder et al., 2006).  
The Bioanalyser produces an electropherogram and a gel-like image which allows the user to 
visually look for degradation, and by comparison to a ladder, allows determination of size of the 
separated fragments.  In addition it measures the ratio between the ribosomal units 18S and 
28S: a 28S/18S ratio close to 2.0 is considered good quality (Becker et al., 2010).  Gradual RNA 
degradation is observed as an increase in the baseline between the 18S and 28S peaks and in 
the ‘fast’ region due to an increased number of shorter fragments.  
The Bioanalyser protocol was followed as per the manufacturer’s protocol and conducted at the 
Genomics Laboratory in the Medical Research Council’s ‘Clinical Sciences Centre’ at Imperial’s 
Hammersmith campus.  
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RNA Nano reagents were equilibrated to room temperature for 30 minutes.  Samples were 
thawed to room temperature and diluted to fall within the assay range (5-500ng/µL).  
A gel-dye mix was created (65µL filtered gel plus 1µL RNA dye concentrate), vortexed 
thoroughly and centrifuged at 13,000 xg for 10 minutes at room temperature.  The gel-dye mix 
was kept on ice and protected from light until loading.   
Samples and the RNA 6000 ladder (1.2µL) were denatured at 70°C for 2 minutes before being 
stored on ice.  A volume (9µL) of the gel-dye mix was pipetted into the relevant well and spread 
through the capillaries of the chip using the Chip Priming Station.  The gel-dye mix (9µL), RNA 
6000 ladder (5µL), denatured ladder (1µL) and samples (1µL) were then added to the relevant 
wells.  After vortexing the chip for 1 minute, it was then loaded into the Bioanalyser for analysis. 
3.2.4 miRNA microarray 
The miRNA microarray is a single-colour microarray.  Each microarray has thousands of 60-mer 
polynucleotide probes that are designed to ‘capture’ and hybridise to complementary miRNA by 
Watson-Crick base pairing.  By labelling the miRNA present in each sample with a green 
fluorescent tag (cyanine-3), the amount of fluorescence detected for each miRNA is 
proportional to the quantity of a particular miRNA present in the sample.  In this way, the global 
expression profile of miRNA in each sample is measured and miRNAs whose levels change in a 
specific phenotype compared with the control phenotype can be ascertained.  The probe design 
is given in Figure 3. 3. 
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Figure 3. 3 - Microarray probe design  
The probe is attached to the glass slide via a stilt (brown) and consists of the hybridisation sequence (black; 
hybridises the miRNA target) and the 5’ extended hairpin (blue; increases specificity and stability of binding 
between probe and miRNA) (Wang, Ach and Curry, 2007).  During the 20 hour hybridisation period, the miRNA 
binds to complementary probes.  Non-specific binding is reduced during the wash steps ensuring that 
mismatched miRNA are washed away.  During scanning, the fluorescence of the cyanine-3 (that was attached 
via a cytosine residue to the miRNA during labelling) is detected.  Reproduced from Agilent Technologies 
(2009b).  
 
Each glass slide consists of 8 individual microarrays on which 8 samples can be run.  The spots 
on the microarrays are referred to as ‘features’ and each feature contains replicate probes: the 
default Agilent feature consists of 100 probes.  For each miRNA, there are 16-20 complementary 
replicate features therefore each microarray consists of approximately 15,000 features (Figure 
3. 4). 
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A – Agilent 8 x 15k miRNA microarray 
 
 
 
 
 
 
 
B -  Enlargement of microarray to reveal features 
 
 
 
 
 
Figure 3. 4 - An Agilent 8x15K glass slide   
The slide consists of eight microarrays which each hybridise one sample (A).  Enlargement of the array reveals 
the individual features (B).  Images generated using FE version 10.7 with false colour image settings: green 
colour range, minimum 8, maximum 640 (from 1 – 65,535) where values less than the minimum are clipped to 
the minimum and values greater than the maximum are clipped to the maximum.  Colour chart ranges from 
black (zero intensity), through blue, cyan, green, yellow, red, magenta and white (maximum intensity).  
 
 
3.2.4.1 Experimental procedure 
Using Agilent’s miRNA Microarray System with miRNA Complete Labelling and Hyb kit, samples 
were prepared for microarray analysis.  The microarray version 3 interrogates 961 miRNAs – 851 
human miRNA (from the Sanger miRBase database version 12) with the remaining 88 probes 
consisting of control probes (15 negative/seven positive) and 66 other non-human miRNA.  
There are currently 1527 miRNAs described in Homo sapiens (November 2011, 
http://www.mirbase.org/cgi-bin/mirna_summary.pl?org=hsa).  
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Since the original analysis, miR-923 has been identified as a fragment of 28S ribosomal RNA 
(rRNA) and miR-1308 as a fragment of transfer RNA (tRNA):  both are therefore no longer 
defined as miRNA (miRBase registry).   
The Agilent miRNA microarray protocol employs the following steps: dephosphorylation, 
denaturing, ligation and drying, hybridisation, washing and scanning.   
Dephosphorylation 
Total RNA was diluted to approximately 50ng/µL in TE buffer.  To an aliquot, 2µL, of the diluted 
sample, 2µL of Calf Intestinal Phosphatase (CIP) Master Mix (0.4µL 10x CIP buffer, 1.1µL 
nuclease-free water, 0.5µ CIP per sample) was added and gently mixed.  The samples were then 
incubated in a heat block at 37°C for 30 minutes, and stored at -80°C until required. 
Denaturation 
A volume, 2.8µL, of 100% DMSO was added to each sample and incubated at 100°C for 7 
minutes; after which the samples were then immediately transferred to an ice-water bath to 
prevent re-annealing. 
Ligation and drying 
The T4 RNA ligase is used to add a fluorescence-modified nucleotide onto the 3’ end of the 
miRNA (Li and Ruan, 2009).  An aliquot, 4.5µL, of the Ligation Master Mix (1µL 10x T4 RNA 
Ligase Buffer, 3µL Cyanine3-pCp, 0.5µL T4 RNA Ligase per sample) was added to each sample, 
mixed by pipetting and briefly spun.  After incubation at 16°C for 2 hours, in which time the 3’ 
end of the miRNA is labelled with a cytosine residue and cyanine-3, the samples were 
transferred to an Eppendorf Concentrator, where they were spun at 45°C until a gel-like pellet 
remained.  The drying process took a minimum of 3 hours; the purpose was to remove any 
residual DMSO whose presence would otherwise adversely affect the hybridisation process.  
The dried samples were stored at -80°C until required. 
Hybridisation  
Hybridisation and the ensuing steps were carried out at the Genomics Laboratory.  The samples 
were re-suspended in 18µL nuclease-free water.  To each sample, 4.5µL of 10x GE blocking 
buffer and 22.5µL of 2x Hi-RPM hybridization buffer was added.  After being mixed and vortexed 
gently, the samples were incubated at 100°C for 5 minutes and transferred to an ice-water bath 
for 5 minutes.  They were then spun quickly to collect any condensation and the entire sample 
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volume loaded onto the microarray gasket (placed in the SureHyb chamber) for hybridisation 
with the microarray for 20 hours in the Agilent oven set at 55°C and 20 rpm.   
The samples were randomised across the slides to reduce any slide bias that may occur and 
reduce the likelihood of loss of a whole treatment group if the slide was to fail. 
Washing 
The kit employs two different wash buffers (Gene Expression Wash Buffer 1 and 2).  After 
hybridisation, the slide/gasket combination was dismantled in Gene Expression Wash Buffer 1 
(at room temperature), before transferring the microarray slide to another dish for 5 minutes of 
washing (Wash Buffer 1, with agitation, room temperature).  A second more stringent wash, 
using Wash Buffer 2, was completed at 37°C for 5 minutes.   
Scanning 
The slides were scanned in the Agilent G2505 scanner as per the settings indicated in Table 3. 2. 
Table 3. 2 - Scan settings 
 
 
 
 
 
3.2.4.2 Additional processing for Batch 1 
Initial image analysis revealed wash artifacts on some microarrays: after consultation with 
Agilent, the slides were re-washed (Wash Buffer 1 at room temperature for 5 minutes) and re-
scanned.  
As Batch 2 did not encounter wash artifacts, the additional washing steps were unnecessary. 
3.2.5  In silico methods 
The images generated by the scanning are stored as Tagged Image File formats.  To generate the 
numeric summaries required for data analysis, the data was extracted using Agilent’s specialised 
image analysis software, Feature Extraction 10.7.3.1 (AFE). 
 
Scan Setting Values for 8 x 15K formats 
Scan region Scan area (61 x 21.6mm) 
Scan resolution (µm) 5 
5µm scanning mode Single Pass 
eXtended Dynamic range (selected) 
Dye channel Green 
Green PMT XDR Hi 100% 
XDR Lo 5% 
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3.2.5.1 Agilent Feature Extraction (AFE) 
The microarray data was extracted using the _D_F_20091031 grid template, the 
miRNA_QCMT_Sep09 quality control (QC) metric set and the miRNA protocol 
miRNA_107_Sep09 amended to include local background subtraction and spatial detrending (as 
this improved the data; represented by a root mean square surface fit value greater than 0).  If 
multiplicative detrending improved the data, in the process adjusting the data to take into 
account regions of the microarray that were brighter or dimmer than other regions, then this 
feature was automatically switched on. 
Each microarray has a number of negative controls positioned across the array, the purpose of 
which is to provide an estimate of the background noise.  Each miRNA is represented by 
multiple probes and replicate features.  For example miR-720 has two different probes which 
differ by 1 nucleotide in length and 16 features (eight of each probe; Table 3. 3).    
Table 3. 3 - Probe sequences for miR-720 
Probe identified Sequence Number of features 
A_25_P00015264 TGGAGGCCCAG 8 
A_25_P00015265 TGGAGGCCCAGC 8 
 
3.2.5.2 AFE Quality Assessment 
The output from AFE contained metrics that were used to assess microarray quality and 
replicate feature variability.  An example report is shown in Figure 3. 5. 
Parameters reported included: estimates of the additive error for the replicated probes 
(measures feature background noise); the percentage of the features that should be called as 
population outliers (indicating samples that should be excluded) and measurements of the 
signal uniformity across the feature replicates.  Based on these parameters, the samples were 
either described as “Excellent”, “Good” or “Evaluate” depending on where they fell within the 
defined thresholds for each classification: in addition to visual inspection of each microarray, 
this was used to identify poor quality samples.  
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Figure 3. 5 - Example AFE report from slide 68, 2_3 
 
3.2.5.3 Overall approach to data processing and analysis 
Quality assessment (QA) indicated that some samples were poor quality (high variability 
between probes) and should be removed from the analysis.  The decision was taken to re-run 
these samples resulting in the samples ultimately being processed in two batches.   To allow 
analysis of the data as a whole, a batch correction method was utilised.  In addition, analysis of 
batch 2 individually was also undertaken.   
Figure 3. 6 demonstrates the workflow for analyses of the dataset as a whole and as individual 
batches.  All analyses (normalisation, filtering, batch correction, Limma modelling) were 
conducted in the R statistical programming language, R version 13.2 (http://www.r-project.org), 
using the “AgiMicroRna” software package, version 2.2, available as part of the BioConductor 
Project (http://www.bioconductor.org).    
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Figure 3. 6 - Data processing approach for combination of batches and analysis of individual batches  
 
3.2.5.4 Normalisation 
Pre-processing steps are those that are performed prior to obtaining the miRNA expression 
levels: i.e. background correction, probe level summarisation and normalisation between arrays.  
The purpose of normalisation is to minimise any experimental biases due to variations in sample 
preparation, such as labelling temperature and hybridisation conditions. 
The AFE software computes a total gene signal (TGS) from all the replicate probes (probe level 
summarisation) – identification of differentially expressed miRNAs could be performed directly 
on the TGS signal.  However, a number of authors have found that normalisation results in 
increased sensitivity and specificity compared with no normalisation. 
Therefore four normalisation methods were assessed in AgiMicroRna and compared with no 
normalisation; those methods were normalisations based on the AFE TGS (scale and quantile) 
and the robust multi-array average (RMA) method with and without background subtraction.  
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The scale method scales the data so that the means of the distribution are equal; it subtracts 
the mean intensity of all data on the array from each intensity measurement on the array, so 
that the mean of the measurements on each array will be zero (Stekel, 2003).  
Quantile normalisation results in the samples all having the same distribution of expression 
values; the mean, median and percentiles will be identical across samples.  As a result, the 
arrays will have reduced variability (Stekel, 2003).  
The RMA estimates the expression measure for each miRNA from all of the probes for that 
particular miRNA.  The arrays are normalised using the quantile normalisation (resulting in the 
samples having the same distribution of expression values), the probe intensities are 
summarised into a single value, transformed to log2 values and an estimate of the miRNA signal 
is produced by fitting a linear model to the transformed data using a median polish procedure to 
estimate model parameters (Irizarry et al., 2003).  RMA can be performed with or without a 
global background correction. 
Assessment of the normalisations was conducted via generation of scatterplots comparing the 
technical replicates from batch 1 with those from batch 2. 
3.2.5.5 Filtering 
After normalisation, removal of those miRNAs that were absent was undertaken with 
AgiMicroRna’s default settings.   
The filtering is based on the AFE-generated “isGeneDetected” flag assigned to each miRNA – a 
flag value of zero indicates that the miRNA is absent in a particular sample, a value of one 
indicates that the miRNA is present.  miRNAs were retained in the analysis if they were declared 
present in at least 75% of samples within at least one experimental condition.  Additionally, the 
miRNA must have been above a specified limit in at least 25% of samples within at least one 
experimental condition.  The limit value was based on the expression of the negative controls 
plus 1.5x the standard deviation.  
3.2.5.6 Reduction of batch effects by ComBat 
ComBat (Combining Batches) is an R script developed by Johnson, Li and Rabinovic (2007); the 
script can be found in Supplementary Materials).  ComBat employs an empirical bayes method 
of batch correction, assuming that the batch effects induce similar deviations in the majority of 
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miRNAs (Reimers, 2010). The aim is to reduce experimental bias introduced by processing 
samples in batches.  
Principal component analysis (PCA) plots were kindly generated in SIMCA-P+12.2 by Dr Jim Ellis 
before and after ComBat to assess the presence, and resolution of, batch effects. 
3.2.5.7 Identification of differentially expressed miRNA by Limma  
AgiMicroRna uses the statistical modelling of the Limma package (Smyth, 2004).  Limma fits a 
linear model to the data fully modelling the systematic part of the data which estimates the 
variability in the data (Smyth, 2004).  In the case of the single channel Agilent microarrays, linear 
modelling is the same as ordinary analysis of variance, or multiple regression, except a model is 
fitted for every gene (Smyth et al., 2011).  Limma then uses an empirical bayes approach to 
moderate the standard errors of the estimated log fold changes (Smyth, 2004), computing a 
moderated t-statistic for each miRNA and contrast (comparison). 
The contrasts of interest are specified (such as a treatment at two different time points) and 
estimated fold changes are calculated.  Simply looking at fold changes between conditions does 
not take into account population variability and the sample size – by using hypothesis testing, 
these issues can be factored in.  For statistical analysis and assessing differential expression, 
Limma uses an empirical Bayes method to moderate the standard errors of the estimated log-
fold changes (Smyth et al., 2011). 
Time course analysis was used to find miRNAs that changed over time differently between the 
treatment groups and vehicle control.  The contrasts for each treatment group were as below: 
 
 
 
The script for the analyses can be found in Appendix… 
 
3.2.5.8 Statistical analysis by BH-FDR 
The null hypothesis is that there are no differences in the mean expression of each miRNA at 
each contrast of interest.  A large number of tests are performed on the data; as such, 
multiplicity of testing needs to be taken into account.  The getDecideTests function in 
cont.difCOMPOUND<- makeContrasts( 
Dif8hr=(hr8.COMPOUND-hr4.COMPOUND)-(hr8.VC-hr4.VC), 
    Dif24hr=(hr24.COMPOUND-hr8.COMPOUND)-(hr24.VC-hr8.VC), 
Dif120hr=(hr120.COMPOUND-hr24.COMPOUND)-(hr120.VC-hr24.VC), 
levels=design)   
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AgiMicroRna summarises the linear modelling results, performs hypothesis testing and adjusts 
p-values for multiple comparisons using the method of Benjamini and Hochberg (BH) (Benjamini 
and Hochberg, 1995).    
For samples with 158 miRNA, even if the samples were identical replicates, in the event of 
multiple testing at the P<0.05, each miRNA would have a random chance of being significant at 
the 5% level.  In this dataset there are 158 miRNAs therefore you would expect to find by 
chance 7.9 significant miRNA (miRNAs that reject the null hypothesis/false positives). This would 
lead to Type I errors:  rejecting the null hypothesis when actually the means of the miRNA 
expression levels are not different. 
The BH method adjusts the p-value for multiple testing and controls the false discovery rate, i.e. 
the number of errors amongst the rejected hypotheses (Benjamini and Hochberg, 1995).  If a 
selection of miRNAs are below the p-value threshold of 0.05, then the expected proportion of 
false discoveries (not actually differentially expressed) within this group are controlled to be less 
than 5% (Smyth et al., 2011).  
3.2.5.9 Clustering 
Unsupervised hierarchical clustering (Eisen et al., 1998) was performed using Cluster 3.0, 
available from http://bonsai.hgc.jp/~mdehoon/software/cluster/software.htm and TreeView 
software, available from http://rana.lbl.gov/EisenSoftware.htm. 
Cluster 3.0 implements an agglomerative hierarchical process whereby the two closest miRNA in 
terms of expression profiles are joined: once joined they are removed from the list of remaining 
items and the next two closest miRNA are joined.  The process is repeated until only one item 
remains (Eisen and de Hoon, 2002).  miRNAs are joined by short branches if they are very similar 
to each other whilst longer branch lengths indicate decreased similarity (Eisen and de Hoon, 
2002).  Cluster 3.0 also returns correlation coefficients for each grouping: the non-parametric 
Spearman’s rank correlation method is more robust against outliers than Pearson correlation 
(Eisen and de Hoon, 2002).   
In this study, data was adjusted by median centering, normalised and clustered using Spearman 
rank correlation similarity metric with average linkage (Enerly et al., 2011).  For all clustering 
analyses, green means negative expression compared to the median of all samples, red means 
positive expression and black means equivalent to.  
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3.2.6 Validation of microarray results using qRT- PCR 
Typically miRNAs that are identified as having altered expression levels in the microarray 
expression data are validated using qRT-PCR. 
qRT-PCR is a two-step method which employs the enzyme reverse transcriptase to generate 
complementary DNA (cDNA) – this is then followed by PCR amplification (denaturation, 
annealing and extension).  The measurement for each sample is taken in the exponential phase 
as this phase exhibits the least variability and is the most reliable (Figure 3. 7).   
 
Figure 3. 7 - PCR phases in log view (delta Rn vs cycle) 
miR-494 expression over 4 concentrations.  The PCR product is doubled during the exponential phase, gradual 
consumption of reagents occurs during the linear phase and product generation ceases during the plateau 
phase when the reagents are exhausted.  Real-time takes the measurement in the exponential phase.  Samples 
A-D all have differing starting amounts of total DNA (10ng to 10pg, three replicates).  Despite the difference 
between each sample being 10-fold (10-fold-dilution series), all the samples seem to plateau at a similar point, 
indicating that if this was measured by typical end-point PCR, the interpretation would be, wrongly, of equal 
expression of miR-494.  Abbreviations: CT = cycle threshold, cycle at which the sample reaches fluorescence 
intensity above the background threshold; Rn = normalised reporter, fluorescent emission value of the 
reporter dye divided by that of the passive reference dye ROX; delta Rn = difference between the Rn of a 
sample and the Rn of early cycles before detection.  
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3.2.6.1 TaqMan® probes 
To measure miRNA levels, Invitrogen designed probes that use the TaqMan® chemistry (Figure 
3. 8).  The fluorescence of each sample at each measurement point is related to the 
accumulation of the PCR product by virtue of the use of the fluorescent TaqMan® Probe.  
 
 
 
Figure 3. 8 - Applied Biosystems miRNA TaqMan chemistry   
The first step of the two-step mechanism is hybridisation of the stem-loop RT primer to the 3’ end of the 
mature miRNA.  The TaqMan® probe is an oligonucleotide probe with a high-energy reporter dye such as 6-
carboxy fluorescein (FAM™) or VIC® attached at the 5’ end and a low-energy minor-groove-binder (MGB) 
quencher molecule at the 3’ end.  When the probe is intact, the reporter dye’s emission is suppressed by the 
quencher – by virtue of fluorescent resonant energy transfer (FRET).  During the annealing stage of PCR, the 
probe anneals between the forward and reverse primer.  As the polymerase progresses down the cDNA 
template adding bases, it encounters the probe and to be able to continue elongation of the nascent amplicon 
it cleaves the probe (5’ exonuclease activity): as a result the distance between the reporter and quencher is 
increased and FRET is stopped.  When the sample is excited by a light source, a fluorescent signal is produced – 
the fluorescence is captured in real-time and used to produce the amplification plot (Chen et al., 2005).  
Reproduced from Applied Biosystems (2011).  
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3.2.6.2 Experimental methods 
Verification of miRNA expression results was determined using Applied Biosystem’s TaqMan 
MicroRNA Assays as per the manufacturer’s protocol.  The protocol is a two-step protocol of 
reverse transcription followed by PCR amplification. 
Reverse transcription (RT) 
Total RNA was diluted to 2ng/µL.  A master mix of RT reagents was made consisting of 100mM 
dNTP mix, MultiScribe™ Reverse Transcriptase (50U/µL), 10x Reverse Transcription buffer, 
RNAse inhibitor (20U/µL) and RT-PCR grade water.  In addition, a master mix omitting the 
reverse transcriptase was made to generate a negative control (no-RT) – if there was 
subsequent amplification of this control then this would indicate that the PCR primers were able 
to amplify genomic DNA.   
Seven µL of the master mix was combined with 5µL total RNA and 3µL of the relevant 5x RT 
primer to produce a 15µL reaction volume per sample. The reaction tubes were loaded into the 
ABI Prism 7700 Sequence Detection System thermocycler and incubated, as per Table 3. 4.  With 
all steps, the reactions and reagents were maintained on ice and RT reactions performed in 
singlet. 
Table 3. 4 - RT and PCR conditions 
 Stage Temperature 
°C 
Time 
RT conditions   
 Holding 16 30 min 
 Holding 42 30 min 
 Holding 85 5 min 
 Holding 4 ∞ 
PCR conditions   
 Holding 95 10 min 
 
Cycling 
95 15 sec 
 60 1 min 
Heated lid function on. 
 
Polymerase Chain Reaction (PCR) 
All volumes refer to one reaction; in reality, creation of mastermixes, whilst reducing variability, 
result in loss of reagents during transfer, therefore percentage excesses were built into the 
calculations.   
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TaqMan Universal PCR Master Mix II (10µL) was added to nuclease-free water (7.67µL), the 
relevant 20x TaqMan Small RNA Assay (1µL) and an aliquot of the appropriate RT product 
(1.33µL).  The reaction mixture (20µL) was added to the well of a 96-well plate and the plate 
sealed with Optical Film.  The plate was centrifuged briefly and kept on ice until loading into the 
Applied Biosystems 7500 Fast Real-Time PCR System. 
All PCR reactions were run in triplicate to provide technical replicates.  In addition to the no-RT, 
a ‘no-template control’ (no-TC) was also run to ensure the reagents were free of contaminants  
– in this case, template was substituted with RT-PCR grade water. 
3.2.6.3 The ΔΔCT method (comparative CT method) 
This method developed by Schmittgen and Livak (2008) allows the user to compare the 
normalised CT values (normalised to endogenous reference) against a calibrator sample (e.g. the 
vehicle control at the relevant time point) and generate fold change differences in miRNA 
expression.  To demonstrate the analysis, an example is provided in Table 3. 5. 
Although the target and reference were amplified in separate wells, they are derived from the 
same input RNA and any factors that impair the amplification of the target will also affect 
amplification of the reference (assuming the efficiency of both is equal) essentially forming a 
paired analysis.  In this manner, the total amount of RNA input, does not impact adversely on 
the downstream analysis (reduction of variance) and the role of the endogenous reference is 
incorporated.   
A central assumption of the ΔΔCT method is that both target and the endogenous control are 
amplified with equal efficiency. Therefore to use this method, this assumption must be tested 
by a validation study and the proper choice of normalising control must be made. 
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Table 3. 5 - Example of the comparative 2
-ΔΔC
T method 
Sample description CT miR CT RNU6B Δ CT   ΔΔCT Fold change 
  A B C D E 
 Control 1 17 25.1 -8.1 
  
 Control 2 18 26 -8.0 
 Control 3 19 27.2 -8.2 
Average ± SD   -8.1 ± 0.1 0.0 ± 0.1 1 (0.93-1.07) 
 Treatment 1 15 25 -10 
  
 Treatment 2 15 25 -10 
 Treatment 3 15 25 -10 
Average ± SD   -10 ± 0.0 1.9 ± 0.1 0.27 (0.29-0.25) 
Column A:  CT miR is the mean CT of the technical replicates for target miRNA 
Column B:  CT RNU6B is the mean CT of the technical replicates for the endogenous reference 
Column C:  ΔCT is the CT of the miR minus the CT of the normaliser (CT miR - CT RNU6B) 
Column D:  ΔΔCT is the difference between the ΔCT of the control and the treatment (ΔCT control - ΔCT 
treatment).  The SD of the ΔΔCT control is treated as a constant.  The variance (standard 
deviation, SD) of the treatment is carried through using standard propagation of errors:  
√(SD.treatment
2
+SD.control
2
) 
Column E: As the CT values are functions of exponential amplification (non-linear), the values must be 
converted using 2
^-ΔΔCT
.  The relative quantity of the treatment to the control is given with 
the lower and upper range in brackets.  The upper range is the fold change plus the SD, 
bottom range is the fold change minus the SD (2
^-ΔΔC
T
±SD
).  The asymmetry of the error is due 
to the conversion of the exponential CT values into linear comparisons.
 
 
3.2.6.4 Normalising control  
The purpose of the control is to normalise expression to the amount of RNA loaded in the 
reactions.  Unlike mRNA analysis, which commonly uses GAPDH or actin as normalisation 
controls, there is no universal endogenous control for miRNA qRT-PCR normalisation.  The small 
nucleolar RNA RNU6B was chosen as the endogenous control as it has been previously used as a 
normalisation control in a prostate cancer study and shown to be stably expressed (Ozen et al., 
2008).  
3.2.6.5 Assessment of efficiency 
One of the control samples was chosen as a representative sample.  Five different total RNA 
quantities, ranging from 10ng down to 10pg, were reverse transcribed and amplified (as 
described above).  
The CT for each miRNA at each dilution was plotted (Log total cDNA ng vs CT) and the slope of 
the line determined – the efficiency was calculated using: 
Efficiency = (10(-1/slope) - 1) x 100 
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3.3 Results 
3.3.1 Phenotypic anchor 
Cells were plated in steroid-depleted media for 2 days before the addition of a single 
concentration of each compound (BIC 10µM, DHT 2nM, MIB 100pM).  Measurements of cell 
number, PSA secretion and miRNA expression were taken at 4, 8, 24 and 120 hours.   The lower 
concentration of MIB was chosen due to the earlier observation that MIB was more potent at 
inducing PSA and proliferation than the natural androgen DHT. 
Proliferation 
Proliferation of LNCaP was assessed over 4 time points for each of the test compounds.  The 
temporal experiment illustrated that as time progressed, proliferation and PSA secretion 
increased (Figure 3. 9). 
Overall, BIC induced a similar trend as the vehicle: there was a slight increase in cell number 
over the study period.  Comparing BIC with the time-matched control, there was a statistically 
significant decrease in cell number at 8 hours, which indicated a possible early response to BIC 
however it must be noted that that the cell number for 8 hours in VC-treated cells appears high.  
At 120 hrs, there is a statistically significant (P<0.01) decrease in cell number, 18% reduction, 
compared with the vehicle control. 
In the case of DHT, there was a time-dependent increase in cell number, reaching a statistically 
significant increase above the time-matched control at 120 hours (122% above the 120 hour 
control).   
Treatment with MIB elicited a time-dependent increase in cell number reaching statistical 
significance at 120 hours (190%, P<0.001). 
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A – Proliferation 
 
B – PSA 
 
Figure 3. 9 - Proliferation and prostate specific antigen (PSA) secretion over time with compound treatment   
Presented as mean of triplicate or quadruplicate cultures with SD error bars.  Statistical analysis using 1-way 
ANOVA for each time point with Dunnett's multiple comparison post hoc test comparing to the control time 
point.  P<0.05 *, P<0.01 ** P<0.001 ***. 
 
 
In conjunction with assessment of proliferation, PSA secretion was assayed at each time point. 
In the control group there was a trend of a steady increase in PSA over time, with an 
approximate 3-fold increase at 120 hours compared with 4 hours.  
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BIC also exhibited a time-dependent increase in PSA: at 120 hrs the level in media was greater 
than 3-fold higher than the level observed in the time-matched control (not statistically 
significant). 
DHT displayed the biological trend of increasing PSA as exposure time increased; there was a 
7.3-fold increase and 10.3-fold increase compared with the control at 24 hours and 120 hours, 
respectively.   
By 24 hours, MIB had induced an 8-fold increase in PSA and, by 120 hours, PSA was 36.2 times 
higher than observed in the time-matched control.   In terms of potency, despite the 
concentration in the media of MIB being 20 times less than DHT, the induction of PSA secretion 
was 3 times more potent (36-fold increase compared with 10.3-fold).  
3.3.2 Extraction Quality Assessment 
Prior to microarray analyses, the quality of the extracted RNA was assessed for impurities and 
degradation. 
All samples had 260/280 ratios greater than 2.0 (mean 2.10, minimum 1.96, maximum 2.24) and 
260/230 ratios greater than 1.8 (mean 2.12, minimum 1.77, maximum 2.86).  The Nanodrop 
results indicated that assessment of the miRNA levels in the samples would not be hindered by 
significant levels of contaminants (hybridisation chemistry in the microarray is known to be 
affected by contaminants from TRIzol®).    
The Bioanalyser was used to measure RNA degradation and genomic contamination: peaks in 
the ‘post’ region would indicate the presence of DNA contamination, thus reducing the certainty 
of RNA quantification; peaks in the ‘inter’ and ‘fast’ region would indicate degradation.  An 
example electropherogram is presented in Figure 3. 10. 
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Figure 3. 10 - Example electropherogram of slightly degraded RNA (A) and intact RNA (B)  
The X axis has units of seconds (s) whilst the Y axis is fluorescence units (FU).  Sample A has a RIN of 7.6; for 
sample B, the RIN is 10.  Both samples are suitable for microarray analysis.  The recommended RIN threshold is 
7.  Peaks in the inter and fast region indicate degradation (Schroeder et al., 2006).  
  
 The RNA integrity number (RIN) was automatically generated from the electropherogram.  All 
samples used for microarray analysis had a RIN greater than 7.6 (mean 9.3, minimum 7.6, 
maximum 10), indicating that the samples would be of suitable quality for microarray analysis 
and had little/minimal presence of genomic DNA that would have interfered with RNA 
quantitation.  
3.3.3 In silico processing 
To investigate miRNA expression, microarray technology was utilised.  
3.3.3.1 Agilent Feature Extraction (AFE) 
The AFE software was used to extract the data from the TIFF files generated by the scanner. 
Forty-eight samples were originally subject to microarray analysis (Batch 1) - 28 samples passed 
the quality control metrics, exhibiting values that fell within the “Excellent” to “Good” 
thresholds.  As previously mentioned, to improve the data set, samples that failed the QA were 
re-run in Batch 2 (with six technical replicates).  Figure 3.11 describes the overall microarray 
process. 
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Figure 3. 11 - Experimental workflow for microarray analysis 
Where samples were re-run, the same extracted total RNA was used.  
 
Of Batch 2, 23/24 samples passed the AFE metrics.  Generally, the second batch had an 
improvement in the QC metrics, exhibiting a reduction in the additive error, lower background 
noise and less outliers (Figure 3.12).  
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A - Batch 1 
B - Batch 2  
 
 
 
B – Batch 2 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. 12 - Coefficient of variation for replicated probes of Batch 1 (A) and Batch 2 (B) 
The probe level replication allows the coefficient of variation (CV) for every miRNA probe set in each array to 
be calculated.  The median is reported – the lower the CV median, the better the array reproducibility. The 
solid black line represents the median, the area above it the upper quartile and the area below the lower 
quartile.  The whiskers represent the maximum and minimum values and the points outside the whiskers are 
potential outliers. As can be seen the number of potential outliers in batch 2 are much reduced compared with 
batch 1. 
 
Figure 3. 13 shows false colour images of the microarrays.  Crosses (x) indicate which arrays 
passed and failed the QA. One sample that failed the QA (J1) was included in analyses as it 
passed three of the four QC metrics (classed as “Excellent”), it was close to the boundary on the 
metric that it failed and there was not enough sample remaining for it be re-run.  
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Figure 3. 13 - False colour images of Batch 1 and Batch 2 microarrays 
A-F Batch 1; G-I Batch 2.  Colour scale minimum 56 - maximum 640.  Batch 2 had a reduction in background 
fluorescence as shown by the darker background, both within the array and the surrounding area.  
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3.3.3.2 Normalisation between arrays 
For normalising between arrays, Pradervand et al. (2009) compared scale, quantile, variance 
stabilising and their own method of invariant normalisation against no normalisation.  They 
found all methods performed better than no normalisation and the most robust methods were 
invariant or quantile.  Rao et al. (2008) compared cyclic loess, quantile and median with no 
normalisation.  Like Pradervand, they found quantile normalisation worked the best at reducing 
variance, suggesting it is a suitable method for normalisation.  Analysis of Agilent’s miRNA 
microarray system using RMA (probe level summarisation) has been reported; the results of 
which were that RMA of the non-background-corrected signal produced more precise signals 
than either RMA with background or the quantile normalised TGS (Lopez-Romero et al., 2010).  
Compared with other methods, such as those employed by MAS5.0, the RMA protocol had good 
accuracy and precision of measurements (Irizarry et al., 2003).  
In this study, scatterplots were used to assess the normalisation methods.  In agreement with 
the afore-mentioned studies, RMA with quantile normalisation was found to be suitable for data 
processing.  
3.3.3.3 Filtering 
Based on miRBase version 12, 851 human miRNAs were present on each microarray, consisting 
of 680 dominant miRNA and 171 *miRNA.  After filtering, Batch 1 contained 165 human miRNA 
of which 7 were exclusive to this batch.  Batch 2 contained 302 human miRNA of which 144 
were only found in this batch.  Of these, 158 were common to both batches (Figure 3. 14).  
 
 
Figure 3. 14 - Venn diagram showing distribution of miRNA across the batches 
Results were visualized using the Venny program (Oliveros 2007). 
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miRNAs which are derived from the subordinate arm are, by definition, deemed to have lower 
expression values, and are suffixed with ‘*’ (termed miRNA*).  Incidentally, where miRNAs from 
both arms have equal expression, they are suffixed with either ‘3p’ or ‘5p’.   
Of ComBat data: 8.3% were star (*) forms whereas 20.2% of Batch 2 were star forms. Of those 
61 miRNA* found in Batch 2, 59/61 (96.7%) were found in the bottom two expression levels 
(Log2 values 6 or 7).  This indicates that the greater sensitivity of the second batch allowed star 
forms, which are generally lower expressed, to be measured (Figure 3. 15). 
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Figure 3. 15 - Expression values as a percentage of miRNAs expressed in LNCaP 
ComBat 1+2 represents the 158 miRNAs that were common to both batches; mean Log2 expression values are 
after normalisation and batch adjustment.  Batch 2 represents the 302 miRNAs found in this batch; Log2 
expression values are after normalisation (no batch correction).    The dataset combining both batches has a 
smaller dynamic range (7-orders of magnitude, Log2) compared with Batch 2 (8-orders of magnitude, Log2).  
There is increased sensitivity in Batch 2, shown by Log2 expression value of 6 being measured in this batch, but 
not in the combined batches.  
 
miRNA names can change, therefore for future tracking it is important to note the accession 
number which is a unique identifier and will not change over time.  For this reason, the details 
of all the human miRNAs present on the arrays can be found on the DVD supplied with the 
thesis.  
 Table 3. 6 documents those miRNA found in each batch after filtering. 
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Table 3. 6 - miRNAs retained in each batch after filtering 
Seven miRNAs were present only in Batch 1, 144 present only in Batch 2 and 158 miRNAs were found in both 
batches. 
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3.3.3.4 ComBat 
The 158 miRNAs found in both batches were manipulated using ComBat, the empirical bayes 
method of batch correction.  Analysis of the two groups of data before and after batch 
correction was performed illustrating that the batch correction was successful in bringing the 
two datasets closer together (Figure 3. 16). Despite the fact that replicate L2 was much further 
away from its replicates, it was decided to retain this sample in the dataset as it had passed the 
QA and there was not an obvious fault that would allow its exclusion. 
A – Before ComBat 
 
 
 
 
 
 
B – After ComBat
 
 
Figure 3. 16 - Scores plots of miRNA data before (A) and after (B) ComBat 
Scores plot of a 3 component PCA model with pareto scaling.  Principal components 1 and 2 (t[1] and t[2]) 
describe the greatest variation in the model.  Batch 1 are coloured in green, batch 2 in red.  Produced in 
SIMCA-P+ 12.2 by Dr James Ellis. 
 
 
Additional plots of the data after ComBat adjustment (samples plotted by time) are provided in 
the Appendix, Figure 7. 1, page 229.  At 4 hours the samples from each batch were well 
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interspersed, whilst at 8 hours samples tended to be closest to other samples within the same 
batch, exhibited by the vehicle control samples grouping by batch rather than by treatment.   At 
24 hours, the samples were intermingled between and across the batches.  At 120 hours, the 
batch adjustment was less successful as the batches remained separated; however, the 
treatment replicates were tightly grouped.  
Although it was clear that some batch adjustment was necessary to enable analysis of the 
microarray data, the batch correction was not entirely successful in removing batch effects.  
Therefore to maintain confidence in the dataset, it is important that the miRNA results are 
validated. 
3.3.4 Discovery of differentially expressed (DE) miRNA (ComBat dataset) 
For data collected over multiple time points, time course analysis can be implemented in 
Limma:  it allows identification of miRNAs which respond differently over time in each treatment 
group relative to the control.  For example, for DHT at 120 hours, the comparison was: 
(DHT at 120 hours - DHT at 24 hours) – (control at 120 hours - control at 24 hours). 
Any miRNA that was determined to be differentially expressed (DE) at 120 hrs would have 
exhibited higher or lower expression than at the 24 hour time point, having taken into account 
how that miRNA may have changed over time in the control condition. 
As mentioned in Section 3.2.5.8, page 89, the method of Benjamin-Hochberg was used to 
control the false discovery rate (fdr.pval). 
3.3.4.1 Vehicle control over time 
At 8 and 24 hours, no DE miRNA were identified.   At 120 hours there were eight miRNA that 
were DE compared with 24 hours; seven of the eight miRNA exhibited higher expression at 120 
hours  (fdr.pval <0.3; Table 3. 7; Figure 3. 17), with fold changes that varied from 1.2 fold to 1.8-
fold.  Only one miRNA, miR-7, exhibited lower expression at 120 hours (Figure 3. 18). 
Additionally, the top five miRNA altered in both directions irrespective of p-value were also 
investigated; interestingly two different clusters were identified; three miRNAs of a six member 
cluster (miR-20a, -17 and -18a) were in the top five miRNA ranked by fold change (downwards 
direction).  Cluster information of miRNAs of interest is given below in Table 3. 8. 
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Although the FDR adjusted p-values were not considered significant after multiple testing, it was 
interesting to note that all three members of the miR-29 family cluster were up-regulated at 
least 1.6 fold at 120 hours compared with earlier.     
 
Table 3. 7 - miRNA expression between VC at 120 hours and 24 hours ranked by fdr.pval and fold change 
(ComBat dataset) 
miRNA C/some Fold 
change 
fdr.pval 
Ranked by fdr.pval (<0.3)   
miR-99a 21 1.5 UP  0.11452 
miR-182 7 1.3 UP 0.11452 
miR-221 X 1.6 UP 0.11452 
miR-196b 7 1.3 UP 0.11452 
miR-1290 1 1.6 UP 0.11452 
miR-30a 6 1.6 UP 0.12676 
miR-181b 1 and 9 1.2 UP 0.15404 
miR-7 9,15 and 19 1.6 ↓ 0.19648 
Top 5 miRNA (ranked by fold change in upwards direction) 
miR-15a 13 1.8 UP 0.32522 
miR-29b 1 and 7 1.7 UP 0.63377 
miR-29a 1 and 7 1.7 UP 0.42147 
miR-29c 1 and 7 1.6 UP 0.55634 
miR-30a 6 1.6 UP 0.12676 
Top 5 miRNA (ranked by fold change in downwards direction) 
miR-20a 13 1.5 ↓ 0.5778 
miR-1207-5p 8 1.5 ↓ 0.51057 
miR-7 9,15 and 19 1.6 ↓ 0.19648 
miR-18a 13 1.7 ↓ 0.39748 
miR-17 13 1.7 ↓ 0.32663 
C/some = Chromosomal location of pre-cursor miRNA 
Fold = the fold change value between the two experimental conditions: up-arrow means that miRNA is up-
regulated at 120 hrs compared with 24 hours; down-arrow means repressed.   
fdr.pval = p-value adjusted for multiple testing (Benjamini-Hochberg procedure). 
Where miRNA are found on more than one chromosome, it may be that they arise from the same or different 
stem-loop precursors on different chromosomes (i.e. miR-29-b-1 on chromosome 7 and miR-29-b-2 on 
chromosome 1). 
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Figure 3. 17 - miRNAs identified with fdr.pval of less than 0.2 at 24 hours and 120 hours   
ComBat adjusted and Log base 2 transformed microarray expression values, are presented as the mean of 
triplicate cultures with SD error bars.  These miRNAs had fdr.pval of less than 0.2 - it can be expected that, on 
average, 1.6 of these miRNA (20%) may be falsely identified as rejecting the null hypothesis (that they are not 
differentially expressed).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. 18 - Expression levels of miR-7 in the vehicle control treated group 
ComBat adjusted and Log base 2 transformed microarray expression values, are presented as the mean of 
triplicate cultures with SD error bars. 
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Table 3. 8 - Cluster information for miRNAs (fdr.adj p-val<0.3) and top five ranked by fold change  
Clusters 
mir-15a/mir-15b/ mir-16-2 
mir-99a/ Let-7c 
mir-29a/mir-29b-1 
mir-29-b2/mir-29c 
mir-182/mir-183/ mir-96 
mir-7-2/mir-1179/mir-3529 
mir-221/mir-222 
mir-181b/ mir-181a 
mir-17/mir-18a/mir-20a/mir-19a/mir-19b-1/mir-92a-1 
The miRNA registry database, miRBase (www.mirbase.org), provides the chromosomal positions of each 
miRNA and clustering information.  miRNAs found within 10 kilobases of each other are considered to be 
clustered and are likely to be co-regulated.  Those miRNA that are DE are underlined. Lower case mir (rather 
than miR) refers to the stem-loop structure rather than the mature form. Where a mature miRNA is produced 
from a stem-loop precursor which has two locations, it cannot necessarily be known which location gave rise 
to the mature miRNA.  In the case of miR-181a/b, each miRNA arises from two stem-loops on different 
chromosomes with miR-181a-1 being clustered with miR-181b-1 and miR-181a-2 with miR-181b. 
 
3.3.4.2 Mibolerone over time 
At 8 hours and 24 hours, none of the miRNAs were identified as being DE compared with the 
earlier time points.  At 120 hours, the microarray data indicated that nine miRNAs were 
identified as down-regulated with respect to 24 hours of treatment and three were up-
regulated (fdr.pval < 0.3; Table 3. 9; Figure 3. 19). 
 
Table 3. 9 - miRNA expression between mibolerone at 120 hours and 24 hours ranked by fdr.pval and fold 
change 
miRNA C/some Fold 
change 
fdr.pval 
Ranked by fdr.pval  
miR-221 X 2.5 ↓ 0.01592 
miR-196b 7 1.5 ↓ 0.15671 
miR-1246 2 1.9 ↓ 0.25493 
miR-1290 1 1.8 ↓ 0.25493 
miR-210 11 1.7 UP 0.25493 
miR-182 7 1.3 ↓ 0.25493 
miR-30a 6 1.8 ↓ 0.28308 
miR-99a* 21 1.2 ↓ 0.28308 
miR-720 3 1.6 UP 0.28308 
miR-105 X 1.1 ↓ 0.28308 
miR-99a 21 1.5 ↓ 0.28308 
miR-7 9,15 and 19 1.8 UP 0.28308 
Top 5 miRNA (fold change upwards direction) 
miR-1207-5p 8 2.1 UP 0.45095 
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miRNA C/some Fold 
change 
fdr.pval 
miR-18a 13 1.9 UP 0.51958 
miR-7 9,15 and 19 1.8 UP 0.28308 
miR-20a 13 1.8 UP 0.74652 
miR-17 13 1.7 UP 0.74652 
Top 5 miRNA (fold change downwards direction) 
miR-30a 6 1.8 ↓ 0.28308 
miR-1290 1 1.8 ↓ 0.25493 
miR-1246 2 1.9 ↓ 0.25493 
miR-26a 3 and 12 2.0 ↓ 0.61722 
miR-221 X 2.5 ↓ 0.01592 
 
C/some = chromosomal location of pre-cursor miRNA. 
Fold = fold change value between the two experimental conditions: up-arrow means that miRNA is up-
regulated at 120 hrs compared with 24 hours; down-arrow means repressed.   
fdr.pval = p-value adjusted for multiple testing (Benjamini-Hochberg procedure). 
Where miRNA are found on more than one chromosome, it may be that they arise from the same or different 
stem-loop precursors on different chromosomes (i.e. miR- 26a-1 from chromosome 3 and miR-26a-2 on 
chromosome 12). 
 
miR-99a, both the star form and mature miRNA, was found to be down-regulated.  Also five of 
those miRNAs found to have changed significantly (P<0.3) over time in the vehicle control group 
were also found to have changed in mibolerone treated over time (e.g. miR-99a, miR-221, miR-
196b, miR-1290 and miR-30a).  The same three members of the miR-17-92 cluster were also 
found to be dys-regulated (by rank, cluster information in Table 3. 10).  Of these 12, four miRNA 
(miR-221, miR-1246, miR-1290 and miR-30a) were found in the ranking table for the top 10 
greatest fold changes. 
 
Table 3. 10 - Cluster information for miRNAs (fdr.adj p-val<0.3) and top five ranked by fold change 
(mibolerone) 
Clusters 
mir-99a/let-7c 
mir-105/mir-767 
mir-182/mir-183/mir-96 
mir-221/mir-222 
mir-17/ mir-18a/mir-20a/mir-19a/mir-19b-1/mir-92a-1 
The miRNA registry database, miRBase (www.mirbase.org), provides the chromosomal positions of each 
miRNA and clustering information.  miRNAs found within 10 kilobases of each other are considered to be 
clustered and are likely to be co-regulated.  Those miRNA that are DE are underlined.  Lower case mir (rather 
than miR) refers to the stem-loop structure rather than the mature form. Where a mature miRNA is produced 
from a stem-loop precursor which has two locations, it cannot necessarily be known which location gave rise 
to the mature miRNA.  In the case of miR-105, the miRNA arises from two stem-loops on the same 
chromosome with both being miR-767.  Incidentally miR-19a, -19b and -92a were not present in batch 1 but 
92a was in batch 2. 
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Figure 3. 19 - miRNAs identified as differentially expressed for mibolerone at 120 hrs versus 24 hours 
(fdr.pval <0.3) 
ComBat adjusted values are presented as the mean of triplicate cultures with SD error bars.   
 
With reference to the phenotypic anchor, at 120 hours of mibolerone treatment, cell number 
had increased 1.9 fold compared with the control and PSA levels were ~36-fold higher than the 
control.  It is reasonable to suggest that the altered miRNA may be associated with the 
increased proliferation and PSA secretion observed in these cultures.  Interestingly the miR-17 
cluster that was previously shown to be down-regulated at 120 hours versus 24 hours of control 
treatment was shown to be up-regulated by the same degree in mibolerone treated cells 
(although not statistically significant).   
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3.3.4.3 BIC over time 
At none of the time points were any miRNA DE at the cut-off value of 0.3.   
3.3.4.4 DHT over time 
Out of the 158 miRNAs present in this dataset, only at 24 hours were there any DE miRNAs: 41 
miRNA were identified (with fdr.pval <0.3, Table 3. 11) with many members of clusters being 
dys-regulated. The vast majority of miRNAs, 90%, were down-regulated at 24 hours of 
treatment compared with 8 hrs: only four miRNAs were up-regulated (miR-494, -1260, -1280 
and -638).  This indicates that the majority of changes occur between 8 and 24 hours and that 
the altered miRNA expression is maintained up to 120 hours of exposure. 
Table 3. 11 - miRNA expression between DHT at 24 hours and 8 hours ranked by fdr.pval (<0.3) and fold 
change.  
miRNA C/some Fold fdr.pval 
Ranked by fdr.pval 
let-7e 19 2.1 ↓ 0.27568 
miR-16 13 and 3 2.4 ↓ 0.27568 
let-7c 21 1.5 ↓ 0.27568 
let-7b 22 1.3 ↓ 0.27568 
miR-494 14 2.5 UP 0.27568 
miR-200b 1 2.3 ↓ 0.27568 
miR-98 X 2.0 ↓ 0.27568 
miR-1290 1 1.7 ↓ 0.27568 
miR-183 7 2.0 ↓ 0.27568 
miR-151-5p 8 1.9 ↓ 0.27568 
miR-23a 19 2.0 ↓ 0.27568 
miR-107 10 2.2 ↓ 0.27568 
miR-23b 9 2.0 ↓ 0.27568 
miR-26b 2 2.3 ↓ 0.27568 
miR-195 17 2.0 ↓ 0.27568 
miR-30c 1 and 6 1.5 ↓ 0.27568 
miR-1260 14 1.7 UP 0.27568 
miR-100 11 1.5 ↓ 0.27568 
let-7a 9,11 and 22 1.7 ↓ 0.27568 
let-7d 9 1.5 ↓ 0.27568 
miR-1280 3 2.3 UP  0.27568 
miR-99a 21 1.5 ↓ 0.27568 
miR-30b 8 2.1 ↓ 0.27568 
miR-1246 2 1.6 ↓ 0.27568 
miR-125b-2* 21 1.5 ↓ 0.27568 
miR-15b 3 2.1 ↓ 0.27568 
let-7i 12 1.6 ↓ 0.27568 
miR-425 3 1.7 ↓ 0.27568 
miR-24 9 and 19 1.9 ↓ 0.27568 
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miRNA C/some Fold fdr.pval 
miR-203 14 1.6 ↓ 0.27568 
miR-638 19 1.4 UP 0.27568 
miR-17 3 2.0 ↓ 0.27568 
miR-25 7 1.5 ↓ 0.27568 
miR-148a 7 2.1 ↓ 0.28423 
miR-374b X 1.4 ↓ 0.28423 
miR-103 5 and 20 2.1 ↓ 0.28423 
miR-15a 13 2.0 ↓ 0.28423 
miR-93 7 1.7 ↓ 0.28423 
miR-221 X 1.5 ↓ 0.28423 
miR-200c 12 1.8 ↓ 0.28423 
 Top 4 miRNA (ranked by fold change in upwards direction 
miR-494 14 2.5 UP 0.27568 
miR-1280 3 2.3 UP 0.27568 
miR-1260 14 1.7 UP 0.27568 
miR-638 19 1.4 UP 0.27568 
Top 5 miRNA (ranked by fold change in downwards direction) 
let-7e 19 2.1 ↓ 0.27568 
miR-107 10 2.2 ↓ 0.27568 
miR-26b 2 2.3 ↓ 0.27568 
miR-200b 1 2.3 ↓ 0.27568 
miR-16 13 2.4 ↓ 0.27568 
C/some = chromosomal location of pre-cursor miRNA. 
Fold = the log2 fold change value between the two experimental conditions: positive values mean that miRNA 
is up-regulated at 24 hrs compared with 8 hours; negative means repressed.   
fdr.pval = p-value adjusted for multiple testing (Benjamini-Hochberg procedure). 
Where miRNA are found on more than one chromosome, it may be that they arise from the same or different 
stem-loop precursors on different chromosomes.  
 
miRNAs whose chromosomal position is within a cluster are detailed in Table 3. 12.  
Significantly, all miRNAs present from miR-16-2/miR-15a/miR-15b cluster have been identified 
as differentially expressed.  Additionally members of the same family (let-7 family), that are 
located in different parts of the genome, are also similarly altered suggesting that these have 
important roles in LNCaP homeostasis, proliferation or PSA secretion. 
Despite indications that these miRNA may be altered, evaluation of the expression values 
revealed there was a high degree of variance in the top ranked miRNAs under 0.3 - only miR-494 
is likely to be truly over-expressed at 24 hours. 
In terms of proliferation and PSA secretion, at 24 hours compared with 8 hours, cell number had 
increased slightly but PSA secretion had increased significantly.  It may be that these miRNAs are 
associated with the increased production of PSA.     
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Table 3. 12 - Cluster information for those miRNAs found to be DE for DHT at 24 hours (fdr.pval <0.3) 
 
Clusters 
mir-16-2/mir-15a/mir-15b 
Let-7c/mir-99a 
Let-7b/let-7a-3/mir-4763 
mir-200b/mir-200a/mir-429 
mir-98/let-7f-2 
mir-96/mir-182/mir-183 
mir-23a/mir-27a/mir-24-2 
Let-7a/let-7f-1/let-7d 
mir-25/mir-106b/mir-93 
mir-200c/mir-141 
mir-195/ mir-497 
mir-30c-1/mir-30e 
mir-100/let-7a-2 
mir-221/mir-222 
mir-30b/mir-30d 
mir-425/mir-191 
mir-23b/mir-24-1/mir-27b/mir-3074 
mir-24-2/mir-23a/mir-27a 
mir-203/mir-3545 
mir-374b/mir-374c/mir-421 
Let-7e/mir-125a/mir-99b 
mir-494/mir-379/mir-411/mir-299/mir-380/mir-
1197/mir-323/mir-758/mir-329-1/mir-329-2/mir-
1193/mir-543/mir-495 
The miRNA registry database, miRBase (www.mirbase.org), provides the chromosomal positions of each 
miRNA and clustering information.  miRNAs found within 10 kilobases of each other are considered to be 
clustered and are likely to be co-regulated.  Those miRNA that are DE are underlined.  Lower case mir (rather 
than miR) refers to the stem-loop structure rather than the mature form. Where a mature miRNA is produced 
from a stem-loop precursor which has two locations, it cannot necessarily be known which location gave rise 
to the mature miRNA. 
 
Although Limma indicated that miR-93 and miR-25 may have been altered after 24 hours and 8 
hours of treatment, analysis of the replicates revealed there was a large amount of variation at 
the 24 hour time point thus making interpretation difficult (Figure 3. 20).   
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Figure 3. 20 - Expression levels of members of the miR-25 and miR-93 in DHT and vehicle-treated groups 
over time  
ComBat adjusted and Log base 2 transformed microarray expression values, are presented as the mean of 
triplicate cultures with SD error bars.   
 
3.3.4.5 Clustering 
Unsupervised hierarchical clustering was performed on the ComBat data set for the normalised 
mean log2 value for each miRNA from each time point.  
To investigate the temporal aspects of miRNA expression, clustering was performed individually 
for the control and treated groups from 4 to 120 hours.  Figure 3. 21 shows that at the earlier 
time points (4, 8 and 24 hours), the samples do not necessarily cluster by treatment group and 
treatment was having little effect on differential mature miRNA expression.  However, by 120 
hours the samples are mostly clustered by their treatment groups indicating that miRNA 
expression is able to distinguish between treatment groups.  
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Figure 3. 21 - Dendrogram of clustering for samples treated with VC, BIC, DHT or MIB at 4, 8, 24 or 120 hours. 
miRNAs were median centered, normalised and clustered using Spearman correlation coefficient (as the 
measure of similarity) and average linkage using Cluster 3.0 with visualisation using TreeView 1.60.  For clarity, 
the heatmap is not displayed. 
 
Aside from identifying the replicates cluster by treatment group, clustering analysis can be used 
to identify miRNAs that have similar expression patterns and may undergo co-ordinated 
expression.  Several miRNA exhibited expression patterns that were highly correlated with 
expression of another miRNA.  For example, the three members of the miR-17-92 cluster found 
to dys-regulated by rank in mibolerone-treated cells at 120 hours exhibited similar expression 
patterns and were highly correlated (Spearman correlation r value of 0.86).  The correlation 
between miR-17 and miR-20a was even more highly correlated (r value 0.979021).  
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Figure 3. 22 - Clustering analysis of 120 hour time point 
miRNAs were median centered, normalised and clustered using Spearman correlation coefficient (as the 
measure of similarity) and average linkage using Cluster 3.0 with visualisation using TreeView 1.60.  Excerpt of 
members of miR-17-92 cluster: this cluster consists of six members: miR-17, -18a, -19a, -19b, -20a and -92.  
Overall correlation for this node was 0.86.  These miRNAs exhibit similar expression profiles.  Green colour 
means negative expression, red means positive expression and black means equal expression compared to the 
median of all samples. 
 
3.3.5 Discovery of DE miRNA (Batch 2) 
As 95.8% of the miRNA from Batch 1 were present in the ComBat dataset and only 52% of the 
miRNA from Batch 2 were present, it was decided to conduct an additional analysis using just 
Batch 2 miRNAs.  In this manner, potentially more miRNA responsive to treatment with the 
compounds could be identified.  Due to the replicate requirements, the only comparisons that 
119 
 
could be made were: VC 4 hours versus VC at 120 hours; VC 120 hours versus DHT at 120 hours; 
and VC 120 hours versus MIB at 120 hours. 
 
cont.dif<-makeContrasts  (DifVC120hr=(hr4.v-hr120.v) 
     Dif120DHT=(hr120.v-hr120.d), 
     Dif120MIB=(hr120.v-hr120.m),  
levels=design) 
 
302 miRNAs were included in the analysis (compared with 158 in the previous analysis).  The 
number of miRNAs significant from fdr.pval <0.1 to <0.3 is given in Table 3.13.  
 
Table 3. 13 - Summary of significant miRNAs at different fdr.pval 
fdr.pval VC 4hrs vs VC 120 hrs VC 120 hrs vs DHT 120hrs VC 120 hrs vs MIB 120 hrs 
0.001 3 0 1 
0.01 6 0 9 
0.1 35 0 18 
0.2 78 0 26 
0.3 131 0 41 
 
Fdr.pval are FDR adjusted p-values using the method of Benjamini-Hochberg to control the false discovery 
rate.  Values are from Batch 2 dataset.  Where VC = vehicle control; DHT = dihydrotestosterone, 2nM; MIB = 
mibolerone 100pM. 
 
3.3.5.1 Vehicle control at 4 hours compared with 120 hours 
Expression levels of a large number of miRNAs were found to be altered between 120 hours and 
4 hours. At P<0.1, 33 miRNAs were up-regulated at 120 hours whilst two were down-regulated 
compared with the 4 hour time point (over 11 % of the total pool of miRNAs).  Six miRNA were 
significant at the P<0.01 level of which miR-338-3p and miR-181a had adjusted p-values of 
0.000559 (highly significant).   
Due to the large number of miRNA found to be DE, Table 3. 14 only details those miRNA with a 
fdr.pval < 0.1.  Of these, ten miRNA exhibited a fold change ≥1.5, with miR-1207-5p exhibiting a 
3.8-fold down-regulation.   
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Table 3. 14 - miRNA expression between 120 hours and 4 hours ranked by fdr.pval (<0.1) and fold change 
(Batch 2 only) 
 
miRNA C/some Fold fdr.pval 
Ranked by FDR (P<0.01) 
  miR-338-3p 17 1.3 UP 0.000559 
miR-181a 1,9 1.6 UP 0.000559 
miR-222 X 1.6 UP 0.00084 
miR-221* X 1.3 UP 0.002993 
miR-181b 1 and 9 1.3 UP 0.00743 
miR-196a 12 and 17 1.2 UP 0.00743 
Ranked by FDR (P<0.05) 
miR-30a* 6 1.4 UP 0.01308 
miR-126* 9 1.2 UP 0.015682 
miR-9* 1, 5 and 15 1.1 UP 0.03034 
miR-196b 7 1.8 UP 0.03034 
miR-10a 17 1.4 UP 0.03034 
miR-92a 13 and X 2.4 ↓   0.03034 
miR-455-3p 9 1.1 UP 0.03034 
miR-182 7 1.5 UP 0.03034 
miR-335 7 1.4 UP 0.039373 
miR-126 9 1.9 UP 0.039373 
miR-9 1, 5 and 15 1.2 UP 0.039373 
miR-1207-5p 8 3.8 ↓   0.042415 
miR-190 15 1.1 UP 0.042415 
miR-146b-5p 10 1.4 UP 0.042415 
miR-30a 8 2.5 UP 0.04914 
miR-188-5p X 1.1 UP 0.04914 
miR-30b* 8 1.1 UP 0.04914 
miR-499-5p 20 1.1 UP 0.04914 
miR-181a-2* 9 1.1 UP 0.049223 
Ranked by FDR (P<0.05) 
miR-153 2 and 7 1.3 UP 0.050255 
miR-200c* 12 1.1 UP 0.063522 
miR-219-5p 6 and 9 1.3 UP 0.071898 
miR-34a 1 2.0 UP 0.076545 
miR-105 X 1.1 UP 0.078579 
miR-99a* 21 1.3 UP 0.078579 
miR-625 14 1.2 UP 0.078579 
miR-30e* 1 1.5 UP 0.095519 
miR-99a 21 1.9 UP 0.095519 
miR-34a* 1 1.1 UP 0.098928 
Top ranked miRNA (P<0.1, upwards direction) 
miR-30a 6 2.5 UP 0.04914 
miR-34a 1 2.0 UP 0.076545 
miR-126 9 1.9 UP 0.039373 
miR-99a 21 1.9 UP 0.095519 
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miRNA C/some Fold fdr.pval 
miR-196b 7 1.8 UP 0.03034 
Top ranked miRNA (P<0.1, downwards direction) 
miR-92a 13 2.4 ↓  0.03034 
miR-1207-5p 8 3.8 ↓ 0.042415 
C/some = chromosomal location of pre-cursor miRNA. 
Fold = the fold change value between the two experimental conditions: ‘up’ means that miRNA is up-regulated 
at 120 hrs compared with 4 hours; ↓means repressed.   
fdr.pval = p-value adjusted for multiple testing (Benjamini-Hochberg procedure). 
Where miRNA are found on more than one chromosome, it may be that they arise from the same or different 
stem-loop precursors on different chromosomes. 
 
Cluster information for miRNA can be found below (Table 3. 15).  The table demonstrates that 
two different clusters (mir-221/222 and mir-181a/181b) have all members of that cluster as dys-
regulated in the vehicle control group over time. 
 
Table 3. 15 - Cluster information for those miRNAs found to be DE for VC at 120 versus 4 hours (fdr.pval 
<0.1) 
Clusters 
mir-338/mir-1250/3065/657 
mir-181a-2/mir-181b-2 
mir-221/222 
mir-17/mir-18a/mir-19a/mir-20a/mir-19b-1/mir-92a-1 
mir-106a/mir-18b/mir-20b/mir-19b-2/mir-92a-1/mir-363 
mir-183/mir-96/mir-182 
mir-532/mir-188/mir-500a/mir-362/mir-501/mir-500b/mir-660 
mir-30d/mir-30b 
 mir-499a/mir-499b 
mir-200c/mir-141 
mir-2964a/mir-219-2 
mir-105-2/mir-767/mir-105-1 
mir-99a/let-7c 
mir-30e/mir-30c-1 
The miRNA registry database, miRBase (www.mirbase.org), provides the chromosomal positions of each 
miRNA and clustering information.  miRNAs found within 10 kilobases of each other are considered to be 
clustered and are likely to be co-regulated.  Those miRNA that are DE are underlined.  Lower case mir (rather 
than miR) refers to the stem-loop structure rather than the mature form. Mir-499 is now known as mir-499a. 
Where a mature miRNA is produced from a stem-loop precursor which has two locations, it cannot necessarily 
be known which location gave rise to the mature miRNA.  
 
 
Ten star miRNA were found.  Of these miRNAs, six pairs of miRNAs (dominant and passenger 
star forms) were found: miR-9, miR-30a, miR-34a, miR-99a, miR-126 and miR-181a.  In all cases, 
the expression levels of the star forms was lower than the dominant forms – this is in agreement 
with other studies which indicate that the star forms are generally found in cells at lower 
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concentrations than the dominant form.   Additionally, the direction of fold change is the same.  
The identification of a number of star forms also indicates that Batch 2 was more sensitive and 
independently gives confidence that those miRNAs are indeed DE. 
In terms of families, the miR-30 family consists of miR-30a to ‘e’ variants, positioned across the 
genome; interestingly three members (either star or dominant strand) of the family were dys-
regulated.   
As many miRNAs were identified as DE: the top seven miRNAs in terms of magnitude of fold 
change (fdr.pval <0.1) are represented graphically (Figure 3. 23).  Of these, miR-99a, -196b and -
30a were also present in the previous analysis using the ComBat adjusted data.  
Other families that were dys-regulated include miR-181 (-a and -b) and miR-196 (-a and -b). The 
expression levels of miR-221, -222, -181a and -181b are represented in Figure 3. 24. 
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Figure 3. 23 - Top ranked miRNAs identified as differentially expressed for VC at 120 hrs versus 4 hours 
(fdr.pval <0.1) 
ComBat adjusted values are presented as the mean of triplicate cultures with SD error bars.   
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Figure 3. 24 - Expression of the miR-221/222 family and miR-181a/b family in the vehicle-treated groups 
over time 
ComBat adjusted and Log base 2 transformed microarray expression values, are presented as the mean of 
triplicate cultures with SD error bars.   
 
3.3.5.2 DHT compared with vehicle control at 120 hours 
Statistical analysis did not reveal any differentially expressed miRNAs at 120 hours of exposure – 
when the p-values were adjusted for multiple testing, they all resulted in the same p-value of 1. 
 
3.3.5.3 Mibolerone compared with vehicle control at 120 hours 
 
Table 3. 16 details the miRNAs that were identified as DE with fdr.pval of less than 0.3.  Some 
miRNAs are represented schematically in Figure 3. 25.  There were 7 star forms, of which four 
had their sister forms present (miR-99, -221, -181a, and -30a). 
 
Table 3. 16 - miRNA expression between mibolerone and the vehicle control at 120 hours ranked by fdr.pval 
and fold change (Batch 2 only) 
miRNA C/some Fold fdr.pval 
Ranked by FDR (P<0.01) 
miR-338-3p 17 1.3 ↓ 0.000741 
miR-222 X 1.6 ↓ 0.002781 
miR-181a 1 and 9 1.5 ↓ 0.002781 
miR-1181 19 1.3 UP 0.002781 
miR-221* X 1.3 ↓ 0.005871 
miR-874 5 1.3 UP 0.007445 
miR-196a 12 and 17 1.2 ↓ 0.009697 
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miRNA C/some Fold fdr.pval 
miR-455-3p 9 1.1 ↓ 0.009697 
miR-210 11 2.5 UP 0.009697 
Ranked by FDR (P<0.05) 
miR-1915 10 3.3 UP  0.019543 
miR-181b 1 and 9 1.3 ↓ 0.023118 
miR-629* 15 1.1 UP 0.028469 
miR-221 X 2.9 ↓ 0.033021 
miR-196b 7 1.7 ↓ 0.045957 
Ranked by FDR (P<0.1) 
miR-615-3p 12 1.2 ↓ 0.054525 
miR-371-5p 19 1.1 UP 0.054525 
miR-1246 2 2.0 ↓ 0.054525 
miR-30a* 6 1.3 ↓ 0.08808 
Ranked by FDR (P<0.2) 
miR-10a 17 1.3 ↓ 0.105464 
miR-126* 9 1.1 ↓ 0.118193 
miR-181a-2* 9 1.1 ↓ 0.150802 
miR-95 4 1.1 ↓ 0.150802 
miR-1290 1 2.0 ↓ 0.150802 
miR-939 8 1.1 UP 0.150802 
miR-720 3 1.5 UP 0.165007 
miR-342-5p 14 1.2 ↓ 0.165675 
Ranked by FDR (P<0.3) 
miR-99a 21 1.8 ↓ 0.204193 
miR-190 15 1.1 ↓ 0.204193 
miR-105 X 1.1 ↓ 0.204193 
miR-182 7 1.3 ↓ 0.204193 
miR-324-3p 17 1.3 UP 0.205091 
miR-134 14 1.1 UP 0.206713 
miR-99a* 21 1.2 ↓ 0.218637 
miR-30d 8 1.5 ↓ 0.218936 
miR-499-5p 20 1.1 ↓ 0.235822 
miR-30b* 8 1.1 ↓ 0.235822 
miR-125b 11 and 21 1.7 ↓ 0.235822 
miR-1308 X 1.2 UP 0.241497 
miR-30a 8 1.8 ↓ 0.260097 
miR-10b 2 1.1 ↓ 0.260097 
let-7c 21 1.3 ↓ 0.281404 
Ranked by fold change (downwards direction, P<0.3) 
miR-221 X 2.9 ↓ 0.033021 
miR-1246 2 2.0 ↓ 0.054525 
miR-1290 1 2.0 ↓ 0.150802 
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miRNA C/some Fold fdr.pval 
miR-30a 8 1.8 ↓ 0.260097 
miR-99a 21 1.8 ↓ 0.204193 
Ranked by fold change (upwards direction, P<0.3) 
miR-874 5 1.3 UP 0.007445 
miR-1181 19 1.3 UP 0.002781 
miR-720 3 1.5 UP 0.165007 
miR-210 11 2.5 UP 0.009697 
miR-1915 10 3.3 UP 0.019543 
C/some = chromosomal location of pre-cursor miRNA 
Fold = the fold change value between the two experimental conditions: ‘up’ means that miRNA is up-regulated 
in mibolerone treated cells compared with vehicle control treated; ↓ means repressed.   
fdr.pval = p-value adjusted for multiple testing (Benjamini-Hochberg procedure). 
Where miRNA are found on more than one chromosome, it may be that they arise from the same or different 
stem-loop precursors on different chromosomes.  Mature mir-1308 is a fragment of tRNA is no longer 
designated a miRNA.  Note that mir-190 is now known as mir-190a. Mir-499 is now known as miR-499a. 
 
To ensure consistency of the data, a comparison was made between those identified in Dataset 
1 and Dataset 2 (the ComBat corrected analysis and the analysis of Batch 2 alone). 11 miRNAs 
were identified to be common between the two datasets at the P<0.3 level: miR-221, -196b, -
1246, -1290, -210, -182, -30a, -99a, -720, -105.  In terms of families, three members of the miR-
30 family (30a, 30d, 30a* and 30b*) were identified as being down-regulated in mibolerone 
treated cells.  miR-10a and -10b were also down-regulated although the extent of the down-
regulation was lower (1.1 to 1.3 fold). 
Clustering information can be found in Table 3. 17. 
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Table 3. 17 - Cluster information for those miRNAs found to be DE for mibolerone at 120 hrs (fdr.pval <0.1) 
Cluster 
GO  
 
mir-338/mir-1250/3065/657 
mir-221/222 
mir-181a-2/mir-181b-2 
mir-371a/mir-371b/mir-372/mir-373 
mir-1234/mir-939 
mir-151b/mir-342 
mir-99a/let-7c 
mir-105-2/mir-767/mir-105-1 
mir-193/mir-96/mir-182 
mir-381/mir-487b/mir-539/mir-889/mir-544a/mir-655/mir-487a/mir-
134/mir-668/mir-485/mir-323b/mir-154/mir-496/mir-377/mir-541 
mir-30d/mir-30b 
 The miRNA registry database, miRBase (www.mirbase.org), provides the chromosomal positions of each 
miRNA and clustering information.  miRNAs found within 10 kilobases of each other are considered to be 
clustered and are likely to be co-regulated.  Those miRNA that are DE are underlined.  Lower case mir (rather 
than miR) refers to the stem-loop structure rather than the mature form. Where a mature miRNA is produced 
from a stem-loop precursor which has two locations, it cannot necessarily be known which location gave rise 
to the mature miRNA. Note that miR-371-5p is now known as miR-371a-5p. 
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Figure 3. 25 - Top ranked miRNAs identified as differentially expressed for mibolerone at 120 hours (fdr.pval 
<0.1) 
Data from Batch 2, values are presented as the mean of triplicate cultures with SD error bars.   
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3.3.6 Confirmation of DE miRNA using real-time RT-PCR 
To validate the differentially expressed miRNAs, a number were tested by qRT-PCR.  The miRNAs 
were chosen to cover high and medium expression values, identified as being dys-regulated in 
different treatment groups, having taken into account variability between the replicates, looking 
at miRNAs that had been down-regulated and up-regulated at different time points, and based 
on the available literature for possible functions.  On this basis, miR-720 (mean expression 
across all the samples of log2 13), miR-221 (log2 8), miR-210 (log2 8), miR-494 (log2 8), miR-1915 
(log2 7), miR-30a (log2 8) and miR-1290 (log2 8) were chosen with RNU6B as the normalisation 
control. 
3.3.6.1 Efficiency analyses 
To use the 2-ΔΔCT method of relative gene expression (Livak and Schmittgen, 2001), an efficiency 
study was required to confirm the central assumption of equal amplification efficiencies 
between the target miRNA and reference endogenous control.   How the ΔCT varies with 
complementaryDNA (cDNA) template quantities can be used to test this assumption (Figure 3. 
26). 
 
Figure 3. 26 - Example of CT values over 5 different concentrations 
As the concentration reaches 10pg, the CT starts to reach the limit of detection, therefore only the top three 
concentrations are used to generate the efficiency data (uses the slope).  A slope of -3.32 represents 100% 
efficiency. Each data point is n=3 technical replicates. 
 
The study showed that the majority of miRNAs (6/8) were amplified within 15% of the 100% 
efficiency: miR-1915 and -1290 had high efficiency values, indicating measurements of fold 
differences would be unreliable (likely to be due to low expression).  
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CT values were highly correlated to RNA input (cDNA) (R
2>0.99) where there is an assumption 
that RNA is converted to cDNA in a 1:1 ratio. 
Table 3. 18 - Efficiencies of miRNA and RNU6B with correlation coefficients 
   Efficiency (%) n Correlation coefficient Slope of ΔCT * 
Normalisation control 
 RNU6B 101 (6.24 SD) 3 0.9739 (0.03SD) - 
miRNA 
 miR-210 103 1 0.9933 0.20 
 miR-221 105 1 0.9968 0.25 
 miR-1915 116 1 0.9882 -0.47 
 miR-30a 109 1 0.9955 -0.34 
 miR-1290 129 1 0.9883 -0.67 
 miR-494 112 1 0.9980 -0.18 
 miR-720 108 1 0.9958 -0.10 
Determined in one experiment with three technical replicates except RNU6B whose efficiency was determined 
in three independent experiments (A, B and C). *Slope of difference is between the normalisation control and 
the miRNA, measured over three concentrations.   In all cases, the no-RT control had no amplification  
 
The slope of the ΔCT for each miRNA versus RNU6B is given in Table 3. 18 with graphical 
representation for miR-720 and miR-494 given in Figure 3. 27. 
 
 
 
 
 
 
Figure 3. 27 - Difference in CT values at 3 concentrations for miR-720 and miR-494 compared with RNU6B.   
The slope of the line should be close to zero to indicate that the difference between the normalizing control is 
not affected by initial starting template quantity. 
 
Due to the poor efficiency in the miR-1915 and miR-1290 samples, further work with these 
miRNAs was not undertaken; although Relative Expression Software (Pfaffl, Horgan and 
Dempfle, 2002) could have been used to measure miRNA differences with different efficiencies, 
there is a risk that calculations may over compensate and the result will not be any more 
reliable.   
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3.3.6.2 Correlation between microarray and qRT-PCR 
As shown in Figure 3. 28, miRNA expression values, measured by microarray (ComBat adjusted 
data) and qRT-PCR, were correlated (r = -0.9122, p-value 0.0308). 
 
Figure 3. 28 - Correlation between microarray and real-time RT-PCR  
Pearson correlation of -0.9122, p-value 0.0308 (two-tailed).  Each individual point is the mean value for 
mibolerone at 120 hours (except for miR-494 which is mean value for DHT at 24 hours).  Real-time normalised 
to RNU6B CT value. N=3. 
  
The correlation data indicates the robustness of the microarray results compared with the real-
time and validates the normalisation for those selected miRNAs. 
3.3.6.3 miR-210, -221, -30a, -720 and -494 
The time course analyses indicated that mibolerone at 120 hours may induce a fold change in 
miR-210 expression (highest ranked FDR and second highest fold change), miR-221 expression, 
miR-30a expression and miR-720 expression (Figure 3. 29).  Verification of the induction, 
compared with the other compounds at 120 hours of exposure was undertaken.  qRT-PCR 
confirmed the fold increase although again there was large amount of variability in the sample.  
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Figure 3. 29 - miRNA expression of miR-210, -221, -30a, -720 and -494 
Determined by qRT-PCR of the same samples used for microarray.  Data is mean of triplicate cultures with SD 
error bars. 
 
 
 
 
A – miR-210 (120 hours) B – miR-221 (120 hours) 
 
 
 
 
 
 
 
C – miR-30a (120 hours) D - miR-720 (120 hours) 
 
 
 
 
 
E – miR-494 (24 hours) 
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3.4 Discussion 
Many miRNA studies have examined the expression levels of miRNA between PCa and benign 
tissues; other comparisons have been made between metastatic and non-metastatic PCa.  
Unlike previous studies, this study was the first to examine miRNA expression levels within the 
same PCa subtype (a metastatic-derived cell line) in the presence of a set of androgen-active 
ligands over time.  To my knowledge, no other study has yet been published that assesses 
miRNAs under the same conditions.  The aim was not to identify those miRNAs that differ 
between PCa states, but identify miRNAs that may be associated with PCa proliferation and the 
biomarker of PCa progression and activity, PSA.  In addition, by looking at baseline changes in 
miRNA over time, it would identify miRNAs that were possibly cell cycle related. 
The hypotheses to be examined were that temporal changes in miRNA profile will occur and 
these changes may be compound- or time- specific.  For example, elevated expression of miRNA 
at a time when the cells are proliferating to a high degree may be involved in the regulation of 
this phenotype.   
3.4.1 Technical issues – quality assessment and batch effects 
Quality assessment of the samples prior to microarray analysis indicated that the samples were 
good quality; despite this, significant problems were encountered with the microarrays which 
lead to difficulties in determining accurately which miRNAs were dys-regulated. 
The poor data generated by the first batch of microarrays was likely due to washing artifacts.  
The decision was taken to repeat those samples that had failed with new wash buffers and wash 
dishes.  AFE showed that the second batch was much improved in terms of quality with 23 out 
of the 24 samples passing the thresholds.   
ComBat was introduced to reduce the batch effects and enable the two distinct datasets to be 
combined; this method requires each batch to have the same population of miRNAs.  However, 
because of the reduced sensitivity of Batch 1, only a small subset of miRNAs (158 out of 866 
human miRNAs) were found to be present in both batches after filtering; indeed Batch 2 had 
over 50% more miRNAs present than Batch 1.  This therefore impacts on the identification of 
dys-regulated miRNAs. 
Although ComBat was successful in bringing the two different batches closer together, some 
differences remained and treatment replicates did not necessarily group together within the 
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same batch even though the extracted samples were of good quality and had passed the Agilent 
Feature Extraction quality control measures.  Ultimately, in this case, the true test of whether a 
data normalisation method was successful is the generation of results that can be verified by a 
different method.   
3.4.2 Real-time verification and concordance between microarray and qRT-PCR 
For those five miRNAs that were used for validation (miR-210, -720, -221, -30a and -494), the 
correlation between the microarray and qRT-PCR data was high.  Chen et al. (2005) found 
concordance between these two methods was variable; there was reduced correlation for lower 
abundance miRNAs.   Due to the high variance in the samples, and the batch issues, 
interpretation of the microarray results was hampered but despite this, the microarray and qRT-
PCR data indicated that miR-210, -221, -494, -720 and -30a were altered by treatment with the 
AR agonist mibolerone or DHT. 
3.4.3 The AR antagonist bicalutamide did not induce any miRNAs 
BIC did not alter the expression of any of the miRNAs present on the microarray.  The purpose 
of the inclusion of BIC as a test agent was that although it is an androgen-antagonist and 
therefore competitively inhibits androgens, and thus would not necessarily have any actions 
other than cancelling out those of its competitor, the nature of its competition could have had 
unforeseen consequences.  For example, BIC recruits a different complement of co-regulators – 
co-repressors rather than co-activators.  Therefore the possibility was that the BIC/AR complex 
may be able to activate the promoters on certain miRNA genes and elicit unexpected effects.  In 
many instances, patients treated with bicalutamide (in conjunction with other treatments such 
as LHRH agonists/antagonists) eventually progress to androgen insensitive PCa and succumb to 
the disease – potentially there is a role for miRNAs to assist in this process due to alterations 
induced by bicalutamide.   
This hypothesis was not borne out by the microarray data – at no time point did BIC affect the 
expression of the 158 miRNAs present in the data set.  As more miRNAs are discovered and 
methods of detection become more sensitive, it is of course plausible that dys-regulated 
miRNAs may be discovered that are due to off-target effects of BIC rather than a function of its 
ability to attenuate DHT-induced effects.  
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3.4.4 Androgen-regulated miRNAs in LNCaP 
In this study, a number of miRNAs were identified as probably being altered by androgens.  Of 
these, miR-210, miR-221 and miR-720 are discussed in Chapter 4.  The others are briefly 
discussed below. 
3.4.4.1 miR-30a 
miR-30a (miR-30a-5p) is located on chromosome 6 and is a member of the miR-30 family which 
consists of five members (miR-30a-e); these members share the seed sequence “GUAAACA” (5’ 
to 3’ direction) but differ in their sequence outside of this region. 
In prostate cancer specimens Porkka et al. (2007) and Ozen et al. (2008) identified that miR-30a 
was down-regulated in PCa versus normal samples.  In vitro, Murata et al. (2010) identified that 
miR-30a was induced 2-fold by 24 hours of 10nM R1881 treatment, but its expression had 
returned to baseline by 48 hours. 
In this study, miR-30a was shown to be at least 2-fold down-regulated by 120 hours of 
treatment with MIB; this finding was confirmed by qRT-PCR.  Few studies have been published 
on this miRNA which makes it difficult to comment on the role of miR-30a in prostate epithelial 
cells, however a small number of targets have been elucidated. 
In non-small cell lung cancer, miR-30a and other family members target Snai1 (Snail), which is a 
transcriptional repressor of E-cadherin (Kumarswamy et al., 2012).  E-cadherin modulates the 
epithelial-mesenchymal transition suggesting a role for miR-30a in invasion and metastasis.   
miR-30a has been shown to target DTL (denticleless protein homolog) in colon cancer cell lines 
(Baraniskin et al., 2012).  Over-expression of this miRNA resulted in growth suppression, 
partially mediated by DTL, as well as increased levels of p53 and CDKN1A (a downstream target 
of DTL).  Baraniskin proposed a model of cell cycle control by miR-30a:  targeting of DTL leading 
to accumulation of p53, increased CDKN1A expression and blockage of the cell cycle.   
Martinez et al. (2011) identified that miR-30 inhibits DNA synthesis and has tumour suppressor 
activity by regulation of the oncogenic TF B-Myb.  In line with these reports, it may be that 
mibolerone-repressed miR-30a contributes to cell cycle progress.  Indeed, miR-30a makes an 
interesting candidate for future studies.  
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3.4.4.2 miR-494 
miR-494 was identified as being 2.5-fold up-regulated by 24 hours of DHT treatment compared 
to the control; this finding was confirmed by qRT-PCR.  This is in agreement with Waltering et al. 
(2010) who found miR-494 to be up-regulated greater than 1.5-fold at 24 hours.  Aside from 
Waltering’s study in cell lines, in tumours it has been reported that that miR-494 was down-
regulated (0.4-fold): the samples consisted of PCa specimens that were organ-confined and also 
those that had extra-prostatic extensions (Ambs et al., 2008).  
miR-494 is a highly conserved intergenic miRNA found on chromosome 14 in a large cluster with 
miR-379, -411, -299, -380, -1197, -323, -758, -329-1, 329-2, -1193, -543 and -495 
(www.mirbase.org; www.TargetScan.org). In agreement with Ambs et al. (2008), no other 
members of this cluster were found to be altered with treatment: this suggests that either miR-
494 can be transcribed independently of the polycistron or that the stability of this miRNA is 
different from the other members of the cluster. 
Very few studies have been published on the role of miR-494; none have looked at this miRNA 
in the context of PCa tumours or cell lines.  A recent study by Bandiera et al. (2011) in HeLa cells 
identified miR-494 as being a so-called “mitomiR” – a miRNA that is involved in crosstalk 
between the nucleus and mitochondria, with preferential localisation in mitochondria.  
Intriguingly, miR-638 was also identified as a mitomiR: this miRNA was also up-regulated by 24 
hours of DHT treatment in this study (1.4-fold).  
Targets of miR-494 were significantly enriched in mitochondrial homeostasis: the most 
significant of which was the mitochondrial translation pathway (Bandiera et al., 2011).  Target 
analysis revealed a host of mitochondrial-encoded targets; additionally Bandiera et al. (2011) 
found Ago2 present in the mitochondria suggesting a functional role.  Kren et al. (2009) 
previously identified enrichment of miR-494 in rat liver mitochondria: the purpose of the miRNA 
in the mitochondria was undetermined.  miR-494 was not predicted to regulate nuclear mRNA 
transcripts that were to be translated in mitochondrial proteins.  The authors of this paper 
suggested that miR-494 could be sequestered into the mitochondria to help control cellular 
function.     
Much research remains to elucidate the role of miR-494 and miR-638 in the mitochondria; 
however, it would be interesting to ascertain whether the increase in miR-494 with DHT 
treatment leads to mitochondrial accumulation of this miRNA (Tominaga et al., 2011). 
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More recently, it was discovered that miR-494 was able to target the RNA-binding protein 
nucleolin in human cervical carcinoma HeLa cells (Tominaga et al., 2011).  Furthermore, miR-494 
and HuR (Hu antigen R, another RNA-binding protein) competed for modulation of nucleolin: 
HuR increased translation whilst miR-494 repressed translation and decreased nucleolin 
stability.  In HeLa, over-expression of miR-494 lowered the cell population, with an increase in 
the apoptosis marker, cleaved poly(ADP-ribose) polymerase (PARP).  This is obviously divergent 
to what was observed in this study as cell number was moderately increased at 24 hours – it is 
possible that the miR-494 effects on nucleolin are cell specific, or there are other factors at 
work.  In any case, further work on the role of miR-494 is clearly warranted. 
3.4.4.3 miR-338-3p 
In this study, miR-338-3p was 1.3-fold increased in the vehicle control group at 120 hours 
compared to 4 hours, whereas with mibolerone treatment, this increase had reversed and it was 
down-regulated by 1.3-fold (in the Batch 2 only dataset, highly significant.) 
Ambs et al. (2008) identified miR-338 as androgen-responsive in vitro (3-fold up-regulation) and 
identified a putative AR binding site in the flanking region. In the profiling studies of PCa, miR-
338-3p was identified as 2-fold down-regulated in PCa compared to normal adjacent prostate 
tissue (Martens-Uzunova et al., 2011).  
Very few studies have been published which mention expression of miR-338-3p – to date (Nov, 
2011) there are six studies in the PubMed database which specifically mention this miRNA in 
their abstract of which only two have investigated what transcripts this miRNA targets.  
The study by Huang et al. (2011) identified that loss of this miRNA was associated with clinical 
aggressiveness in hepatocellular carcinoma.  In vitro studies of liver cell lines found ectopic 
expression suppressed migration and invasion whilst down-regulated miR-338-3p induced 
migration and invasion.  SMO (smoothened) was identified as a target of this miRNA: SMO 
activation leads to activation of zinc finger transcription effectors such as Gli, resulting in the 
expression of target genes involved in proliferation, differentiation and ECM interactions (Huang 
et al., 2011).   
MMP9 is a matrix metalloproteinase necessary for degradation of the basement membrane and 
extracellular matrix: both of these processes are critical steps in tumour invasion and metastasis 
(Huang et al., 2011).  The Huang study identified that ectopic miR-338-3p was able to inhibit 
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liver cell invasion by reducing SMO and, consequently, MMP9 expression.  Thus the results 
suggest that, if this were to hold true in PCa cells, decreased expression of miR-338-3p could be 
a mechanism for prostatic invasion due to de-repression of SMO and SMO-induced MMP9. 
Interestingly, the miR-338-3p is hosted by the gene encoding the apoptosis-associated tyrosine 
kinase (AATYK) and is highly correlated with the host gene expression (Baskerville and Bartel, 
2005).  AATYK was shown to be induced during apoptosis and, in myeloid pre-cursor cells, may 
be required for growth arrest (Baskerville and Bartel, 2005).  Therefore if AATYK is lost or 
reduced in PCa, it may contribute to the unrestrained growth observed and complement the 
prostatic invasion induced by a lack of miR-338-3p repression of SMO.   Further work validating 
the expression of this miRNA in PCa cells and assessing the levels of SMO and AATYK could be 
potentially very interesting.  
3.4.4.4 miR-181 
The miR-181 family consists of four members (a-d) that are found in three different genomic 
locations: mir-181a-2 is clustered with mir-181b-2 on chromosome 9; mir-181a-1 is clustered 
with mir-181b-1 on chromosome 1; and mir-181c is clustered with mir-181d on chromosome 
19. 
In PCa profiling studies, miR-181a has been shown to be up-regulated (Ambs et al., 2008) whilst 
miR-181b has been shown to be down-regulated in PCa tumours (Martens-Uzunova et al., 2011, 
Schaefer et al., 2010).  Ambs et al. (2008) identified that miR-181b was down-regulated in 
LNCaP with R1881 treatment and observed a putative AR binding site in the flanking regions of 
miR-181b-1, indicating that it could be under AR transcriptional control. 
In this study, expression of various miR-181 family members was altered at different time points 
with different compounds, albeit with low fold changes.  Of note, miR-181b was modestly 
down-regulated, whilst miR-181a was 1.5-fold down-regulated with mibolerone treatment for 
120 hours. 
The miR-181 family share the same seed region.  They have been shown to target pro- and anti-
apoptotic members of the BCl-2 family: BCl-2, MCl-2 (both pro-survival) and BCl-2-L11 (BH3-only 
pro-apoptotic) (Ouyang et al., 2012).  Thus the overall net effect of this miRNA family is likely to 
depend on the levels of the targets and the balance of the individual family members, either 
favouring a pro- or an anti-apoptotic profile. 
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Shin et al. (2011) found that K-ras, of the Ras family of oncogenes, was a target of miR-181a.  
Therefore it may be androgen-mediated repression of miR-181a contributes towards the 
proliferative phenotype observed in mibolerone-treated cells via de-repression of K-ras.  
3.4.5 Concordance with published reports 
Using in vitro studies, a few miRNAs have been purported to be androgen-regulated (Figure 3. 1, 
page 73): induction of some, but not all, of these miRNAs was observed in this study.    
There are a number of different reasons why miRNAs may be identified in one study as being 
differentially expressed but not in another study.  Git et al. (2011) looked at five different 
microarray platforms and found differences in the number of DE calls (due to differences in 
sensitivity and specificity of each platform) and that the magnitude of dys-regulation was 
different between the platforms (ratio compression) with occasional spurious values.  Ach, 
Wang and Curry (2008) identified that the method of RNA extraction additionally altered the 
expression of some miRNAs: for example, miR-29b, miR-33 and miR-219 were much lower in 
TRIzol® prepared samples compared with mirvana™ and miRNeasy™. 
Thus the discrepancies could be due to:  
- different ligands 
o a single concentration of mibolerone or DHT in this case, the synthetic androgen 
R1881 in Shi et al. (2007), Ambs et al. (2008) and Ribas et al. (2009);  
- time point measurements 
o 4, 8, 24 and 120 hours in this study, 24 hours in Waltering et al. (2010), 72 hours 
in Ribas et al. (2009);  
- different assay platforms  
o Agilent microarray V3 in this study, Agilent V2 in Waltering et al. (2010), custom-
made arrays in Ribas et al. (2009) and Ambs et al. (2008), Northern blot in Shi et 
al. (2007); 
- culturing conditions.  
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3.4.6 Let-7 in Prostate Cancer 
The let-7 miRNA family is the largest and encompasses nine variants (Let-7a–i) who vary by as 
little as one nucleotide each.  In this study, all eight members of the let-7 family (let-7a to let-7i) 
were present in the prostate epithelial cell line LNCaP and had the highest expression of any of 
the families.  This is in agreement with two other studies that assessed miRNA levels in LNCaP 
(Xu et al., 2010; Sun et al., 2011): for example, the let-7 family contributed nearly 9% of the total 
miRNA reads.    
Despite the high expression in LNCaP, the let-7 family is known as a tumour suppressor of colon 
and lung cancers; it has been shown to target the Ras oncogene (Johnson et al., 2005). Because 
the microarray, and most other studies, give only relative measurements of the miRNAs 
between different conditions it is difficult to know whether the expression seen in LNCaP is low 
compared to tissue samples; the expression levels of a ‘tumour suppressor’ miRNA family in 
cancer cells of metastatic origin would reasonably be expected to be low, not high.  
Shi et al. (2007) identified that the abundance of let-7c was increased in the AR-positive lines 
(CWR22R, PC-346C, LNCaP, cds1, and cds2), compared with the AR-negative cell lines (DU145, 
PC3, pRNS-1-1, and RWPE-1), suggesting a link to the AR signalling pathway. 
Over-expression of let-7 has been reported to regulate transcripts involved in cell-cycle control 
and proliferation.  Dangi-Garimella et al. (2009) found that elevated let-7 expression inhibits 
HMGA2, a chromatin remodelling protein that activates pro-invasive and pro-metastatic genes, 
including Snail.  
Despite the high expression of this miRNA family, LNCaP continue to proliferate happily: one 
potential mechanism for this discord could be over-expression of another pathway during 
carcinogenesis or metastatic progression to counteract the tumour suppressor effects of let-7.  
It would be interesting to silence the let-7 family members in LNCaP to see whether 
proliferation increases and establish exactly what the role of this family is in this cell line; 
perhaps their tumour suppressing ability may be cell type or context dependent. 
The net impact of any given miRNA will be the sum of all its interactions; as different cell types 
exhibit different transcriptomes, it may be that this family has tumour suppressor oncogene 
status depending on the cellular context.  This has been observed with other miRNAs, such as 
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miR-29, which were oncogenic or tumour suppressive depending on the cell type (Gebeshuber, 
Zatloukal and Martinez, 2009).  
3.4.7 miR-99a, IGF-1R and PSA  
In a recent study in LNCaP and C4-2, the miR-99 family (miR-99a, -100 and -125b) was repressed 
by 72 hours of R1881 treatment; low expression of these miRNAs was concordant with high 
levels of PSA and proliferation (Sun et al., 2011).   With over-expression of miR-99a/100, PSA 
(mRNA and protein) and cell growth were reduced, suggesting a possible tumour suppressive 
role.   
This observation was confirmed in this study where with 120 hours of 100pM mibolerone 
treatment, miR-99a was 1.8-fold and miR-125b was 1.7-fold down-regulated. DHT (2nM) for 24 
hours lead to 1.5-fold down-regulation.  It may be that the higher concentration of DHT is able 
to activate the repressive mechanism at 24 hours which is lost over time as DHT is metabolised 
by 3-HSD (present in LNCaP), whereas the lower but sustained presence of mibolerone 
(synthetic non-metabolisable ligand) requires more time to activate the repression, hence the 
down-regulation is only observed at 120 hours.  Interestingly, between miRNAs dys-regulated by 
DHT at 24 hours and mibolerone at 120 hours, let-7c, miR-1290, miR-99a, miR-1246 and miR-
221 were common in support of this hypothesis. 
Three direct targets of the miR-99 family have been identified: SMARCA5, SMARCD1 and the 
growth regulatory kinase mTOR (Sun et al., 2011).  Sun et al. (2011) suggested that repression of 
the three targets by the miR-99 family could contribute to PSA repression with SMARCA5 and 
SMARCD1 (chromatin-remodelling factors) being required for the expression of PSA protein at 
the post-transcriptional step.   
3.4.8 Clustering 
Although clustering analysis can be a useful method to visualise miRNA with similar expression 
patterns in a particular dataset, allowing analysis of how they may co-vary within a given 
population, it has limitations for small sample sets such as in this project.  As noted in Allison 
and colleagues’ review (2006), clustering on less than 50 samples is generally not reproducible 
and is therefore of limited value.  Despite this, clustering did identify several miRNAs that were 
highly correlated with the expression of others; for example, some members of the miR-17-92 
cluster. 
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3.4.9 Factors that affect miRNA expression 
A recent paper by Kim et al. 2012 suggested that when cells were cultured at low density, 
TRIzol® was less efficient at extracting those miRNAs with a low GC content and high ΔG.  The 
most dramatic of their findings was a 50% reduction in miR-141 in low- compared to high-
density cultures.  This finding would imply that androgen-induced proliferation would result in 
increased miR-141 due to the positive effect of high cell density on extraction efficiency.  
However, miR-141 induction was not observed in either the ComBat or Batch 2 datasets, in 
agreement with other studies utilising LNCaP (Waltering et al., 2010). 
Of those extraction-sensitive miRNAs identified by Kim et al. (2012), four have been shown to be 
up-regulated by androgens: miR-29b (Murata et al., 2010; Waltering et al., 2010; Ribas et al., 
2009); miR-106b (Murata et al., 2010); miR-20a (Ribas et al., 2009); and miR-21 (Ribas et al., 
2009; Waltering et al., 2010).  Therefore it could be that increased cell number due to androgen-
induced proliferation is responsible for the up-regulation observed in these studies and the 
extraction method played a part in the miRNA changes observed. Confirmation of these findings 
using different extraction methods would clarify whether these were real biological effects.  
Hwang and colleagues (2009) found that cell-to-cell contact globally activated miRNA biogenesis 
in cell lines that undergo proliferative arrest upon cell-cell contact and in cancer cell lines that 
do not.  In confluent cells, Drosha processing efficiency and RISC formation is enhanced (post-
transcriptional mechanisms); they proposed that the general increase occurs through 
association with accessory factors, or by post-translational modification, rather than an increase 
in transcription (except for miR-34a) (Hwang, Wentzel and Mendell, 2009).  In the Batch 2 only 
dataset, miR-34a was indicated as being up-regulated at 120 hours of vehicle-treatment (2-fold 
higher than at 4 hours).  If miR-34a expression is dependent on cell density then this up-
regulation is no surprise; however, this increase was not seen with neither DHT nor mibolerone 
treatment, both of which had significantly increased cell number compared with the control.  It 
is unclear why this difference occurs. 
It was interesting to note that some miRNAs, such as miR-7, -221, -1290, -30a and -99a, had 
expression levels that varied over time in the control condition, and these were also affected by 
mibolerone at 120 hours.  This indicated that these miRNAs may be involved in cell cycle 
progression, maintenance of the prostatic phenotype or other processes important to cell 
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function.  Knock out studies (or over-expression transfection studies) would shed light on 
possible mechanisms. 
3.4.10 Conclusion 
This study highlights how miRNAs can be altered by androgens – it would therefore be of use for 
profiling of miRNAs in PCa to be performed in conjunction with assays that measure the 
androgen levels in the patients (both circulating and tissue levels) as this may, in part, 
contribute to the discrepancies that have been observed in the literature. 
As may be appreciated, there are a number of miRNA that deserve further research.  Of note, 
miR-125b was abundantly expressed in LNCaP, in agreement with Sun et al. (2011); the role of 
this miRNA in PCa has not been studied.  Further work validating the expression of those 
miRNAs would be of worth and may help to further elucidate the role of miRNAs in the prostatic 
phenotype. 
This study also has implications where inferences are drawn from measurements made at a 
single time point, which do not necessarily take into account baseline changes in miRNA over 
time.  This study did not identify any dys-regulated miRNAs between 4 and 8 hours of treatment 
in agreement with Waltering’s study (2010) - however, differences were noted between other 
time points indicating that miRNAs levels are dynamic and are not only influenced by 
mechanisms that control their transcription, but also their degradation.   
As a number of miRNA have been shown to be influenced by cell density, reporting the plating 
density or degree of confluency at the point of miRNA measurement, seems to be very 
important and could account for the differences observed between this and other studies. 
Although in vitro studies are far removed from clinical samples, some of the differentially 
expressed miRNAs found here have been shown to be altered in tissue samples and they may 
still offer suitable avenues for further investigation.  In the prostate, epithelial cells are found 
with a variety of different cell types and participate in complex paracrine mechanisms of cell 
communication – thus an obvious limitation of this study is that it was conducted in a single cell 
line and, like the other published profiling studies, does not take into account the paracrine 
effects of neighbouring cells which are likely to influence miRNA expression.  Despite this 
drawback, the profiling approach did identify suitable candidates for further exploration into the 
androgen-induced phenotype. 
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4. miR-720, miR-221, miR-210 and pathway analysis 
4.1 Introduction 
In Chapter 3, it was shown that a number of miRNAs had temporal and compound dependent 
expression profiles.  The purpose of this chapter was to investigate the role of miR-720, miR-221 
and miR-221.  Structural details of these miRNAs can be found in Table 4. 1. 
Microarray analysis revealed that miR-720 was the most highly expressed miRNA present in 
LNCaP (mean expression across all samples of log2 13).  Confirmation by qRT-PCR revealed that 
miR-720 had the highest expression, as evidenced by the lowest threshold cycle, of all the 
miRNAs that were validated.  miR-720 was first cloned and identified in neuroblastoma cells 
(Afanasyeva et al., 2008) and using deep sequencing techniques has since been found in the 
transcriptomes of melanoma samples (Stark et al., 2010), breast epithelial cells (Pigati et al., 
2010) and LNCaP prostate epithelial cells (Xu et al., 2010). 
miR-221 had a temporal and compound-dependent expression profile: it was down-regulated by 
mibolerone treatment at 120 hours of exposure compared to the control.  miR-221 shares the 
seed sequence with miR-222 and thus shares a high percentage of targets; their up-regulation 
has been reported in a number of tumour types and they have been considered to act as 
oncomiRs or tumour suppressor miRNAs dependent on the environmental context (Garofalo et 
al., 2012).  
miR-210 had a temporal and compound-dependent expression profile: it was up-regulated by 
mibolerone treatment at 120 hours of exposure compared to the control.  miR-210 is an intronic 
miRNA found within the mRNA transcript AK123483 and flanked by HRAS and RASSF7 (Chan and 
Loscalzo, 2010).  Numerous authors have shown that miR-210 is induced in low oxygen 
conditions and that this is due to the presence of functional hypoxia response elements (HRE) in 
regions upstream of the miR-210 gene; these are targeted by HIF1α, hypoxia inducible factor 1 
alpha (Camps et al., 2008; Huang et al., 2009; Kulshreshtha et al., 2007).    
The purpose of miRNA pathway analysis is to estimate the impact co-expressed miRNAs have on 
a particular biological pathway: DIANA-mirPath is one such method that generates putative 
mRNA targets of selected miRNA and provides lists of pathways that may be significantly 
affected by dys-regulated miRNA.  
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Table 4. 1 - Details of miR-720, miR-221 and miR-210 
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4.1.1 Aims and hypotheses 
4.1.1.1 miR-720 
The presence of high levels of miR-720 in LNCaP, under all conditions but enhanced with 
mibolerone at 120 hours, supports the notion that it could be playing an important role in the 
prostate epithelial cell physiology.  The hypothesis was that reduced miR-720 expression may 
contribute to, or be the driver for, androgen insensitivity in prostate cancer, exhibiting low 
expression in androgen insensitive LNCaP and high expression in androgen responsive LNCaP.  
The aim was to first compare the expression of miR-720 in different cell lines; in the event that 
there was a difference, the next step would be to measure the levels of predicted targets.   
4.1.1.2 miR-221 
The focus of this work was to use bioinformatics to identify potential targets and confirm target 
up-regulation in the presence of down-regulated miR-221.  The hypothesis was that androgen 
repressed miR-221 may contribute to androgen-induced proliferation.  The aim was to assess, 
dose-dependently, the levels of miR-221 and a putative target.  
4.1.1.3 miR-210 
The hypothesis was that aside from being a so-called hypoxamiR (hypoxia-associated miRNA), 
miR-210 may also be androgen-regulated, directly or indirectly, in LNCaP cells.  The aim, 
therefore, was to investigate the mechanism and consequences of androgen-induced miR-210. 
4.1.1.4 Pathway analysis using DIANA-mirPath 
The aim of the analysis was to identify biological pathways that may be significantly altered by 
dys-regulated miRNAs. 
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4.2 Material and Methods 
4.2.1 Experimental design of miR-720 studies 
To identify possible roles of miR-720 in LNCaP, target analysis was undertaken using MicroCosm, 
TargetScan and miBridge (see Section 4.2.5, page 148).  Target analysis revealed that this miRNA 
could be involved with androgen sensitivity; therefore, the level of miR-720 was assessed in 
androgen sensitive LNCaP and androgen insensitive PC-3 and LNCaP-R cell lines.  
4.2.2 Experimental design of miR-221 studies 
The effect of mibolerone on miR-221 expression levels at different concentrations (1pM to 
10nM) was assessed at 120 hours.  Measurements of proliferation and PSA were also 
undertaken.   In silico methods were employed to identify putative targets of the dys-regulated 
miRNA whilst immunoblotting assessed any changes in putative target protein levels.   
4.2.3 Experimental design of miR-210 studies 
miR-210, vascular endothelial growth factor (VEGF), EGF and Mnt expression were measured 
over a dose range of 1pM to 10nM mibolerone treatment.  miR-210, VEGF and EGF were 
measured under normoxic and hypoxic conditions. 
4.2.4 Cell culture 
4.2.4.1 miR-720 
Cells were cultured in T75 flasks, eight flasks per cell line, until 70-80% confluency.  Four flasks 
of each cell line were harvested for RNA extraction by TRIzol® with the remaining flasks being 
subject to radioimmunoprecipitation (RIPA) buffer extraction for subsequent protein analyses 
(see Section 4.2.6, page 150).   
LNCaP were grown in their normal culture media as previously described (Section 2.2.4, page 
52). 
LNCaP-R were a generous gift from Dr Charlotte Bevan, Imperial College London.  LNCaP-R are 
derived from LNCaP but have lost their sensitivity to androgens after sustained culturing (over 6 
months) and do not alter their growth rate in the presence of androgens (Pousette et al., 1997).  
LNCaP-R were maintained in RPMI-1640 supplemented with 10% FBS and 2mM L-glutamine.     
The PC-3 cell line was a generous gift from Dr Hector Keun, Imperial College London.  This PCa 
epithelial cell line does not contain detectable AR and is characterised as androgen-independent 
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(growth rate is not altered in the presence of androgens).  PC-3 were maintained in RPMI-1640 
supplemented with 10% v/v FBS and 2mM L-glutamine. 
4.2.4.2 Dose-response 
All dose-response experiments were conducted in LNCaP and treated with 1pM to 10nM of 
mibolerone for 120 hours and assayed for proliferation and PSA (as per Section 2.2.8, page 53 
and Section 2.2.9, page 55). The cellular lysate after RIPA extraction (see below) was collected.   
4.2.4.3 Hypoxia culturing conditions 
Based on previous reports (Giannakakis et al., 2008; Quero et al., 2011) 16 hours of 1% O2 was 
used to induce hypoxia in LNCaP. 
Cells were grown to approximately 70% confluency in T75 flasks.  The media was refreshed 
(normal culturing media) and six flasks were transferred to the Sanyo MCO-018M incubator set 
to hold the oxygen concentration at 1% (hypoxia).  Six flasks were maintained concurrently in 
control conditions (21% O2 normoxia).  
After 16 hours, the normoxic and hypoxic flasks were split into two groups: one group harvested 
for RNA extraction and half for protein extraction as previously described; this gave four groups 
of triplicate cultures. 
4.2.5 In silico target analysis  
Several in silico programs are available for putative target identification: TargetScan, 
MicroCosm, miBridge, PicTar, DIANA-microT, TargetRank, RNA22 and miRGator.   
The degree of complementarity of the miRNA seed region to the mRNA target is the main focus 
of these programs with some, or all, of the following factors concerning the binding site within 
the mRNA UTR: phylogenetic conservation, accessibility, type, number, clustering and 
positioning, and thermostability of the miRNA-mRNA pair (Hammell, 2010).  How the programs 
define and implement the parameters varies, often with different programs placing a special 
emphasis on a particular factor.  Selection rules, conservation differences, cut-offs and different 
implementation of the afore-mentioned parameters all combine to produce different putative 
targets and thus there may be little overlap between the methods.  Therefore it was considered 
prudent to employ three different methods, each with its own strengths and weaknesses, to 
mine for mRNA targets.    
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To identify possible mRNA targets, TargetScan (release 5.1, www.targetscan.org), miBridge 
(http://sitemaker.umich.edu/mibridge/home) and MicroCosm Targets 
(http://www.ebi.ac.uk/enright-srv/microcosm/htdocs/targets/v5/) were implemented.   
The different factors employed by the programs are outlined.  The seed region (nucleotide 
position 2-7 at the 5’ end of the miRNA) is considered important for target recognition.  
Depending on the program, for identification of an mRNA target, the seed must either be 
perfectly matched, have no more than a single mismatch, or have multiple mismatches.   In 
addition, different binding site types (Figure 1. 9, page 38) are used in different algorithms.  
Across species conservation of the mRNA target site is considered to be an important factor in 
target identification based on the assumption that an mRNA target that is conserved across 
closely-related species will more likely be biologically and functionally significant (and therefore 
less likely to be a false positive).  The rationale for utilising thermodynamic considerations is that 
a low minimum free energy of hybridisation will promote a stable miRNA:mRNA duplex thus 
allowing sufficient time for the RISC proteins to work (Hammell 2010).  RISC-bound miRNA must 
access the complementary binding site on the mRNA; local accessibility of the mRNA binding 
site generally correlates with the percentage of AU nucleotides next to the seed region 
(Hammell, 2010).  The last parameter that is commonly used is the clustering and positioning of 
the binding site within the mRNA transcript.  There may be multiple binding sites and, 
depending on the algorithm, the site score for each target may either result from simple 
addition of the score for multiple sites or may be enhanced (resulting in a score greater than 
what would be achieved by addition).   
Although miRNAs are known to target the 3’ untranslated region (UTR) of the mRNA, a number 
of experiments have indicated that the miRNAs may also target mRNA 5’ UTR (Lee et al., 2009).  
As yet, miBridge is the only program to address this issue.  
Interestingly, it has been shown that target sites in the coding region enhance regulation 
mediated by target sites in the 3’UTR (Fang and Rajewsky, 2011) although this knowledge is not 
yet incorporated into any of the methods (Massie et al., 2011). 
An important point to note is that although a large number of targets are predicted, there is a 
high degree of false positives:  for example, Ørom and Lund (2009) confirmed only 7 out of 45 
miRNAs predicted to target cyclin D1.  This highlights the difficulty of in silico target prediction.  
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However, as more data is gathered regarding other factors that influence target recognition, the 
algorithms will no doubtably improve.   
Once the list of predicted targets is generated, investigation of the targets begins: the approach 
taken was to filter the vast lists for likely targets based on rank (only the top 30 were 
considered), seed type (only 8-mer), biological plausibility (only those targets whose mRNA has 
been reported to be expressed in LNCaP) and previous literature (a role has been reported for 
this target in LNCaP).   
4.2.6 Immunoblotting 
Immunoblotting was performed as described previously (page 58) with a few improvements: 
lysis buffer, loading buffer and the washing time were optimised to increase experimental 
efficiency. 
RIPA buffer was used to lyse cells.  RIPA buffer - 50mM Tris HCl pH 8, 150mM sodium chloride, 
1% Triton X-100, 0.5% sodium deoxycholate and 0.1% sodium dodecyl sulphate – was prepared 
in advance and stored at -20°C until required.  At the end of an experiment, the cells were 
rinsed with ice-cold PBS and lysed with 100-200µL of lysis buffer (99% v/v RIPA and 1% v/v 
Pierce 100x Halt Protease Inhibitor).  Cells were scraped from the flask using a cell scraper and 
collected into pre-cooled micro-centrifuge tubes.  The tubes were continually inverted for 30 
minutes at 4°C to ensure complete lysis.  To pellet cellular debris, the samples were centrifuged 
at 12,000 xg for 20 minutes and the protein-containing supernatant collected.     
Five-times loading buffer stock consisted of 66mM tris pH 6.8, 26% v/v glycerol, 2.1% w/v 
SDS, and 0.01% w/v bromophenol blue.  Working solution consisted of 95% stock loading buffer 
and 5% mercaptoethanol.  In this study, 50µg protein was loaded per lane.  To reduce 
background, the final wash was increased to 30 minutes.  
To aid identification of protein bands, aside from the pre-stained ladder, Cell Signalling’s 
Biotinylated Protein Ladder Detection Pack (chemiladder, catalogue number 7727) was used: 
the biotinylated protein ladder was boiled at 95°C for ten minutes prior to use.   For detection of 
the chemiladder, the HRP-linked anti-biotin antibody was added to the secondary antibody at 
1:1,000.   
Conditions of the antibodies used for this Chapter are given in Table 4. 2.   
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Table 4. 2 - Details of antibodies 
 Antibody Species Molecular 
weight 
Catalogue 
number 
Dilution 
1° anti-HIF-1α Mouse 132 kDa sc-13515 1:1,000 
1° anti- Mnt Rabbit 62kDa sc-769 1:1,000 
1° anti-β-actin Mouse 42kDa A5441 1:1,000 
1° anti-IRX5 Rabbit 50kDa sc-98397 1:1,000 
2° anti-mouse Goat - sc-2031 1:10,000 
2° anti-rabbit Donkey - sc-2313 1:10,000 
For detection of chemiladder, secondary antibody was supplemented with anti-biotin antibody at 1:1,000.  All 
antibodies were supplied by Santa Cruz except for anti-β-actin (Sigma-Aldrich).  Antibodies were diluted in 
blocking buffer.  Primary antibodies are represented by 1°, secondary antibodies by 2°. Molecular weight data 
obtained from supplier datasheet. 
 
The Mnt positive control lysate (catalogue number sc-112501, Santa Cruz) was boiled prior to 
use for 5 minutes at 95°C.  In the blot, Mnt appears as multiple distinct bands between 
approximately 80kDa and 45kDa (Figure 4. 1) whilst IRX5 appears as a doublet around 100kDa. 
 
A – Santa Cruz catalogue image B – In–house reference 
 
 
Figure 4. 1 - Reference Mnt protein bands from Santa Cruz positive control Mnt 
(A) - Human Mnt expression in non-transfected and transfected (lane A and B, respectively) 293T whole cell 
lysate.  Taken from http://www.scbt.com/datasheet-112501-mnt-h-293t-lysate.html.  Accessed 27.01.12 
(B) - In-house determination of positive control (A). Loaded 6µg and exposed for 3 minutes. Where K is the 
protein size in kiloDaltons.  
 
4.2.7 qRT-PCR of miRNA 
Expression levels were assessed as previously discussed in Section 3.2.6.2, page 93. 
4.2.8 qRT-PCR of VEGF and 18S  
The Applied Biosystems High Capacity cDNA reverse transcription kit with RNase inhibitor (Part 
number 4374966) with the VEGF TaqMan® Gene Expression Assay (Hs00900055_m1, catalogue 
number 4331182) or TaqMan Ribosomal RNA Control Reagents (catalogue number 4308329) 
was employed to measure VEGF and 18S levels, respectively.  At the time of purchase, the 
information provided by the supplier indicated that the assay for VEGF may detect genomic 
DNA, therefore prior to analysis, DNAse treatment was required.  
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Deoxyribonuclease I (DNase) treatment 
The Sigma AMPD1 kit uses DNase I (deoxyribonuclease I) and the Reaction Buffer to digest any 
contaminating DNA.  The DNase is inactivated by the addition of the Stop Solution (EDTA to 
chelate the calcium and magnesium ions) and heating.  
The DNase was mixed gently by flicking.  A master mix consisting of equal volumes of Reaction 
Buffer and amplification grade DNAse I was prepared immediately before use.    Into each 
sample tube, 8μL of diluted RNA (2μg total RNA in TE buffer), and 2μL of the master mix was 
added.  The tubes were mixed gently and incubated at room temperature for 15 minutes; after 
which, 1μL of Stop Solution was added.  Each sample was then heated at 70°C for 10 minutes 
before being chilled on ice. 
Reverse Transcription 
Unlike the miRNA RT which converts a specific miRNA to cDNA, this kit reverse transcribes all 
mRNAs present in the sample (Figure 4. 2). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. 2 - Workflow for VEGF and 18S using TaqMan Gene Expression Assay 
All samples were run in triplicate for technical replication and each plate contained no RT controls and no 
template controls. 
 
The kit components and DNase-treated samples were thawed and maintained on ice 
throughout.  A master mix of the RT components was created (with and without the MultiScribe 
enzyme).  After adding an aliquot (10μL) of the master mix to 10μL of the samples, each 
consisted of: 2μL 10X RT buffer, 0.8μL 25x dNTP mix (100mM), 2μL 10X RT Random Primers, 1μL 
MultiScribe™ Reverse Transcriptase, 1μL RNase Inhibitor, 3.2μL nuclease-free H2O and 10μL of 
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sample (1800ng DNAse-treated RNA). All RT reactions were performed in singlet and with the 
No-RT control.  
After brief centrifugation, the reaction tubes were loaded into the ABI Prism 7700 Sequence 
Detection System thermocycler and incubated (Table 4. 3).   
Table 4. 3 - RT and PCR conditions 
 Stage Temperature  °C Time 
RT conditions   
 Step 1 25 10 min 
 Step 2 37 120 min 
 Step 3 85 5 min 
 Step 4 
Step g 
4 ∞ 
PCR conditions   
 Holding 95 10 min 
 Cycling 95 15 sec 
 60 1 min 
RT performed in ABI Prism 7700 Sequence Detection System with heated lid function on.  PCR performed in 
Applied Biosystems 7500 Fast Real-Time PCR System. 
 
 
VEGF PCR 
The TaqMan Universal 2x Master Mix was used for this assay.  Diluted cDNA samples were 
created: an aliquot was diluted to 15μg/μL (total 60ng in 20μL), providing enough for each 
sample to be run in triplicate (3 technical replicates plus excess) and also leaving enough for 18S 
determination. 
A PCR master mix was generated and to each 4μL of sample, 16μL of the master mix was added. 
The master mix consisted of 1μL 20x gene expression assay, 10μL of TaqMan Universal PCR 
Master Mix (2x, No AmpErase UNG) and 5μL of RNase-free H2O per 4μL of sample.  The NTC 
control had replacement of sample with water. 
The samples and technical replicates were centrifuged, 20μL was transferred to each well of the 
96-well reaction plates, sealed and centrifuged again before running on the Applied Biosystems 
7500 Fast Real-Time PCR System machine. 
18S ribosomal control PCR 
Ordinarily the control (i.e. RNU6B) would be run on the same plate, however, the large number 
of samples precluded this. Therefore, after the VEGF measurement was taken, measurement of 
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18S for all the samples was conducted.  Whilst the VEGF assay was running, the 18S samples 
were prepared and maintained on ice until loading on the machine. 
cDNA samples were diluted to 10ng in 9.7μL (1.03ng/μL).  A PCR master mix was created 
consisting of 0.1μL 10μM Ribosomal RNA Forward Primer, 0.1μL 10μM Ribosomal RNA Reverse 
Primer, 0.1μL 40μM Ribosomal RNA Probe (VIC™) and 10μL of TaqMan Universal PCR Master 
Mix (2x, No AmpErase UNG) per 9.7μL of diluted sample cDNA.  Therefore, each PCR tube 
contained 10ng cDNA. 
The PCR conditions were the same as Table 4. 3, page 153. 
4.2.9 Epidermal Growth Factor (EGF) ELISA 
EGF expression was measured using Invitrogen’s Human EGF ELISA kit (KHG0061, catalogue 
number 51144287), as per the manufacturer’s recommendations.  The kit includes all reagents 
and materials required.  The amount of EGF was determined by comparison to the standard 
curve which was run concurrently with the samples.   
Samples and reagents were thawed and brought to room temperature.  The kit utilised a 96-well 
plate format: each well was provided pre-coated with anti-EGF polyclonal antibody (‘capture 
pAb’).  The samples or standards, 100μL of each, were added to each well and incubated 
overnight at 4°C to aid capture of the EGF by the pAb; one well was left empty to act as a blank.  
After incubation, the plate was washed four times by ‘flooding’ with Wash Buffer.  Human-EGF 
Biotin Conjugate, 100μL, was added to each well, except for the blank, and incubated at room 
temperature for 1 hour.  Four washes followed, then addition of 100μL Streptavidin Working 
Solution (except for the blank).  After 30 minutes of incubation at room temperature, the plate 
was washed another four times before 100μL of Stabilised Chromogen was added to all wells, 
including the blank.  The plate was incubated in the dark for 25 minutes at room temperature; 
finally 100μL of Stop Solution was added to all wells.  Addition of the Stop Solution caused a 
change in colour, the intensity of which was proportional to EGF concentration.  EGF levels were 
read on the Tecan Sunrise™ microplate absorbance reader at 450nm within 10 minutes of 
adding Stop Solution. 
4.2.10 miRGen 2.0 Promoter Analysis 
Available from http://diana.cslab.ece.ntua.gr/mirgen/, miRGen 2.0 is a publicly available web-
based, or downloadable, database that is used to analyse miRNA promoter regions; it can be 
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used to identify possible transcription factors that are able to bind upstream of miRNA genes 
(Alexiou et al., 2010).  
4.2.11 Luciferase reporter assay 
Luciferase assays are the gold standard of target confirmation for miRNA.  Using GeneCopoeia’s 
dual reporter system, which utilises firefly (hLuc) and Renilla luciferases (RLuc) on the same non-
viral vector, putative mRNA targets of miRNA can be assessed.  The assay measures the activity 
of the two different luciferases sequentially from a single sample: the hLuc reporter gene allows 
assessment of detection of any regulatory effect of the miRNA on the mRNA whilst the second 
reporter gene, RLuc, acts as an internal control for signal normalization and accounts for 
transfection efficiency (Figure 4. 3).  
A – pEZX-MT01 B – pEZX-MR04 
 
 
 
Figure 4. 3 - Schematic of IRX5 3’UTR-containing vector (A) and (B) miRNA pre-cursor expression vector  
(A) The IRX5 expression vector contains the 3’UTR of IRX5 cloned downstream of the firefly luciferase gene 
coding gene under the control of the human SV40 promoter.  Renilla luciferase under the control of the CMV 
promoter is the internal control (tracking gene).  
(B) The miRNA pre-cursor clone non-viral expression vector.  The precursor miRNA is processed intracellular 
into the mature miRNA. 
Diagrams taken from GeneCopoeia (www.genecopoeia.com)  
 
Firefly luciferase catalyses the conversion of luciferin to oxyluciferin with the production of light; 
the intensity of the light produced is related to the amount of luciferase produced.  In the 
presence of targeting of the 3’UTR by a particular miRNA, translation is blocked, there is a 
reduction in firefly luciferase, less substrate conversion and therefore less light.  The 
transfection normaliser, RLuc, catalyses the oxidation of coelenterazine to coelenteramide with 
the production of CO2 and the emission of light (at 475nm). 
All reagents and vectors required for the dual reporter luciferase were purchased from 
GeneCopoeia (Table 4. 4).  The assay, Luc-Pair™ (LPFR-M010), provides enough reagents for 100 
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wells.  OptiMEM® was purchased from Invitrogen and the white 96-well plates (clear bottoms) 
were Corning® CLS3610.   
Table 4. 4 - Details of vectors required for luciferase assay 
Vector Catalogue number Concentration 
miR-221 HmiR0369-MR04 66nM 
IRX5 3' UTR target HmiT000326-MT01 50nM 
miR control vector CmiR0001-MR04 65nM 
3'UTR control target  CmiT000001-MT01 55nM 
Intracellular processing of the scrambled miRNA control (CmiR) leads to production of a non-targeting 
sequence. The IRX5 3'UTR expression vector (HmiT) constitutively expresses the 3'UTR of the IRX5 mRNA.  
Intracellular processing of the miR-221 expression vector (HmiR) leads to production of mature miR-221.  
 
To enable the assay to work, the manufacturer’s protocol must be optimised: there are many 
factors that must be taken into consideration, such as how many cells must be plated, whether 
to co-transfect or sequentially transfect, how much of each vector should be transfected, in 
what ratio they should be transfected and how long after transfection should the luciferase 
activity measurement be taken.  Therefore initial work consisted of testing different conditions 
(cell number, amount of vector to transfect and time until measurement of luciferase activity).  
This work was completed in collaboration with Qianxin Wu (Biomolecular Medicine) and 
additional quantities of the vectors necessary for optimisation were kindly produced by Dr 
Baojun Wang of the Molecular Microbiology laboratory at Imperial. The final protocol is detailed 
below. 
Cells were plated in normal media on Day One into 24-wells at 60,000 cells/mL/well  – the cell 
number was determined to give 70-80% confluency at time of initial transfection. 
On Day Two, cells were transfected with the 3’UTR expression vector.  HmiT and EndoFectin™ 
Plus were brought to room temperature.  DNA (HmiT) was diluted with OptiMEM® to 800ng 
HmiT per well (Solution 1). EndoFectin™ Plus was diluted with OptiMEM® to give 2.4µL 
EndoFectin™ Plus and 32.6µL OptiMEM® per well (Solution 2).   Solution 2 was added drop-wise 
to Solution 1, with gentle swirling of the tubes.  The mixture was then incubated for 15 minutes 
at room temperature.  
To transfect cells, the normal growth media was aspirated and replaced with 430µL OptiMEM.  
DNA/EndoFectin™ mixture, 60µL, was added directly to each well and the plate gently swirled.  
Three hours later, 250µL per well of special growth media (normal media with 30% FBS rather 
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than the normal 10% FBS) was added.  The cells were returned to the incubator for a further 24 
hours.  
On Day Three, cells were transfected with the pre-cursor miRNA expression vector (HmiR).  
HmiR and EndoFectin™ Plus reagent were brought to room temperature.  DNA was diluted with 
OptiMEM® to give 260ng HmiR per well (Solution 1).  EndoFectin™ Plus was diluted with 
OptiMEM® to give 0.8µL of EndoFectin™ plus 34.2µL of OptiMEM® per well (Solution 2).  
Solution 2 was added drop-wise to Solution 1 with gently swirling.  The mixture was then 
incubated for 15 minutes at room temperature. 
To transfect cells, the normal growth media was aspirated and replaced with 430µL OptiMEM®.  
DNA/EndoFectin™ mixture, 60µL, was added directly to each well and the plate gently swirled.  
Three hours later, 250µL per well of special growth media was added (normal media with 30% 
FBS rather than the normal 10% FBS).  The cells were returned to the incubator for a further 24 
hours. 
On Day Four, the cells were transferred, by pipetting up and down, from the 24-well plates to 
the white-walled 96-well plates for reading of luciferase activity.  The cell suspension from each 
well was centrifuged briefly (5 minutes at 1000rpm) and the pellet re-suspended in 80µL of 
fresh OptiMEM® media and plated into 96-well plates (80µL per well).  Luciferase was measured 
24 hours after plating into the 96-well plate (Day Five). 
Luciferase assay 
The assay measures Renilla and Gaussia sequentially from the same sample.  Luciferase assay 
reagents were equilibrated to room temperature and Working Solutions prepared: Working 
Solution 1 consisted of 0.5% Substrate I in 99.5% Solution I whilst Solution 2 consisted of 0.5% 
Substrate II in 99.5% Solution II.  
The media was aspirated from each well.  To measure hLuc activity, 100µL of Working Solution 1 
was added per well, incubated for 10 minutes and the activity measured on the luminometer.  
To measure RLuc activity, 100µL of Working Solution 2 was added per well, incubated for 10 
minutes and then the activity measured.  Luminescence was measured in the FLUOstar OPTIMA 
plate reader. 
Values were background subtracted where the background was the EndoFectin™ only control 
values.  Percentage inhibition was calculated using relative light units (RLU) and determined by: 
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% inhibition = (A – B )/ A 
 
where:  A = Luc/RLuc (HmiT) 
B = Luc/RLuc (HmiT+HmiR) 
 
4.2.12 Pathway analysis by DIANA-mirPath 
The purpose of pathway analysis is to estimate the impact co-expressed miRNAs may have on a 
particular biological pathway by identifying putative mRNA targets of selected miRNA. 
DIANA-mirPath is a web-based program that utilises a combination of three target prediction 
tools.  Each analysis consists of an input list of user-defined dys-regulated miRNAs.  Once the 
targets of multiple miRNA are identified, DIANA-mirPath performs an enrichment analysis of the 
predicted target genes by comparing those genes to all available pathways in the Kyoto 
Encyclopaedia of Genes and Genomes (KEGG) database (Kanehisa and Goto, 2000).   
The enrichment analysis is performed by a Pearson’s chi-squared test based on the number of 
genes in the dataset found to participate in a particular pathway and the number of genes 
expected by chance to be a member of that pathway, having taken into account the pathway 
size and input number of miRNA (Papadopoulos et al., 2009).  Aside from assessing the impact 
of each miRNA individually, the program also assesses the combined miRNAs and their targets 
(Union) and looks for mRNAs that are targeted by all the miRNA (Intersection).   
The output of the analysis is the enrichment p-value of the dataset for the Union, all miRNAs 
individually and the Intersection (represented by the negative natural logarithm of the p-value).   
The –ln P for the Union dataset in a specific pathway represents the co-ordinated down-
regulation of the pathway by all the miRNAs from the input list if the input list of miRNA consists 
of those that are up-regulated by treatment.    
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4.3 Results 
4.3.1 miR-720 
TargetScan, MicroCosm and miBridge were utilised to search for predicted targets; the results 
for miR-720 are detailed in Table 4. 5.   
DNA (cytosine-5-)-methyltransferase 3A (DNMT3A) was identified as a putative target of miR-
720 by TargetScan, ranking 1st in a list of 5 targets.   There is one highly conserved 8-mer site in 
the 3’UTR between position 868 and 874 of DNMT3A 3’UTR (Figure 4. 4A).    DNMT3A is a 
member of the family of DNA methyl transferases: the function of this DNMT is thought to be de 
novo methylation rather than maintenance methylation.  The addition of a methyl group 
prevents binding of TFs and initiation of transcription thereby acting as a silencing mechanism.  
As such, areas that are hyper-methylated, compared to the normal level of methylation, are 
silenced and conversely areas of the genome that are hypo-methylated have a more ‘open’ 
chromatin conformation and are more transcriptionally active (May, 2010).  
Table 4. 5 - Putative targets of miR-720 by TargetScan, miBridge and MicroCosm 
TargetScan miBridge 
DNMT3A ADCY9 CNNM1 KCNMB1 PHACTR4 SMCR8 
DCUN1D4 AHDC1 CPT1B KIAA1026 PIK3R6 SNX18 
SAMD4B AKAP5 CYP4F11 KIAA1303 PLA2G5 SPAG6 
KCTD15 ANKRD13C DAK KIAA1967 PLCD1 SPATA13 
HNRNPA2B1 ANKRD44 DBF4B LAIR1 PNKD SPPL3 
  AP4S1 DENND3 LRRC14 PNLDC1 ST3GAL1 
  APOL1 DHFR MAPK4 POU4F1 STK40 
  ARHGAP25 DIXDC1 MN1 PPARA SYNPO2L 
  ARMC5 ENTPD7 MSRB2 PPP2R5C TCF19 
  ASF1B FBLIM1 NCOR2 PRIC285 TCF21 
  BCL9 FEM1A NDRG4 REPIN1 TWIST1 
  BNIPL GEN1 NDST1 RERE UCK1 
  C1orf104 GJD3 NKX2-3 RFK VIPR2 
  C1orf151 GRM6 OGFOD2 RPS6KL1 VPS53 
  C4orf30 HSPB7 OPRL1 RSPH1 WIZ 
  C5orf38 IFNGR2 OTUD7B SAMD4B ZFYVE20 
  CARHSP1 IHPK1 PBLD S???? ZNF554 
  CDK2AP2 ITPRIPL2 PCGF5 SETD1A ZNF91 
  CLIP2 JMJD2B PCYOX1 SLIT1   
TargetScan targets are listed by rank (DNMT3a is most likely target, HNRNPA2B1 is least).  miBridge does not 
rank targets.  http://sitemaker.umich.edu/mibridge/target_predictions  Accessed 28.03.11.  MicroCosm did 
not predict any targets. Only SAMD4B was identified by TargetScan and miBridge. Unfortunately ‘S????’ was 
replaced with 40057 when importing the data into Microsoft Excel and the identity of this putative target can 
now no longer be identified (miBridge is no longer available, March 2012).   
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Pang et al. (2006) profiled gene expression in LNCaP and LNCaP-R.  Of particular interest, they 
identified several genes involved in DNA methylation that were higher in LNCaP-R: for example, 
DNMT3A.  The level of DNMT3A was 4.3-fold higher in LNCaP-R compared with LNCaP cells.  
Using 5-aza-2’-deoxycytidine, a DNA methyltransferase inhibitor, they were able to restore 
androgen responsiveness in LNCaP-R and indeed coerce the cells into an appearance that more 
closely resembled its parent LNCaP;  thus providing evidence of a crucial role for DNMT3A in 
androgen responsiveness.  In support of this, Izbicka et al. (1999) showed that DNA 
methyltransferase inhibitors can restore androgen responsiveness in the androgen-independent 
prostate cancer line DU-145.  
To test the potential role of miR-720 in androgen sensitive and insensitive cell lines, basal 
expression of miR-720 was determined by qRT-PCR in LNCaP, LNCaP-R and PC-3.  The 
expectation was that if miR-720 was involved in regulation of DNMT3A expression and thus 
androgen insensitivity, then expression would be lower in PC-3 and LNCaP-R, as these are 
androgen insensitive and have higher DNMT3A levels. 
qRT-PCR identified that there was no difference in expression of miR-720 in the three cell lines 
although there was a large variability in the PC-3 cell line (Figure 4. 4B). 
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A – miR-720 targeting of DNMT3a mRNA 
 
B – miR-720 in LNCaP, LNCaP-R and PC-3 
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Figure 4. 4 - Putative targeting of DNMT3A by miR-720 and miR-720 expression in LNCaP, LNCaP-R and PC-3 
A – Complementary base pairing between DNMT3a mRNA nucleotide two and eight of the seed region (purple 
text) of miR-720 (8-mer, blue text).  There is one single 8-mer site in the 3’UTR region between position 875 
and 882 of DNMT3a 3’UTR.  3’ UTR NM_022552, NM_153759.3, NM_175629. Abbreviations: ORF = open 
reading frame  
B – Basal miR-720 expression in LNCaP, LNCaP-R and PC-3.  Data are from triplicate cultures with SD error bars.  
 
 
4.3.2 Dose response of mibolerone 
To identify whether miR-210 and miR-221 were altered in a dose-responsive manner by 
treatment with androgen, androgenic stimulation was first confirmed by measurement of PSA 
and proliferation. 
Cells were treated with different concentrations of mibolerone for 120 hours: as observed 
earlier in Chapter 2 (phenotypic anchor), the result was a potent effect on proliferation and PSA 
(Figure 4. 5).  
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Figure 4. 5 - PSA and proliferation in LNCaP with 120 hours of mibolerone 
Data are mean of at least six independent cultures with SD error bars. Statistical analysis of PSA (prostate 
specific antigen) and proliferation conducted using 1-way ANOVA with Dunnett’s post-hoc test comparing 
against the vehicle control (VC) where *** indicates P<0.001, **P<0.01 and *P<0.05.  
 
As can be clearly seen in Figure 4. 5, concentrations of 100pM and above induced a statistically 
significant increase in proliferation (P<0.001) with a maximal proliferative effect of 
approximately 2.5-fold versus the control.  Equally, PSA secretion was induced in a 
concentration-dependent manner with concentrations above 100pM eliciting a highly 
statistically significant increase (P<0.001). 
4.3.3 miR-221 
Concurrent with the concentration dependent effects on the phenotypic anchor, miR-221 was 
down-regulated up to 4-fold by mibolerone treatment (Figure 4. 6A). Both PSA and proliferation 
were significantly inversely correlated (P<0.05) with miR-221 expression: Pearson r values of -
0.8780 and -0.9053, respectively. 
TargetScan, miBridge and MicroCosm were implemented for in silico analysis of putative targets 
of miR-221.  Between the three methods employed, over 1500 putative targets were found.  
However, there was little concordance between the methods – only six miRNAs were found by 
all programs (Figure 4. 6B).    IRX5 was identified as a possible target: 24th in the list generated 
by TargetScan and 446th in the list generated by MicroCosm.  It was one of 42 miRNAs common 
between the two methods but was not found by miBridge.   
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The immunoblot of IRX5 consistently produced a specific band at approximately 100kDa – IRX5 
has been shown to form homo- and heteromeric complexes with IRX3 and 4 as well as itself (He, 
Jia and Takimoto, 2009) so this higher molecular weight band may be an IRX5 homo- or hetero 
dimer.  Densitometry showed that IRX5 protein levels increased in a dose-dependent manner to 
greater than 2-fold by 1nM (Figure 4. 6C).   
Computational tools (TargetScan and MicroCosm) predicted an evolutionarily-conserved binding 
site for miR-221 in the 3’UTR of the IRX5 (Figure 4. 6D).  To determine whether this miRNA was 
able to target IRX5, the 3’UTR of IRX5 was cloned downstream of the hLuc gene in a reporter 
plasmid.  The dual-reporter vector was transfected into LNCaP; 24 hours after the final 
transfection the activity of both luciferases was measured using the manufacturer’s protocol.  
Preliminary luciferase results indicated a 56% reduction in light output, indicative of targeting of 
the IRX5 mRNA by miR-221 (Figure 4. 6E). 
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A - miR-221 expression 
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B - In silico targets 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Rank 
Target MicroCosm  TargetScan 
HECTD2 786 11 
 GABRA1 897 13 
 SBK1 1155 57 
 FOS 838 162 
 BBC3 187 950 
 SNCB 1092 202 
 
C- IRX5 immunoblot D – miR-221 targeting of IRX5 mRNA 
 
 
 
 
 
 
 
 
 
 
 
 
vc
1p
M
10
pM
10
0p
M
1n
M
10
nM
0
100
200
300
400
500
%
 o
f 
V
C
 
 
IRX5 
β-actin 
247 
↓ 
253 
↓ 
[MIB] 
165 
 
E - Preliminary luciferase reporter assay 
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Figure 4. 6 - Expression of miR-221, putative targets, IRX5 expression, schematic of miR-221 targeting IRX5 
UTR and validated targets of miR-221 
(A) miR-221 expression, data are mean of triplicate cultures with SD error, normalised with RNU6B. 
(B) Summary of overlapping targets for miR-221. MicroCosm had 1095 targets, TargetScan 307* and miBridge 
225. * Targets include those of miR-221 and -222.  
(C) Immunoblotting of IRX5 protein normalised to β-actin.  Protein level was quantified by densitometry. Data 
are mean of triplicate lanes. 
(D) Targeting of the 3’UTR of IRX5 mRNA at position 247-253 by miR-221. Complementary base pairing 
between IRX5 mRNA nucleotide two and eight of the seed region (purple text) of miR-221 (8-mer, blue text).  
There is one single 8-mer site in the 3’UTR region.  
(E) LNCaP, 60,000 cells, were plated into 24-well plates (Day 1).  On Day 2, cells were transfected with 800ng 
target sequence (3’UTR expression vector)/well.  On Day 3, cells were transfected with 260ng of miR-221 
expression vector (ratio of 3:1, target sequence to miR-221 mimic).  On Day 4, cells were transferred into 96-
well plates.  On Day 5, the activities of firefly luciferase and Renilla luciferase were measured sequentially.  
Data is background subtracted (EndoFectin™ control values).   
Abbreviations: ORF = open reading frame; PSA = prostate specific antigen; RLU = relative light units; UTR = 
untranslated region. 
 
4.3.4 miR-210 
Cells were treated with mibolerone for 120 hours.  Concurrent with increases in PSA expression 
and proliferation, miR-210 was dose-dependently induced by mibolerone treatment up to 4-fold 
at 10nM (Figure 4. 7A), although the expression of both PSA and proliferation was not 
significantly correlated.  This result indicates that this miRNA is directly or indirectly under 
androgenic control. 
There are a number of validated miR-210 targets such as the Max-binding protein Mnt (Zhang et 
al., 2009) (Figure 4. 7B).  Figure 4. 7C depicts the immunoblotting result for Mnt protein: Mnt 
protein is decreased with increasing mibolerone concentration in agreement with miR-210 
targeting of Mnt mRNA and in conjunction with growth promoting effects of decreasing Mnt.   
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miR-210 was dose-dependently increased with mibolerone treatment under normoxia.  miR-210 
has been reported to be up-regulated under hypoxia due to HIF-1α up-regulation.  Therefore to 
test whether this holds true in LNCaP, the cells were exposed to hypoxia and miR-210 
expression measured.  As can be seen in Figure 4. 7D, miR-210 is up-regulated greater than 4-
fold by 16 hours of hypoxic conditions (1% O2).  
Probing for HIF1α protein was undertaken.  Unfortunately, despite numerous attempts a 
specific signal for HIF1α was not detected.  Therefore, to try and investigate the mechanism of 
miR-210 further, and establish whether it is induced due to increased HIF-1α expression, 
analysis of a protein that is down-stream of HIF1α was undertaken (VEGF).  VEGF mRNA levels 
were assessed by qRT-PCR and normalisation was achieved with the 18S ribosomal control and 
CT method.  The results indicate that in normoxic conditions, and despite the large degree of 
variability between replicates, mibolerone induced VEGF expression to a maximal 3-fold 
increase at 10nM treatment.  VEGF expression was significantly correlated with miR-210 
expression (Pearson correlation of 0.86, P<0.05; Figure 4. 7E). 
Previously, it has been reported that LNCaP secrete EGF, which acts in an autocrine manner and 
stimulates the expression of mTOR and subsequently HIF1α, potentially providing a mechanism 
for miR-210 induction in a normoxic environment.  Therefore it was hypothesized that the 
mechanism for miR-210 induction was via stabilisation of HIF1α due to autocrine stimulation 
from mibolerone-induced EGF secretion.  EGF levels in the cellular supernatant were assessed 
using Invitrogen’s EGF ELISA kit.  EGF was not detected in the LNCaP media – the reading was at 
baseline.  The standard curve performed well, indicating that there was not a problem with the 
assay itself.  The results indicate that EGF is not stimulated by mibolerone, or that the level of 
EGF is below the limit of detection for this assay, and that if HIF1α stabilisation is responsible for 
the miR-210 induction, it is unlikely to be because of increased EGF secretion. 
At 1% O2 VEGF mRNA was induced 10-fold compared to the levels in normoxia (Figure 4. 7G).  
This indicates that although VEGF is induced by mibolerone, the induction is not as strong as 
observed under hypoxia. 
Other miRNAs have been identified as altered by hypoxia, for example miR-26a.  Validation by 
qRT-PCR of miR-26a expression was conducted in the samples used for microarray analysis 
(Figure 4. 7J): 100pM of mibolerone did not induce expression of this miRNA. 
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Analysis of the miR-210 promoter region using miRGen 2.0 highlighted a number of different 
transcription factors (TF) that were predicted to bind, such as AP-1, Pax-4, and Oct-1 (Table 4. 
6).   
 
A - miR-210 expression B – miR-210 targeting of Mnt 3’UTR 
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C – Mnt expression 
 
 
 
 
 
 
 
 
 
 
 
 
D – VEGF in mibolerone-treated LNCaP (normoxia) E – Pearson correlation between VEGF and miR-
210  
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F – miR-210 expression in hypoxia and normoxia G - VEGF in normoxia and hypoxia 
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H – EGF standard curve I - EGF expression 
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Figure 4. 7 - miR-210, Mnt and VEGF expression with mibolerone treatment and in hypoxia and normoxia 
A – miR-210 expression with mibolerone treatment for 120 hours.  Data are mean of triplicate cultures with SD 
error bars (except VC which is two replicates). 
B - miR-210 targeting of Mnt by four 6-mer binding sites. Base pairing at positions 2524-2529, 3619-3624, 
3823-3828, 3998-4003 of Mnt 3’ mRNA (total length 4865 nucleotides, NM_020310.2, positive strand).  
C – Mnt expression with mibolerone treatment for 120 hours.  Total protein (50µg) was loaded per lane.  Due 
to a technical problem, the blot was unable to be used to determine β-actin levels, however the ponceau 
shows that the amount of protein loaded into each lane was approximately equal.   
D – VEGF mRNA expression with mibolerone treatment for 120 hours.  Data are mean of triplicate cultures 
with SD error bars (except VC which is two replicates).   
E – Pearson correlation between mean miR-210 and mean VEGF expression.  Significant correlation of 0.8663.   
F – Basal miR-210 expression in normoxia and hypoxia.  Cells were grown in normoxia (21% O2) or hypoxia 
(1%) for 16 hours. Data are mean of triplicate cultures with SD error bars. Data is normalized to normoxia.  
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G – Basal VEGF mRNA expression in normoxia and hypoxia.  Cells were grown in normoxia (21% O2) or hypoxia 
(1%) for 16 hours. Data are mean of triplicate cultures with SD error bars. Data is normalized to normoxia 
H – Standard curve of EGF.  Data are mean of two replicates per standard. 
I – EGF protein expression from mibolerone-treated LNCaP.  Data are mean of seven replicates for samples 
with SD error bars and two replicates for EGF blank (0 pg/mL EGF).   
J – miR-26a expression.  Data are mean of triplicate cultures with SD error bars. 
Abbreviations: AU = arbitrary units; BIC = bicalutamide; DHT = dihydrotestosterone; EGF = epidermal growth 
factor; MIB = mibolerone; N = represents any non-complementary base; VC = vehicle control; VEGF = vascular 
endothelial growth factor. 
 
 
 
 
 
Table 4. 6 - Transcription factors that may target the miR-210 gene 
Name Transcriptional start site 
Pax-4 First miRNA, Experimental 
Oct-1 First miRNA 
USF First miRNA, Experimental (x2) 
Nkx2-5 First miRNA, Experimental 
ARP-1 First miRNA 
AP-1 x 2 First miRNA 
HNF-4 First miRNA, Experimental 
OCT-x First miRNA 
Elk-1 First miRNA, Experimental 
Pax-6 Experimental 
v-Myb Experimental 
MyoD Experimental 
R Experimental 
Cart-1 Experimental 
SREBP-1 Experimental 
c-Ets-1(p54) Experimental 
Putative TF binding sites were identified using miRGen 2.0 (Alexiou et al., 2010). miRGen 2.0 integrates four 
different studies  that identified miRNA transcripts and their promoter regions either experimentally or by 
computational means. Transcriptional start site (TSS) binding sites are defined as being located from 5kb 
upstream to 1kb downstream of the TSS.  ‘First miRNA’ means the start site of the first miRNA in each cluster 
serves as a proxy for an unknown TSS. ‘Experimental’ means the TSS was determined experimentally.  The TF 
USF had two experimentally determined TF binding sites in two different locations.  Accessed 13.12.11.   
 
 
 
 
4.3.5 Pathway analyses 
Pathway analyses using DIANA-mirPath was conducted on miRNA that were dys-regulated as 
identified by the microarray data.  This was conducted with the aim of identifying significant 
pathways that may play a role in the prostate epithelial phenotype.  
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4.3.5.1 DHT: miR-99a, -100, let-7a, -7c, -7d 
Microarray analysis of the ComBat dataset showed that with 24 hours of DHT treatment, miR-
99a, miR-100, let-7a, let-7c and let-7d were all significantly down-regulated (Figure 4. 8).  
Analysis of their family members and clustering patterns revealed an intriguing relationship – 
miR-99a is clustered with let-7c; the miR-99 family consists of miR-99a, miR-99b and miR-100; 
miR-100 is clustered with let-7a and let-7d.  Therefore, it may be that DHT treatment repressed 
the miR-99 family at different genomic locations (chromosomes 9, 11, 21 and 22).  
 
 
 
 
 
 
 
 
 
 
 
Figure 4. 8 - Expression of miR-99a/b, -100, let-7a/c/d in the vehicle and DHT-treated cells over time 
ComBat adjusted and log2 transformed microarray expression values, are presented as the mean of triplicate 
cultures with SD error bars.  Blue is vehicle control whilst red is DHT-treated expression values.   
 
The sequences of the miR-99 family and three members of the let-7 family are given in Table 4. 
7. 
Table 4. 7 - Sequences of mature miRNA from miR-99 family and let-7 family with accession numbers 
miRNA Accession Sequence (5’ to 3’ direction) 
miR-99a-5p MIMAT0000097 AACCCGUAGAUCCGAUCUUGU
G miR-99b-5p MIMAT0000689 CACCCGUAGAACCGACCUUGC
G miR-100-5p MIMAT0000098 AACCCGUAGAUCCGAACUUGU
G let-7a-5p MIMAT0000062 UGAGGUAGUAGGUUGUAUAG
UU let-7c MIMAT0000064 GAGGUAGUAGGUUGUAUGG
UU  let-7d-5p MIMAT0000065 
 
AGAGGUAGUAGGUUGCAUAG
UU Seed region in green, highlighted in yellow which positions differ between the miR-99 family and highlighted in 
pink those that differ in the let-7 family.  All miRNAs are 22 nucleotides in length.  Sequences obtained from 
www.miRBase.org.  The families share the GUAG motif.  
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Pathway analysis of those five down-regulated miRNA identified 12 pathways that were 
significantly enriched (in descending order of significance based on Union –ln p value): bladder 
cancer, MAPK signalling pathway, Type II diabetes mellitus, glioma, chronic myeloid leukaemia, 
pancreatic cancer, p53 signalling pathway, ECM-receptor interaction, calcium signalling 
pathway, melanoma, adherens junction and colorectal cancer.     
However, the Intersection dataset, which comprises putative mRNA transcripts that are 
targeted by all of the input miRNAs, identified only one gene that was significant: insulin-like 
growth factor 1 receptor (IGF-1R, –ln p-value of 6.84).  
The regions of the IGF-1R 3’UTR which are complementary to the miR-99a family and let-7 
family are given in Table 4. 8. 
Table 4. 8 - Positions of regions in IGF-1R 3’UTR that are complementary to miR-99a/b, -100 and let-7a/c/d 
Position in IGF-1R 3’UTR miRNA Seed type 
99-105 let-7a 7mer-A1 
99-105 let-7c 7mer-A1 
99-105 let-7d 7mer-A1 
2614-2620 let-7a 8mer 
2614-2620 let-7c 8mer 
2614-2620 let-7d 8mer 
5597-5603 miR-99b 8mer 
5597-5603 miR-100 8mer 
5597-5603 miR-99a 8mer 
6656-6662 let-7a 7mer-m8 
6656-6662 let-7c 7mer-m8 
6656-6662 let-7d 7mer-m8 
Details of site pairing from TargetScan Human version 5.2 (June 2011).  8mer = exact match to the mature 
miRNA seed plus position 8 followed by an ‘A’; 7mer-A1 = exact match to the mature miRNA seed followed by 
an ‘A’; 7mer-m8 = exact match to the mature miRNA seed and position 8.  Abbreviations: IGF-1R = insulin 
growth factor 1 receptor; UTR = untranslated region. 
 
Decreased expression of these miRNAs in the DHT-treated cells may lead to a co-operative de-
repression of IGF-1R and increased receptor protein levels.  In the microarray experiments miR-
99a was abundantly expressed, ranking 7th in both the ComBat and Batch 2 only datasets with a 
mean expression of log2 12.  The let-7 family was the highest expressed family with an average 
expression of log2 12.  Therefore it is likely that IGF-1R is under considerable repression if it is 
indeed targeted by any combination of these miRNAs. 
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4.3.5.2 Mibolerone: dys-regulated miRNA in ComBat data and Batch 2 only 
A comparison between the DE miRNAs found in each dataset was done at the P<0.3 level.  All of 
the miRNAs that were identified in the ComBat data set, except miR-7, were also DE in the 
analysis of Batch 2 alone.   
As may be expected, there were no transcripts that were targeted by all the miRNA but 40 
pathways were significantly enriched (P<0.01 level) for targets of those dys-regulated miRNA 
(Table 4. 9).  Of particular interest are the prostate cancer (Figure 4. 9), ErbB (Figure 4. 10), 
mTOR (Figure 4. 11) and p53 (Figure 4. 12) pathways.  
 
Table 4. 9 - Pathways significantly enriched (P<0.01) for targets of dys-regulated miRNAs in mibolerone-
treated cells at 120 hours of exposure 
KEGG Pathway Class Pathway 
ID 
# of Genes 
(Union)  
-ln(p-value) 
(Union)  
Axon guidance Organismal 
systems/Development 
4360 67 24.45 
ErbB signalling pathway  Signal transduction 4012 48 17.61 
Regulation of actin 
cytoskeleton  
Cellular processes/Cell 
motility 
4810 90 16.18 
Ribosome  Genetic information 
processing/ translation 
3010 2 14.66 
Oxidative phosphorylation  Energy metabolism 190 8 14.48 
Prostate cancer  Cancer 5215 46 14.43 
Glioma  Cancer 5214 35 12.8 
Focal adhesion  Cellular processes/ Cell 
communication 
4510 81 12.79 
Ubiquitin mediated 
proteolysis  
Genetic information 
processing/ Folding, sorting, 
degradation 
4120 59 12.25 
MAPK signalling pathway  Signal transduction 4010 99 11.66 
Wnt signalling pathway  Signal transduction 4310 63 10.91 
Long-term potentiation  Nervous system 4720 33 10.7 
Renal cell carcinoma  Cancer 5211 35 10.23 
Metabolism of xenobiotics 
by cytochrome P450  
Xenobiotic biodegradation 
and metabolism 
980 2 10.05 
Colorectal cancer  Cancer 5210 41 10.02 
Adherens junction  Cellular processes; Cell 
Communication 
4520 36 10.02 
Arachidonic acid 
metabolism  
Metabolism; Lipid 
metabolism 
590 2 9.22 
Type II diabetes mellitus  Endocrine and metabolic 
disease 
4930 22 8.55 
Chronic myeloid leukaemia  Cancer 5220 36 8.37 
mTOR signalling pathway  Signal transduction 4150 25 8.2 
Pancreatic cancer  Cancer 5212 34 7.5 
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KEGG Pathway Class Pathway 
ID 
# of Genes 
(Union)  
-ln(p-value) 
(Union)  
Non-small cell lung cancer  Cancer 5223 27 7.31 
TGF-beta signalling 
pathway  
Signal transduction 4350 39 6.73 
Amyotrophic lateral 
sclerosis (ALS)  
- 5030 12 6.31 
Glycolysis / 
Gluconeogenesis  
Carbohydrate metabolism 10 6 6.21 
DNA replication  GIP; Replication and repair 3030 1 6.06 
Endometrial cancer  Cancer 5213 25 5.98 
Circadian rhythm  4710 9 5.8 
Valine, leucine and 
isoleucine degradation  
Amino acid metabolism 280 3 5.77 
Tryptophan metabolism  Amino acid metabolism 380 6 5.64 
Linoleic acid metabolism  Lipid metabolism 591 1 5.64 
Notch signalling pathway  Signal transduction 4330 20 5.51 
Complement and 
coagulation cascades  
Immune system 4610 8 5.31 
Neurodegenerative 
Diseases  
- 1510 19 5.26 
Thyroid cancer  Cancer 5216 15 5.15 
Fatty acid metabolism  Fatty acid metabolism 71 4 5.11 
Melanogenesis  Endocrine system 4916 40 5.08 
Acute myeloid leukaemia  Cancer 5221 25 4.92 
Base excision repair  GIP; Replication and repair 3410 2 4.84 
p53 signalling pathway  Cell growth and death 4115 29 4.67 
miRNAs included in the DIANA-mirPath analysis were: let-7c, -105, -10a, -10b, -125b, -134, -181a, -181b, -182, -
190, -196a, -196b, -210, -222, 221, -30a, -30d, -324-3p, -338-3p, -342-5p, -371-5p, -455-3p, -499-5p, -615-3p, -
874, -939, -95 and -99a.  The following miRNAs were not available in the database (except miR-7 which was 
available but was not common between the datasets): miR-720, -1915, -1290, -1246, -1181, -1308, -30b*, -
126*, -629* and -181a-2*. 
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Figure 4. 9 - Annotation of the prostate cancer KEGG pathway by DIANA-mirPath analysis 
This pathway was significantly enriched for targets of these miRNAs: let-7c, -105, -10a, -10b, -125b, -134, -
181a, -181b, -182, -190, -196a, -196b, -210, -222, 221, -30a, -30d, -324-3p, -338-3p, -342-5p, -371-5p, -455-3p, 
-499-5p, -615-3p, -874, -939, -95 and -99a.    All those in yellow are putative targets of the miRNAs. 
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Figure 4. 10 - Annotation of the ErbB KEGG pathway by DIANA-mirPath analysis 
This pathway was significantly enriched for targets of these miRNAs: let-7c, -105, -10a, -10b, -125b, -134, -
181a, -181b, -182, -190, -196a, -196b, -210, -222, 221, -30a, -30d, -324-3p, -338-3p, -342-5p, -371-5p, -455-3p, 
-499-5p, -615-3p, -874, -939, -95 and -99a.    All those in yellow are putative targets of the miRNAs. 
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Figure 4. 11 - Annotation of the mTOR signalling KEGG pathway by DIANA-mirPath analysis 
This pathway was significantly enriched for targets of these miRNAs: let-7c, -105, -10a, -10b, -125b, -134, -
181a, -181b, -182, -190, -196a, -196b, -210, -222, 221, -30a, -30d, -324-3p, -338-3p, -342-5p, -371-5p, -455-3p, 
-499-5p, -615-3p, -874, -939, -95 and -99a.    All those in yellow are putative targets of the miRNAs. 
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Figure 4. 12 - Annotation of the p53 signalling KEGG pathway by DIANA-mirPath analysis 
This pathway was significantly enriched for targets of these miRNAs: let-7c, -105, -10a, -10b, -125b, -134, -
181a, -181b, -182, -190, -196a, -196b, -210, -222, 221, -30a, -30d, -324-3p, -338-3p, -342-5p, -371-5p, -455-3p, 
-499-5p, -615-3p, -874, -939, -95 and -99a.    All those in yellow are putative targets of the miRNAs. 
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4.4 Discussion 
The aims of this Chapter were to investigate a set of miRNAs that were identified by the 
microarray analysis as being dys-regulated with different treatments and investigate their 
function in LNCaP.  
4.4.1 miR-720 
In the LNCaP deep sequencing study by Xu and others (2010), expression of miR-720 was low 
whilst let-7a was exceedingly high (relative read count of 1 and 307,803 respectively).  In 
Chapter 3’s microarray study, miR-720 was the most highly expressed miRNA (high expression 
confirmed with qRT-PCR), whilst let-7a levels were also high (log2 13-14).  These contradictory 
measurements of miRNAs between sequencing technology and microarray prompted further 
study of this miRNA.    
Using in silico analyses, DNMT3A was identified as a potential target of miR-720.  A number of 
investigators reported that DNMT3A expression varies between androgen-sensitive and -
insensitive states.  Therefore there was potential that miR-720 may contribute towards 
androgen insensitivity by targeting DNMT3A.  However, qRT-PCR of PC-3, LNCaP and LNCaP-R 
did not reveal differential expression of miR-720.  It therefore seems unlikely that miR-720 is 
involved in the mechanism for differences in DNMT3A expression in LNCaP and its androgen 
insensitive subline LNCaP-R and is not associated with androgen insensitivity.   
As of November 2011, only one report had been published which identifies a target of this 
miRNA.  Chikh et al. (2011) identified p63 as a target of miR-720 through translational inhibition.  
Up-regulation of miR-720 in primary keratinocytes slowed cell proliferation whilst loss of p63 
resulted in an absence of proliferating cells in the epidermis.  The mechanism for up-regulation 
of miR-720 was by knockdown of iASPP (inhibitor of apoptosis stimulating protein of p53).  
iASPP inhibits the tumour suppressor p53 and thus knockdown of iASPP would be pro-apoptotic.  
Clearly in the microarray experiment, the cells were exposed to mitogenic stimuli in the 
mibolerone treated cells so it is unlikely that the high expression of miR-720 was due to iASPP 
loss.     
Interestingly, the p63 gene, TP63, was not identified in this in silico analysis using TargetScan, 
miBridge and MicroCosm Targets, which highlights the limitations of using a bioinformatic 
approach to miRNA target identification.   
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The p63 gene, found on chromosome 3, encodes two main groups of transcripts generated by 
two independent promoters: those with a transactivation domain, TAp63; and those without 
the TA domain, ∆Np63 (Grisanzio and Signoretti, 2008).  Each of these isotypes has alpha, beta 
and gamma forms and performs different functions; for example, ΔNp63α represses p53- or 
TAp63γ-mediated transcription, but the gamma variant is only able to repress p53-mediated 
transcription (Yang et al., 1998).   The three isotypes that contain the TA domain are able to 
transactivate p53 reporter genes and induce apoptosis whilst the ∆N isotypes are able to 
suppress transactivation of p53 and the TA isotypes (Signoretti et al., 2000).    
Signoretti et al. (2000) studied different PCa cell lines and normal prostatic basal cells and 
identified that ΔNp63 mRNA was undetectable in LNCaP, whilst the TA isoform was detectable, 
although at 14-fold less than normal basal or PC-3 cells.  In terms of protein expression, LNCaP 
were found not to express p63 protein.  Thus it may be that high miR-720 expression 
contributes to the lack of p63 protein expression despite the presence of TAp63 mRNA (albeit 
low expression). 
In summary, although miR-720 may not be associated with androgen insensitivity it may still 
have an important role in prostate biochemistry and/or prostate cancer.  Further work is clearly 
warranted to establish targets of this miRNA and elucidate its function. Knock down 
experiments using antagomiRs directed against miR-720 with measurement of indices such as 
cell proliferation, invasive ability and cell death would help clarify miR-720’s role.    
4.4.2 miR-221 
In this project, treatment of LNCaP with the AR-agonist mibolerone had a dose-responsive effect 
on proliferation, PSA secretion and miR-221 expression (repression).   
In human PCa specimens, nine studies have shown miR-221 to be up-regulated in PCa 
(Appendix, Table 7.1, page 217). For example, Sun and colleague’s recent study (2011) found 
miR-221/222 was increased in PCa: castration-resistant samples had >4-fold increase compared 
to normal samples, although the hormone-sensitive PCa were significantly down-regulated 
(19/21 primary tumours).  In vitro, other groups have shown differential expression in cell lines 
with differing androgen sensitivity: for example, Sun et al. (2009) found >5-fold increase in miR-
221 expression in castration-resistant cell lines compared with LNCaP. 
180 
 
A few reports have addressed miR-221’s role in LNCaP physiology: Galardi et al. (2007) found 
that miR-221/222 positively regulated the cell cycle by virtue of targeting p27 (p27 inhibits G1-S 
transition).  Stable transfection of these miRNAs increased the number of cells in S-phase and 
the growth rate.   Transfection of a miR-221 mimic significantly stimulated the growth of LNCaP 
(>1.5-fold) (Zheng et al., 2011).  However, Tong et al. (2009) found transfection of miR-222 
decreased LNCaP growth by 36% - they did not transfect miR-221 as they hypothesised that as it 
shares the same seed, it could reasonably be expected to target the same transcripts. 
Two studies have shown miR-221 to be repressed by androgens (Ambs et al., 2008; Waltering et 
al., 2010) and that this repression may be mediated by a putative ARE upstream of the miR-221 
gene (Ambs et al., 2008).  In agreement with the afore-mentioned studies, androgen-dependent 
repression was observed in this study.    
Target identification 
As of January 2012, there were 15 reported direct targets of miR-221 involved in a variety of 
processes (Table 4. 10). 
Table 4. 10 - Known targets of miR-221 
Known 
targets 
Official full name Role Reference 
p27
Kip1
 cyclin-dependent kinase 
inhibitor 1B 
CDK inhibitor Galardi et al. (2007) 
p57
Kip2
 cyclin-dependent kinase 
inhibitor 1C 
CDK inhibitor Medina et al. (2008) 
TIMP3 TIMP metallopeptidase 
inhibitor 3 
Tumour suppressor Lu et al. (2011) 
DICER1 dicer 1, ribonuclease type III miRNA biogenesis Cochrane et al. (2010) 
ETS-1 v-ets erythroblastosis virus E26 
oncogene homolog 1 (avian) 
Inflammation and tube 
formation 
Zhu et al. (2011) 
ARHI/DIRAS3 DIRAS family, GTP-binding RAS-
like 3 
Tumour suppressor  Chen et al. (2011) 
PTEN Phosphatase and tensin 
homolog  
Tumour suppressor Chun-Zhi et al. (2010) 
PUMA p53 up-regulated modulator of 
apoptosis 
Tumour suppressor  Zhang et al. (2011) 
Bmf Bcl2 modifying factor Pro-apoptotic BH3-only Gramantieri et al. (2009) 
Kit v-kit Hardy-Zuckerman 4 feline 
sarcoma viral oncogene 
homolog (Drosophila) 
Proto-oncogene Felli et al. (2005) 
DVL2 Dishevelled, dsh homolog 2  Signal transduction (Wnt 
pathway) 
Zheng et al. (2011) 
FOXO3 Forkhead box O3 Apoptosis Di Leva et al. (2010) 
TRPS1 Trichorhinophalangeal 
syndrome type 1 
Member of GATA family of 
transcriptional repressors 
Stinson et al. (2011) 
ICAM-1 Intercellular adhesion 
molecule 1 
Cell adhesion  Hu et al. (2010) 
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Known 
targets 
Official full name Role Reference 
ERα Oestrogen receptor alpha Transcription factor (Zhao et al., 2008) 
Only those where a direct link has been shown (i.e. by luciferase reporter assay) are included. 
 
In this study, in silico target analysis identified many putative targets of this miRNA: IRX5 was 
chosen for further analysis based on published data and biological plausibility.  mRNA 
transcripts may be targeted by more than one miRNA: however, no other miRNAs were 
predicted to target IRX5 (www.targetscan.org) whilst IRX5 is predicted to have a single 8-mer 
seed match to miR-221 in the 3’UTR region.  
IRX5 is a homeobox-containing TF of the Iroquois gene family (Myrthue et al., 2008).  Homeobox 
(60 amino acid residue in the DNA binding motif)-containing TFs have been found to influence 
components of the cell cycle machinery (Del Bene and Wittbrodt, 2005).  Concurrent with miR-
221 repression by mibolerone, was a dose-dependent increase in IRX5 protein level as would be 
expected of a true target.   
Although a strong specific band at 100kDa was consistently observed using immunoblotting, 
IRX5 is a 50kDa protein.  Immuno-precipitation identified that IRX5 can interact with IRX3, IRX4 
and itself (He, Jia and Takimoto, 2009); therefore the slower migration may have been due to 
strong dimer formation that persisted despite the reducing conditions.  Alternatively, it may be 
a technical artefact due to loading large quantities of protein per lane (50µg) and cysteine 
oxidation (IRX5 contains 4 cysteine residues).  Crow, Karasavvas and Sarris (2001) showed that 
protein aggregation was mediated via cysteine oxidation during the stacking phase in 
discontinuous buffer systems.  The IP-10 protein, which contains four cysteine residues, 
migrated at nearly double its expected molecular mass due to aggregation and this was 
dependent upon the presence of reduced sulfhydryl residues, the amount of protein loaded per 
lane (no aggregation at 0.5µg, 50% aggregation at 10µg) and on the concentration of APS (at 
>6µg, 0.1% APS increased aggregation).   
To confirm the identification of this band a number of methods exist, such as: including a 
negative control whole cell lysate; providing stronger reducing conditions followed by 
iodoacetamide to irreversibly block sulfhydryls; analysing nuclear fractions rather than the 
whole cell lysate to enable less total protein to be loaded per lane; immunoblotting with 
antibodies for the other IRX family members. 
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The luciferase reporter assay is the gold standard method used to provide evidence of a direct 
interaction of a particular miRNA with the putative mRNA.  The luciferase reporter assay was 
utilised to confirm whether IRX5 was a direct target of miR-221. Unfortunately due to the 
number of variables that needed to be optimised and the very limited amount of luciferase 
reagents available, only one concentration of miR-221 and the 3’UTR vector was successfully 
assayed with the final protocol.  However, preliminary results were promising with a ~50% 
reduction in RLU in the presence of miR-221: tentatively, this suggests that the IRX5 3’UTR may 
indeed be targeted by miR-221 as predicted in silico.  To confirm the specificity of this 
interaction, i.e. that this interaction is only specific to this particular mRNA sequence and this 
miRNA sequence, additional controls need to be undertaken using the scrambled miRNA mimic 
and control vector encoding a non-target 3’UTR.  The combinations and expected outcome if 
the targeting is specific are detailed below: 
- control plasmid (CmiT) plus control miRNA  (CmiR) = no effect on light production  
- control plasmid (CmiT) plus miR-221 (HmiR) = no effect on light production  
- IRX5 plasmid (HmiT) plus control miRNA (CmiR) = no effect on light production 
- IRX5 plasmid (HmiT) plus miR-221 (HmiR) at different concentrations = concentration 
dependent decrease in light production  
Additionally, transfection of an anti-miR for miR-221, or over-expressing miR-221, whilst 
assessing IRX5 protein and mRNA levels would provide evidence of targeting, and whether the 
effect of the miRNA was either translational inhibition or degradation.  
What is the significance of IRX5 up-regulation? 
Myrthue and colleagues (2008) found over-expression of IRX5 in LNCaP reduced p21 protein 
levels.  p21, also known as Cip1, is a cyclin-dependent kinase (CDK) 2 inhibitor and an inhibitor 
of the cell cycle with roles in cell death, DNA repair, senescence and aging (Jung, Qian and Chen, 
2010).  It is also able to inhibit proliferation independent of CDK2 via inhibition of PCNA 
(proliferating cell nuclear antigen); PCNA is required for S-phase progression (Abbas and Dutta, 
2009).  Down-regulation of IRX5 reduced cell numbers by 60%, via anti-proliferative and 
apoptosis-mediated mechanisms, indicating a role for IRX5 in cell cycle (Myrthue et al., 2008).  
Therefore by targeting IRX5, androgen-mediated repression of miR-221 may contribute to 
growth. 
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4.4.3 miR-210 
Over 35 transcripts are reported targets of miR-210 with roles in diverse cellular processes such 
as proliferation, nucleic acid binding, angiogenesis and differentiation (Figure 4. 13). 
 
Figure 4. 13 - Targets of miR-210 
Reproduced from Chan and Loscalzo (2010). 
 
Gene Ontology analysis by Giannakakis et al. (2008) found that the targets of miR-210 were 
enriched in gene categories such as regulation of cellular processes, transcription and 
metabolism, i.e. processes that are critically affected by hypoxia, and may functionally 
contribute to tumour progression.  
The roles that can be ascribed to miR-210 are dependent upon the presence and absence of its 
targets: at present, it is unclear whether miR-210 acts as either a positive or negative regulator 
of proliferation and activity is likely to depend on the specific cellular context.   
For example, the E2F family are TFs that control expression of genes required for DNA synthesis 
at the G1/S transition (Giannakakis et al., 2008). The family includes E2Fs that activate G0 cells 
to cycle (activating E2Fs) and also those repressive E2Fs which are weak activators involved in 
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gene silencing in quiescent or differentiated cells (Giannakakis et al., 2008).  The E2F3 gene 
encodes two transcripts (E2F3a and b) which share the same 3’UTR and exhibit divergent 
functions: E2F3a is induced when quiescent cells are stimulated to divide whilst E2F3b is present 
in both quiescent and dividing cells (Giannakakis et al., 2008).  By targeting both forms of E2F3, 
miR-210 is heavily involved in the regulation of the cell cycle in response to hypoxia.     
Paradoxically, repression of other targets in a different context are pro-proliferative: of 
particular interest is the Max -binding TF Mnt (Zhang et al., 2009).  Mnt is a basic helix-loop-
helix-leucine-zipper (bHLHZip) TF which hetero-dimerises with Max, repressing transcription by 
recruiting co-repressor proteins which act to recruit several proteins involved in chromatin 
modification (Hooker and Hurlin, 2006).  When Max is bound with c-Myc, there is interaction 
with co-activators to recruit histone acetyltransferases and induction of transcription of cell 
cycle control proteins and ultimately entry into the cell cycle.  As such, Mnt is known as a c-Myc 
antagonist.  Thus by down-regulating Mnt, miR-210 appears to promote cell cycle progression. 
The aim of the miR-210 study was to investigate the mechanism of miR-210 induction and 
identify whether its target Mnt is appropriately dys-regulated.  In this study, mibolerone 
induced dose-dependent increases in PSA, proliferation, miR-210, and VEGF mRNA with a 
concurrent decrease in the miR-210 target Mnt: Mnt down-regulation is consistent with 
promotion of cell cycle progression through Mnt-mediated de-repression of c-Myc (Zhang et al., 
2009). 
c-Myc forms a hetero-dimer with its binding partner Max, binds to the sequence CACGTG and 
other related ‘E-box’ sequences, leading to transcriptional activation; whilst Mnt:Max acts as a 
transcriptional repressor (Figure 4. 14) (Hooker and Hurlin, 2006).  
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Figure 4. 14 - The Myc, Max and Mnt interaction 
The Myc gene family consists of three members, c-Myc, N-Myc and L-Myc.  Each contains a bHLHZ (basic helix-
loop-helix leucine zipper) motif at the C-terminus.  Myc is dependent on its binding partner Max for its 
transcriptional activity.  Repression is via the tethering of co-repressor proteins Sin3A and Sin3B: these 
function as scaffolds for the recruitment of proteins involved in chromatin modification, e.g. histone 
deacetylases.  In contrast, c-Myc:Max interact with co-activator proteins such as TRAP and CBP/p300 to recruit 
histone acetyltransferases and induce transcription.  Aside from Myc, Max interacts with Mad1, Mxi1, Mad3, 
Mad4 and Mnt (also known as Mad6, Rox, Mxd6). In the normal cell, in the absence of mitogens, c-Myc is at 
very low levels: c-Myc is strongly up-regulated during entry in the cell cycle, after which is it rapidly decreased 
and then is at a consistently low level throughout proliferation: this is likely due to a negative feedback 
mechanism in the presence of high levels of Myc. This auto-regulation is lost in many tumours. Reproduced 
from Hooker and Hurlin (2006). 
 
Three reports have shown that, in vitro, cells that lack or have lost Mnt expression take on the 
phenotypic expression of cells that over-express c-Myc (Hooker and Hurlin, 2006).  Loss of Mnt 
would presumably increase the basal pool of available Max to dimerise with Myc: a 
consequence of which might be a reduction in the competition for binding to shared Myc target 
genes – indeed some targets of Myc have been shown to be up-regulated in Mnt-deficient cells 
(Hooker and Hurlin, 2006).  Myc targets include cell-cycle related proteins such as cyclin D2, 
CDK4 and CDK inhibitors p15/INK4b and p21/Cip1.  
However, loss of Mnt may not be functionally equivalent to an over-expression of Myc:  Myc 
would still be under strict regulation by the factors that normally control its expression.  It would 
be of interest to elucidate whether the decrease in Mnt allows increased interaction of Max 
with c-Myc or whether other as yet unknown factors come into the fore.  For example, there are 
other proteins such as Mga and the Mxd family which bind Max, so alterations of free Max will 
not necessarily lead to a functional change if other proteins are able to compensate.  
Alternatively, the levels of other proteins, such as Miz1, which activates transcription with Myc, 
186 
 
may also change and thus negate the effects of additional free Max.  Assessing the impact of 
decreased Mnt in LNCaP could be examined by analysing the expression of Myc targets in the 
presence of varying concentrations of Mnt. 
4.4.3.1 Mechanisms of miR-210 induction 
There are a number of possible mechanisms for the miR-210 induction in the presence of 
normal oxygen levels, which include both HIF and non-HIF mediated processes. 
4.4.3.1.1 Non-HIF1α mediated 
Induction by TFs other than HIF 
Immunoblotting for HIF1α protein was undertaken but due to technical issues, a specific signal 
could not be attained.  The lack of signal found in the immunoblot of HIF1α could indicate that 
perhaps the induction of miR-210 was not mediated by HIF1α.  It is possible that TFs other than 
HIF1 could be responsible for the up-regulation of miR-210. 
Previous studies have not identified an ARE in the promoter region of the miR-210 gene.  
However, this does not preclude miR-210 from being under AR control in co-operation with 
another TF such as JunD (Mehraein-Ghomi et al., 2010).  In support of this, the miRGen 2.0 
results indicate other TFs such as AP-1 could be responsible for the induction of miR-210 rather 
than HIF1α. 
Kulshresha et al. (2007) used ChIP analysis to show that HIFα was recruited to the promoter of 
miR-26a-2 and was significantly induced in all four cancer cell lines tested.  In this study, mature 
miR-26a levels were assessed by qRT-PCR but the data revealed no differential expression at 120 
hours compared to the control. It is therefore likely that either the mechanism for miR-210 
induction was independent of HIF1α, accounting for the lack of response in miR-26a, or that 
hypoxia-associated miRNAs are cell specific, which is supported by the findings of numerous 
other studies (Giannakakis et al., 2008; Kulshreshtha et al., 2007).  For example, Quero et al. 
(2011) found that miR-373 was not induced in hypoxic LNCaP but was in hypoxic HeLa cells 
(Giannakakis et al., 2008).  Indeed of the three cell lines Giannakakis and colleagues tested 
(SKOV3, 2008 and HeLa), 20, 17, and seven miRNA were induced, respectively, but only miR-210 
was found in all cell lines. 
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In support of a non-HIF-mediated mechanism, Mutharasan et al. (2011) found cells that lacked 
intact HIF signalling, HIF1β knock out lines, still had increased miR-210 in response to hypoxia.  
Indeed, Akt was able to induce miR-210 expression independent of HIF; the mechanism for this 
effect remains to be elucidated.  
4.4.3.1.2 HIF mediated 
miR-210 is a well known ‘hypoxamiR’ which is induced by hypoxia in numerous cell types.  
Hypoxia results from an imbalance of oxygen levels and requirements; in tumours, it is 
commonly as a result of expansion of the tumour with cells furthest away from oxygen rich 
arteries experiencing the greatest degree of hypoxia.  
HIFs are transcription factors that co-ordinate the response to low oxygen tension and activate 
transcription of genes critical for survival. There are a number of points in the hypoxia pathway 
at which alterations can affect the expression of HIF1α other than reduced oxygen tension: for 
example, although degradation of HIF1α mRNA is predominantly oxygen dependent, its protein 
synthesis is oxygen independent and can be activated by signalling pathways such as PI3K.  
Figure 4. 15 illustrates the factors that influence HIF levels. 
 
Figure 4. 15 - Role of HIF in response to low oxygen tension 
HIF-1 is a transcription factor heterodimer consisting of HIF1α and HIF1β.  HIF1β (also known as ARNT, 
arylhydrocarbon receptor nuclear translocator) is constitutively expressed whilst the presence of HIF1α 
protein is primarily oxygen-dependent. Hydroxylation at prolines 402 (P402) and 564 (P564) by prolyl 
hydroxylases (PHDs) in normoxia results in degradation.  Recognition of the hydroxylated residues by VHL 
targets HIF-1 for proteasomal degradation (ubiquitin-proteasome pathway).  In hypoxia, a lack of proline 
hydroxylation results in stable expression and transcriptional activation of genes (via binding at the hypoxia-
response element, HRE) such as VEGF that are critical for survival, especially in low oxygen environments.  
Hydroxylation at Asparagine 803 (A803) by FIH (factor inhibiting HIF) regulates the activity of HIF1 but not its 
stability.  Diagram taken from Denko (2008). 
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Under hypoxic conditions, activation of HIF results in activation of genes involved in cell survival 
and adaptation to hypoxia (Huang et al., 2009); such as those involved in angiogenesis, glycolysis 
and glucose transport (e.g. VEGF, PGK and GLUT1).   HIF1α also induces genes leading to cell 
cycle arrest and cell death such as p21, p27 and NOXA (Huang et al., 2009).  Therefore the fine 
balance of these activities may determine whether the outcome is survival or death.  
For simplicity, classical HIF1α activation concerns changes in oxygen tension leading to HIF1α 
stabilization whilst non-classical refers to HIF1α stabilisation by means other than decreased 
oxygen level. 
Classical HIF1α activation 
High cell density leading to local hypoxia 
In this study, experiments were conducted to assess whether the major co-ordinator of hypoxia, 
HIF1α, was induced.  However, immunoblot analysis was unable to provide a definitive answer 
due to a lack of a signal in the samples in the region of interest and excessive non-specific 
binding. 
Despite the fact that the cell culture conditions were normoxic, with the normal atmospheric 
oxygen concentrations of 21%, it is possible that miR-210 was not induced by mibolerone per se, 
but rather that it was a function of high cell density and proliferation caused by androgens, 
leading to a local hypoxic effect.   
However, Quero et al. (2011) found that in normal conditions the miR-210 expression was 
unaltered by culturing at high cell density: in their experiments, cells were plated at the 
equivalent of 6,250,000 cells in T75 in normal media.  Therefore in the dose-response 
experiment utilised in this study, whereby the initial cells inoculation is less than 1 million and 
the final number of cells after 5 days is less than the initial starting number of the Quero study, 
it is unlikely that miR-210 induction is via a general density-sensitive mechanism. 
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Non-classical HIF1α mediated 
Androgen-induced growth factor mediated activation of HIF1α  
The regulation of HIF is not just dependent on oxygen availability; enzymes involved in its 
regulation can be influenced by various factors. 
Zhong et al. (2000) previously reported that exogenous EGF, phorbol 12-myristate 13-actetate 
(PMA) and FBS increased expression of HIF1α protein, transcriptional activity and VEGF 
expression in PCa cells under conditions of normoxia. Growth factors, such as EGF activate PI3K.  
In 2003, Mabjeesh and colleagues reported that in LNCaP under normoxic conditions, androgens 
(100pM R1881) were able to induce HIF1α protein (not mRNA) by a proposed autocrine loop 
involving PI3K and AKT (PI3K/AKT/FRAP pathway) (Mabjeesh et al., 2003). Whilst DHT did not 
influence HIF1α mRNA levels, HIF1α protein expression was increased by androgens and there 
was a subsequent increase in VEGF protein expression (not quantified).  Mabjeesh and 
colleagues (2003) found inhibition of the PI3K pathway by the inhibitor LY294002 blocked the 
DHT-induced HIF1α increase.  As this induction was reduced by anti-EGF, they proposed that 
under androgen stimulation, production of EGF and EGFR would increase in LNCaP; EGF would 
stimulate the PCa cells, likely in an auto- and paracrine fashion, to activate the PI3K pathway 
and result in protein stabilisation of HIF1α.  
Ravenna et al. (1995) reported that after prolonged treatment with R1881, there was a marked 
increase in EGF release. Therefore it was reasonable to hypothesise that miR-210 induction in 
mibolerone-treated cells was via EGF stimulation resulting in increased HIF1α protein levels.  
The non-specific binding meant that HIF1α levels could not be analysed but to try to elucidate 
whether EGF was playing a role in miR-210, analysis of EGF levels by ELISA was undertaken.  
However, the ELISA did not reveal that EGF was stimulated: rather, EGF was undetectable in the 
conditioned media (below the level of the standards).  This indicates that either the amount of 
EGF in the media was below the limit of detection (1pg/mL) or that basal levels of EGF are low 
and androgens do not stimulate production. Although Mabjeesh and colleagues (2003) 
suggested that EGF was stimulated by androgens, 1nM DHT for 6 days, other authors have 
found no such induction (Connolly and Rose, 1990), which is concordant with the result 
reported herein.  
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Other studies have reported that the EGF receptor is up-regulated by androgens (Pignon et al., 
2009).  Therefore it may be that rather than EGF itself leading to HIF1α stabilisation, increased 
activity of EGFR in a low EGF environment may be responsible.  Accordingly analysis of the EGF 
receptor would determine whether the EGFR is responsible for the increase in HIF1α with 
androgenic stimulation. 
In the present study, mibolerone induced VEGF mRNA expression in a dose-responsive manner, 
up to 3-fold at 10nM.  VEGF is a pro-angiogenic protein:  its known effects on vascular 
endothelial cells include increased proliferation, migration and vascular permeability (Stewart et 
al., 2001). The most potent inducer of VEGF is thought to be hypoxia, consistent with the data 
presented herein, but other inducers include cytokines and growth factors such as PDGF, EGF 
and IGF-1 (Stewart et al., 2001). Although VEGF was induced with mibolerone treatment, it 
could be due to IGF rather than EGF.  The implications of VEGF induction by androgens would be 
promotion of survival in low oxygen environments and subsequently tumour expansion.   
In the hypoxic environment, VEGF was induced 10-fold with 16 hours of 1% oxygen – this is 
similar to what was observed by Quero et al. (2011) (10-fold at 24 hours with 0% oxygen).  If 
VEGF is induced by androgen-regulated HIF1α stabilization it is likely that the strength of 
regulation is much lower as hypoxia induced VEGF 10-fold whilst the highest concentration of 
mibolerone was only able to produce a 3-fold induction. 
Stabilisation of HIF1α due to increased H2O2 via AR/JunD induction of SSAT promoter 
Another possible mechanism for HIF1α stabilisation is the AR in complex with the TF JunD which 
binds directly to the spermidine/spermine N1-acetyltransferase (SSAT) promoter resulting in 
androgen-dependent up-regulation of H2O2 (Figure 4. 16; Mehraein-Ghomi et al., 2010).   
 
 
 
Figure 4. 16 – Androgen-induced SSAT expression results in increased H2O2 production 
Binding of the AR in complex with JunD at the SSAT promoter results in increased SSAT transcription, 
ultimately leading to increased ROS production.  Abbreviations: APAO = N’-acetylpolyamine oxidase; SSAT = 
spermidine/spermine N1-acetyltransferase; H2O2 = hydrogen peroxide.  
191 
 
 
miRGen promoter analysis identified that there is a putative binding site in the miR-210 
promoter region for AP-1.  JunD is a member of the AP-1 transcription factor family, which is a 
heterodimer of proteins from the Fos and Jun families (c-Fos, FosB, Fra-1, c-Jun, JunB & JunD); 
therefore there is potential for interaction with the miR-210 promoter and the AR.   
Interestingly Mutharasan and colleagues (2011) found that in cardiomyocytes, miR-210 over-
expression had a cyto-protective effect against H2O2-induced cell death.  Therefore it may be 
that androgens induce reactive oxygen species (ROS) production but that miR-210 compensates 
for this effect and protects LNCaP.    
Stabilisation of HIF1 due to increased ROS  
Pinthus et al. (2007) identified that testosterone increased the level of basal ROS and increased 
activation of phosphorylated p38 and phosphorylated AKT, in an AR dependent manner, leading 
to increased expression of clusterin, catalase and superoxide dismutase.  Treatment with n-
acetyl cysteine (reducing agent) reversed these effects.  The authors suggested that increased 
cellular levels of ROS trigger AKT phosphorylation and enhance survival.   
In vivo, similar results were identified: in the absence of endogenous or exogenous androgens, 
there was a reduced expression of 4-hydroxynoneal protein adducts – these are peroxidation 
induced therefore their absence signals a reduction of ROS. 
Lu et al. (2010) found androgens up-regulate NADPH oxidase (NOX) protein and mRNA leading 
to an increase in reactive oxygen species.  Potentially, ROS increases can impact on proline 
hydroxylation of HIF1α: therefore the net result of increased ROS could be HIF1α stabilisation in 
normoxia and consequently increased transcription of HIF1α’s targets, including miR-210.  This 
would provide a potential mechanism as to miR-210 induction in normoxia.  Lu et al. (2010) 
suggested that NOX could be increased via NFκB as NFκB is regulated by androgens.   
One suitable approach to assess whether increased ROS production is ultimately the cause of 
miR-210 induction would be to repeat the mibolerone dose-response experiments in the 
presence of inhibitors of NOX (e.g. apocynin) or in the presence of a general ROS scavenger such 
as the anti-oxidant N-acetyl cysteine as described by Lu et al. (2010).  
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HIF1α interaction with the AR  
Alternatively the AR may be able to interact with HIF1α directly.  Recently Horii et al. (2007) 
analysed HIF1α levels in hypoxia and normoxia in the presence and absence of 10nM DHT at 20 
hours of exposure (hypoxia was 2% O2).  Under normoxic conditions, DHT did not induce HIF1α 
expression (lack of a band by immunoblot).  Under hypoxic conditions, in the presence of DHT, 
HIF1α and the AR were co-immuno-precipitated with one another, suggesting that there is some 
interaction with one another under these conditions.   In addition, HIF1α protein was up-
regulated by DHT under hypoxic conditions; the authors suggested that through physical 
interaction with the AR, HIF1α protein might be stabilised.  
Non-genomic signalling of the AR – interaction with PI3K 
Aside from pathways upstream of PI3K resulting in its activation, Baron et al. (2004) showed 
that in vitro androgens induced activation of the PI3K pathway, in a non-genomic manner by 
promoting accumulation of phosphoinositide-3-P phospholipids.  Direct interaction between the 
AR and the p85alpha regulatory subunit of class 1(A) PI3K resulted in increased phosphorylation 
of AKT at ser473 and thr30 residues which are required for full activation of AKT.   
PI3K are a family of protein kinases: Class I PI3Ks are heterodimers of regulatory and catalytic 
subunits. Class IA PI3Ks phosphorylate PIP2 (phosphatidylinositol-4,5-bisphosphate) to the 
second messenger PIP3 phosphatidylinositol-3,4,5-trisphosphate. Accumulation of PIP3 leads to 
co-localisation of signalling proteins with a PH domain (pleckstrin homology) and subsequent 
activation and downstream PI3K signalling (Engelman, 2009).  
4.4.3.2 miR-210 in PCa 
miR-210 has been found to be dys-regulated in two PCa profiling studies, both studies found an 
increase in the metastatic versus non-metastatic samples between 4-fold and 48-fold (Martens-
Uzunova et al., 2011; Watahiki et al., 2011).  As miR-210 is known to be a hypoxamiR, it may be 
that the increased expression of miR-210 in the metastatic samples represents local hypoxia due 
to the advanced nature of the disease.   
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4.4.3.3 Implications of miR-210 over-expression 
Few papers have been published that study the implication of miR-210 over-expression.  It is 
likely that miR-210 over-expression will have cell type or context specific effects.  For example, 
Kulshreshtha et al. (2007) found over-expression of miR-210 in a head and neck cancer cell line 
did not affect cell growth under normoxia or 2% oxygen conditions whilst Huang et al. (2009) 
found in vivo miR-210 repressed tumour growth initiation whilst there was no in vitro growth 
advantage.  Therefore it is likely that it is cell type specific or there are other factors that 
influence the growth promoting effects. 
4.4.4 Pathways altered by androgens 
A bioinformatic analyses was conducted using the DIANA-mirPath web-based platform that 
interrogates three different miRNA target prediction algorithms and identifies KEGG pathways 
that may have significant enrichment.  Although useful, pathway analysis has a number of 
limitations that should be considered.  For example, it gives equal weight to putative targets yet 
some targets may be more critical to the pathway than others.  The magnitude of change is also 
not considered: it is plausible that a 2-fold change in a particular target may have less impact on 
a pathway than a 1.5-fold change in another target.  DIANA-mirPath also does not incorporate 
known targets unless they are identified as putative targets by the algorithms that it employs to 
generate the target lists.  As such, the effects of bona fide targets may be excluded.  However, 
pathway analysis is still a useful tool that indicates which biological pathways could be 
influenced by dys-regulated miRNA and therefore can be used to generate hypotheses for 
future research.  
IGF-1R 
In Chapter 3, both DHT and mibolerone were found to down-regulate members of the miR-99 
family and let-7 family.  Pathway analysis of miR-99a, -100 and let7a/c/d predicted that IGF-1R, 
a type II tyrosine kinase, was a target of these miRNA: this has recently been confirmed by 
Lerman et al. (2011) who showed that IGF-1R is a direct target of miR-99a resulting in 
translational inhibition.  
Androgens have been shown to up-regulate IGF-1R and expression of one of its cognate ligands, 
IGF-1.  Pandini et al. (2005) found treatment with androgen (R1881) for 24 hours up-regulated 
IGF-1R expression (mRNA and protein) and sensitised prostate cancer cells to the mitogenic and 
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motogenic effects of IGF-I.  AR DNA binding and transcriptional activity was not essential for IGF-
1R up-regulation: it involved activation of the Src/Raf-1/ERK pathway (non-genomic AR 
signalling pathway; Pandini et al., 2005).  Bidosee et al. (2010) found 10pM mibolerone 
increased both IGF-1R and IGF-1 expression.  
DHT treatment is associated with increased activity of the Elk-1 transcription factor (Peterziel et 
al. (1999).  Using the miRGen 2.0 database to search for TF binding sites in the miR-99 family 
and those members of the let-7 family that were down-regulated by DHT, it can be seen that 
each of those miRNAs have potential sites in the regions upstream of the precursor that harbour 
motifs complementary to the Elk-1 motif “aatacaGGATGttcca”.  Thus one mechanism by which 
these miRNAs may be repressed by androgens, resulting in increased IGF-1R, is by binding of the 
TF Elk-1. 
PI3K activation by growth factor binding to receptor tyrosine kinases leads to increased HIF1α 
protein synthesis (Thomas and Kim, 2009).  Therefore it may be that androgen activation of the 
non-genomic AR signalling pathway and Elk-1 activation represses miR-99a, resulting in 
increased IGF-1R activity and mTOR, increased HIF1α protein synthesis and miR-210 expression. 
General pathways 
DIANA-mirPath of all of the miRNA identified in mibolerone-treated cells as dys-regulated 
showed that a number of pathways were affected: for example, the MAPK pathway was 
significantly enriched for the targets of these miRNAs.   In PCa, generally this pathway is 
considered to promote growth and the emergence of hormone refractory disease (Xu et al., 
2010).  
Other pathways that were significantly affected included the PCa pathway, pathways involved in 
lipid and amino acid metabolism, signal transduction, focal adhesion and cell maintenance.  
Interestingly, in support of the IGF-1R model mentioned above, the mTOR pathway was also 
significantly enriched.  Overall, this indicates a multi-faceted and co-operative effect of these 
miRNAs on different pathways. 
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5. Summary 
The overall hypothesis of this project was that miRNAs may be associated with the proliferative 
and PSA-secreting phenotype in LNCaP epithelial cells, as induced by the natural AR agonist 
DHT, the synthetic AR agonist mibolerone, the reported environmental AR antagonist 
vinclozolin, and the therapeutic AR antagonist bicalutamide.  To address this hypothesis, the 
aims were to: 1) characterise the androgenic response to treatment in terms of proliferation 
and PSA secretion; 2) determine whether androgenic chemicals can elicit a miRNA response; 3) 
investigate the temporal and concentration-dependent aspects of the miRNA response; 4) 
establish whether AR agonists or antagonists differentially affect miRNA expression; and 5) 
explore potential and proven biochemical targets of those differentially expressed miRNA.  
In Chapter 2, the androgenic response of LNCaP to the androgen agonists and antagonists was 
characterised.  As expected, mibolerone and DHT had a strong effect on LNCaP’s proliferative 
and PSA secreting ability.  There was an apparent disagreement with other reports which 
suggest that vinclozolin is an AR antagonist: in this study, vinclozolin exhibited a positive effect 
on LNCaP’s proliferation.  The two degradation products of vinclozolin are reported to be AR 
antagonists and agonists thus differences in proportions of degradation product and parent 
compound could account for these differences.  It may well be that factors such as compound 
storage conditions and in vitro culturing methods affect the proportion of these compounds and 
thus determines whether the overall effect of vinclozolin in solution is AR antagonistic or 
agonistic.  Chapter 2 also showed how DHT can have dichotomous effects on proliferation 
dependent upon whether DHT is provided in the presence of FBS or steroid-depleted FBS.  Most 
studies that assess androgen regulation of miRNA use dccFBS to model the low androgen 
conditions associated with androgen deprivation therapy.  Presumably those miRNA that are 
androgen-regulated would also be dys-regulated in the FBS-containing media despite the 
opposite effect that DHT has on proliferation in this context; it would be very interesting to 
establish whether this hypothesis is true.   
Analysis of temporal and compound-specific changes in miRNA expression was undertaken in 
Chapter 3. A number of miRNAs were found to have time and compound specific changes in 
expression levels.  The batch issues that arose raised a number of issues with normalisation and 
batch correction protocols; ultimately, the only way to prove that the approach taken was 
correct was by verification of miRNA that were identified as dys-regulated.  Technical validation 
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using qRT-PCR was performed for selected miRNA which provided confidence that certain 
miRNAs were indeed altered by androgen treatment and confirmed that the approach taken to 
normalization and batch correction was valid.  When designing miRNA profiling experiments, 
the use of sufficient replicates cannot be over-emphasised.  In the event of hybridisation failure 
or other technical problems, the loss of one replicate would then not unduly interfere with 
downstream analyses.  Allison et al. (2006) indicated that analysis of pooled samples provides 
greater power although if one replicate in the pool is far from the others, then the result may be 
skewed.  
Interestingly, most dys-regulated miRNAs occurred 24 to 120 hours after androgenic 
stimulation.  This time delay may be due to the necessary processing steps required before the 
mature miRNA can be detected – i.e. the primary miRNA transcript is induced at earlier time 
points and the mature form takes longer to be generated. Alternatively it may be that 
transcription is induced some time after the androgen stimulation and is the result of the 
indirect effect of androgens (i.e. AR induction of a TF that then stimulates miRNA expression).  
For example, Castellano et al. (2009) found that oestrogen stimulation resulted in increased pri-
miRNA at 3 hours but mature forms were only detectable at 24 to 72 hours. 
Analysis of miRNA expression in the vehicle control group over time revealed temporal changes 
in miRNA expression in the absence of treatment.  Different studies involve differing periods of 
conditioning to low androgen conditions before commencement of treatment (i.e. lengths of 
culturing in dccFBS before treatment) and thus may be a factor in the variability observed 
between different studies.  
Further investigation of miR-720, miR-210, miR-221 and pathway analysis was undertaken in 
Chapter 4.  Little is known about miR-720 expression, particularly in prostate epithelial cells.  
Despite offering a biologically plausible mechanism for androgen insensitivity via DNMT3a 
targeting, the lack of differential expression of miR-720 between androgen sensitive and 
insensitive cell lines suggests that it is not involved in this phenotype.  However, the high 
expression of miR-720 likely confers some advantage to LNCaP and it remains an intriguing 
miRNA for future analysts to study.   
Most interesting of all, the hypoxamiR miR-210 was induced by mibolerone at 120 hours.   
Although they did not report any dys-regulation of miR-210, hidden away in the supplementary 
materials of Waltering et al. (2010), the cluster analysis identified that miR-210 was induced at 
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24 hours by 100nM DHT in LNCaP-pc3.1 cells; this supports the theory of androgen-induced 
miR-210 expression.  It is therefore unlikely that the miR-210 induction is specific to mibolerone; 
it would be of interest to establish what concentrations of DHT are required to elicit the 
induction.  Unfortunately, the precise mechanism for this induction remains to be elucidated.  
However, a number of theories were presented which may explain the mechanism of up-
regulation including HIF-mediated (Figure 5. 1) and non-HIF mechanisms; it may be that one 
pathway predominates or pathways contribute equally.   
 
 
Figure 5. 1 - Possible mechanisms of miR-210 up-regulation - all roads lead to HIF?  
Androgens have been shown to up-regulate EGFR (Pignon et al., 2009), and IGFR1 and IGF1 (Pandini et al., 
2005; Bidosee et al., 2010).  Activation of IGFR leads to increased PI3K activity (Thomas and Kim, 2009).  
Reactive oxygen species (ROS) are increased due to androgen treatment (Pinthus et al., 2007) via increases in 
NOX 2 and 4 (Lu et al., 2010) and AR/JunD activation of the SSAT promoter.  Androgens have been shown to 
repress miR-99a leading to increased mTOR (Sun et al., 2011). 
 
One of the most important points to clarify would be the effect of cell number on this up-
regulation.  If indeed high cell numbers lead to hypoxia in normoxic culturing conditions, this has 
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ramifications for cell culture work: other responses could well be attenuated by the generation 
of hypoxic conditions leading to inaccurate or false results.   
IRX5 was identified by bioinformatics as a putative target of miR-221 and was shown to be anti-
correlated (when miR-221 levels are decreasing, IRX5 protein levels are increasing) as would be 
expected of a true target.  The known target Mnt, down-regulated due to increased miR-210, 
was also shown in this study; one consequence of this may be increased free Max and Myc 
transcriptional activity.  Interestingly, in Chapter 3, miR-30a was shown to be decreased by 
mibolerone treatment and members of the miR-17-92 cluster were up-regulated: increased 
expression of Myc has been shown to repress miR-30a (as well as miR-30c and 30e) and up-
regulate the miR-17-92 cluster (Chang et al., 2008) and thus activation of miR-210 may be 
responsible for these dys-regulations.  It would be interesting to assess whether other targets of 
Myc are altered in the presence of increased miR-210 expression. 
More recently, cells have been found to secrete miRNA, with some authors postulating that 
these secreted miRNAs could be a mode of signalling (Kosaka et al., 2012), whilst others have 
found extracellular and intracellular miRNA populations are different with some miRNAs being 
selectively retained (Pigati et al., 2010).  In theory, the reduced level of miR-221 could be due to 
increased secretion of this miRNA and thus extracellular accumulation.  This possibility remains 
to be investigated. 
Interestingly, the data does not support a temporal- or compound-dependent androgenic 
fingerprint per se.  Rather, it is likely that the level of proliferation induced by these compounds 
determines the miRNA profile.  It perhaps would have been more appropriate to query miRNA 
expression in LNCaP treated with concentrations of each AR-active compound that induced a 
similar level of proliferation, to determine whether there are compound-dependent effects; the 
differing effects of DHT and mibolerone on miRNA expression are likely to be due to the 
different levels of proliferation induced.  DHT is metabolised in LNCaP whilst mibolerone is not, 
thus it would be interesting to assess whether DHT supplementation each day leads to a miRNA 
profile that more resembles mibolerone.  In this manner, compound specific effects on miRNA 
expression, independent of proliferation, could be elucidated. 
The time course analysis conducted in this project highlights the importance of assessing 
changes over time; in part, this explains the differences in reported androgen-induced miRNAs.  
Aside from technical factors such as miRNA measurement technology and processing factors, 
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other aspects that play a considerable role in attenuating miRNA expression are the compound 
used, culturing conditions (such as density-related factors), length of exposure, and cell line 
variants. 
It is well known that culturing cells for prolonged periods of time can result in phenotypic drift – 
thus it is important to note the passage number of the cells that are being used.  For the miRNA 
analyses in this study, cells were within ten passages of the original passage number obtained 
from the ATCC.  It is conceivable that miRNA differences between published studies could also 
be influenced by the time in culture and passage number.  This was supported by the 
observation that miRNA expression changed in the control group over time.  
Other considerations that were not investigated in this project are the influences of other cell 
types: in the prostate, epithelial cells are found with other cell types, such as the basal cell 
types, intermediate and supporting stromal types.  Feedback and crosstalk between the cell 
types are likely to influence miRNA expression, and certainly do influence expression of mRNA, 
thus altering the sum effect of any given miRNA.   
It is worth noting that the observations made in this project may only be valid for this cell line. It 
would be fruitful to consider whether other cell lines, such as non-cancerous prostate cell lines, 
are similarly affected by androgens, and, investigate the reasons for any discordance.  The 
majority of androgenic studies are conducted in LNCaP but it would be beneficial to study other 
cell lines to better capture the diversity of PCa.  Within this context, it has been shown that 
androgenic effects differ dependent upon the cell line under study.  It is perhaps interesting to 
recall that approximately 25% of tumours exhibited the same AR mutation found in LNCaP; wild-
type AR activation may well lead to different miRNA expression profiles.  Analysis of differences 
in androgen-regulated miRNAs due to cell line specific factors could have important and far 
reaching implications offering new avenues for therapeutic intervention.   
The number of factors that impinge on miRNA expression in the absence of androgenic 
stimulation highlights the inherent issues and difficulties in translating specific in vitro responses 
into relevant in vivo knowledge.  Whilst in vitro models can provide useful insight into the 
behaviour of miRNAs in prostate cancer, it must be borne in mind that by subtly changing the 
culturing conditions, the phenotypic response can be dramatically altered.  However, such 
responses can be very helpful in interpreting mechanisms of action. 
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It is worth noting that differential miRNA expression does not imply causality, i.e. those miRNA 
which are differentially expressed may not be directly involved in the proliferative and PSA-
secreting phenotype and may occur as the result of these processes rather than be drivers for 
these effects.  Thus functional analyses are important to determine the function of a particular 
miRNA in a particular cellular context. As it has been noted previously, the function of a miRNA 
is dependent on the expression of its targets and the presence or absence of a target may affect 
the stability of the miRNA.  These inter-dependencies illustrate the complex and elegant control 
mechanisms that operate at the molecular cellular level.  
To address the question posed in the title of the thesis, it can be seen that miRNAs do play a role 
in the prostate epithelial phenotype.  In summary, this work confirms my original hypothesis 
that AR ligands influence miRNA expression in prostate epithelial cells.  The results presented in 
this thesis provide new information that can be used to better understand the biology of 
miRNAs in prostate cancer epithelial cells, offering mechanistic insights into chemicals with a 
similar mode of action.   
miRNAs have been implicated in a number of diseases and biological processes: they have great 
potential to be used as diagnostic aids, biomarkers of cancer progression or prognosis, or indeed 
as therapeutic interventions.  By understanding the miRNA control/regulatory pathway, miRNAs 
could inform future therapeutic directions offering new opportunities for drug development. 
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7. Appendix 
7.1 miRNA in clinical PCa specimens 
Table 7. 1 - Summary of dys-regulated miRNA in clinical PCa specimens 
miRNA Volinia  Porkka Ozen  Ambs  Tong  Schaefer  Szczyrba  Martens-Uzunova Wach  Carlsson  
 56 PCa 5 PCa; 4 CRPC 16 PCa 60 PCa 40 PCa  24 PCa 5 PCa 
(pool) 
102 Pca 20 PCa  19 PCa 
 7 
norm. 
4 BPH 10 
norm. 
16 adj. 
norm. 
adj. 
norm 
adj. 
norm 
5 norm 
(pool) 
adj.norm adj. 
norm 
 adj. 
norm 
  All HR 
PCa 
     PCa. 
P 
L. 
PCa 
PCa. 
T 
  
Let-7a  ↓      Up    Up  
Let-7b  ↓  ↓ ↓     Up    
Let-7c  ↓  ↓ (y)    Up      
Let-7d Up ↓  ↓          
Let-7f   ↓ ↓    Up      
Let-7g  ↓  ↓          
Let-7i Up   ↓ Up         
1         ↓ (y)  ↓ (y)   
100   ↓ ↓  ↓        
10b*         ↓     
101        ↓    Up  
103  ↓            
106a*          Up    
106a Up       Up    Up  
106b*          Up    
106b     Up (y)   Up Up   Up  
124a              
125a  ↓  ↓ Up   ↓ (if 5p)      
125b  ↓  ↓ (y)   ↓ ↓      
1274b            Up  
128a     ↓         
126     ↓     ↓    
126*        Up  ↓   ↓ 
130a           ↓   
130b         Up     
133a     ↓    ↓  ↓   
133b         ↓  ↓   
136*            ↓  
139-5p          ↓    
141*              
141   ↓         Up  
142-3p         Up ↓    
142-5p          ↓    
143*         ↓  ↓   
143  ↓      ↓ (y)   ↓ (y)   
145*         ↓  ↓   
145  ↓ (y)  ↓ (y) ↓ ↓ (y) ↓ ↓ (y) ↓ (y) ↓ (y) ↓ (y) ↓ (y)  
146 Up             
146a          ↓    
148 Up             
148a   ↓     Up Up     
149 ↓      ↓ (y)  ↓     
150          ↓    
152        ↓      
153         Up     
155          ↓    
15a              
15b        Up      
16  ↓  ↓          
17          Up  Up  
17-5p Up             
181a     Up         
181b       ↓ (y)   ↓    
182*       Up (y)  Up Up    
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miRNA Volinia  Porkka Ozen  Ambs  Tong  Schaefer  Szczyrba  Martens-Uzunova Wach  Carlsson  
 56 PCa 5 PCa; 4 CRPC 16 PCa 60 PCa 40 PCa  24 PCa 5 PCa 
(pool) 
102 Pca 20 PCa  19 PCa 
 7 
norm. 
4 BPH 10 
norm. 
16 adj. 
norm. 
adj. 
norm 
adj. 
norm 
5 norm 
(pool) 
adj.norm adj. 
norm 
 adj. 
norm 
  All HR 
PCa 
     PCa. 
P 
L. 
PCa 
PCa. 
T 
  
182     Up  Up (y)  Up   Up  
1826            Up  
183*         Up     
183       Up (y)  Up Up    
184   Up           
187 Up             
188     Up         
19b   ↓        Up   
191 Up             
193b*         ↓     
193b         ↓     
194     Up         
195 Up ↓           ↓ 
196a     Up         
197 Up             
198 Up  Up           
199a*  ↓      ↓      
199a  ↓            
200a    ↓          
200b*          Up    
200b    ↓        Up  
200c*          Up    
200c     Up   Up (y)    Up (y)  
204         ↓     
205   ↓ ↓ ↓  ↓(y)  ↓ (y)     
20a Up       Up   Up Up  
20b            Up  
202  Up            
203 Up             
206 Up             
21 Up   ↓    Up Up   Up  
210  Up        Up 
(y) 
   
214 Up           ↓  
218     ↓   Up      
22   ↓     ↓      
221*         ↓     
221  ↓  ↓ ↓ ↓ (y) ↓ (y) ↓ ↓  ↓ ↓  
222  ↓  ↓  ↓ (y) ↓(y)  ↓ (y) ↓ (y)  ↓  
223 Up       ↓  ↓    
224         ↓     
23a  ↓            
23b  ↓  ↓  ↓ (y)        
24        ↓      
25 Up    Up   Up Up     
26a  ↓  ↓ Up        ↓ 
26b   ↓ ↓    Up      
27a Up  ↓     ↓      
27b   ↓     ↓   ↓   
29              
29a*             ↓ 
29a   ↓ ↓    ↓  ↓ ↓   
29b   ↓ ↓       ↓   
29c    ↓          
296  Up            
30a   ↓ ↓          
30b   ↓ ↓    Up      
30c Up  ↓ ↓          
30d           Up  Up 
30e        ↓      
31     Up  ↓ (y)       
301b         Up     
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 56 PCa 5 PCa; 4 CRPC 16 PCa 60 PCa 40 PCa  24 PCa 5 PCa 
(pool) 
102 Pca 20 PCa  19 PCa 
 7 
norm. 
4 BPH 10 
norm. 
16 adj. 
norm. 
adj. 
norm 
adj. 
norm 
5 norm 
(pool) 
adj.norm adj. 
norm 
 adj. 
norm 
  All HR 
PCa 
     PCa. 
P 
L. 
PCa 
PCa. 
T 
  
(y) 
302c*   Up           
302d*            ↓  
32 Up    Up (y)    Up     
320  Up      ↓      
328         ↓     
329     ↓         
338-3p         ↓     
340     ↓         
342-3p             Up 
342-5p          ↓    
345   Up  ↓         
34a*             ↓ 
34a Up   ↓ ↓         
34b     Up    ↓     
361-3p          ↓    
363          Up    
368       ↓       
370  Up   Up         
373*  Up            
375     Up  Up (y) Up (y) Up   Up (y)  
378*         ↓   ↓  
378         ↓     
410     ↓         
424        ↓      
425*             Up 
425-5p     Up    Up 
(y) 
    
449a     Up 
(499) 
        
455-3p         ↓ ↓    
455-5p         ↓     
483-3p         ↓     
485-3p         ↓     
487     ↓         
490     ↓         
491   Up           
494     ↓         
497  ↓             
498  Up            
503  Up            
512-3p           Up   
513   Up           
520h     ↓         
551b          ↓ ↓   
583         Up     
615-3p         Up     
622             Up 
634       Up       
663         Up     
7     ↓    Up     
720            ↓  
768-3p            Up  
801         Up     
9*           Up   
92  ↓   Up         
92a-1*           Up   
93     Up    Up   Up  
95 Up        Up     
96       Up (y)  Up     
99b    ↓ Up         
99a  ↓  ↓          
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(pool) 
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 7 
norm. 
4 BPH 10 
norm. 
16 adj. 
norm. 
adj. 
norm 
adj. 
norm 
5 norm 
(pool) 
adj.norm adj. 
norm 
 adj. 
norm 
  All HR 
PCa 
     PCa. 
P 
L. 
PCa 
PCa. 
T 
  
              
Details of fold change cut offs, number of clinical specimens, p-value cut-offs etc given in the table. All   
Where: ↓, down-regulated; up, up-regulated; in PCa vs neoplastic tissues; (y) indicates the result was 
confirmed by qRT-PCR. 
Volinia et al. (2006): microarray, miRNAs -18-2, -136-2, -196-1, -199a-2, -92-2, -29b-2, -181b-1, -93-1, -16-1, -
124a-1, -26a-1, -24-1, -199a-1 were identified as being dys-regulated in PCa versus normal tissue.  However, 
due to changes in the miRNA naming convention, and because the accession numbers were not published in 
this study, it is unclear which mature miRNA the authors are referring to, e.g. miR-124a-1 could be miR-124-3p 
or -5p. Therefore they are omitted from the table.  FDR 1% and P<0.01, any fold difference.  
Porkka et al. (2008): microarray; ‘all’ means dys-regulated in all PCa samples (CRPC and untreated PCa); CRPC 
means castration resistant cases only. 
Ozen et al. (2008): microarray, P<0.05.  
Ambs et al. (2008): microarray, P<0.01, FDR 5%, primary tumours (likely to be organ-confined). 
Tong et al. (2009): bead-based hybridisation, P<0.05, Bonferroni correction, organ-confined. 
Szczyrba et al. (2010): deep sequencing, equal or greater than 1.5 fold, must be more than 0.1% of total 
miRNA reads. 
Martens-Uzunova et al. (2011): ‘PCa.P’ refers to up or down-regulated in PCa samples versus adjacent normal 
from prostatectomy samples; ‘L.PCa’ refers to up- or down-regulated in lymph node metastases compared to 
normal adjacent; ‘PCa.T’ refers to up- or down-regulated in PCa specimens versus normal adjacent in samples 
of TURP-origin. (y) in this case indicates that qRT-PCR confirmed the change in normal versus malignant (Group 
I versus Group 2). P<0.005. 
Wach et al. (2011): Microarray, P<0.05, FDR 5%, high grade/Gleason 7-9. 
Carlsson et al. (2011): TaqMan®™ microRNA cards, P<0.001. 
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Table 7. 2 - miRNAs differentially expressed between androgen sensitive and insensitive cell lines 
miRNA Xu Mattie Lin deVere White 
let-7a   Up    
let-7b   Up    
let-7c   Up    
let-7e   Up    
let-7f   Up    
let-7i   Down    
miR-100  Down Down   Down 
miR-103   Down    
miR-106a Up     Up 
miR-106b   Up    
miR-107   Down    
miR-10a   Down    
miR-10b Down      
miR-124 Down      
miR-125a   Down    
miR-125b    Down 
miR-1277 Up      
miR-128b     Down  
miR-130b   Down    
miR-1323 Down      
miR-146a     Down  
miR-148a   Up    
miR-148b Down  Up    
miR-151   Down    
miR-15a   Up    
miR-15b   Down    
miR-16    Down 
miR-18   Up    
miR-181a   Down    
miR-183   Down    
miR-184     Up  
miR-191   Down    
miR-195   Up    
miR-19b     Down  
miR-200b Down      
miR-200c   Up    
miR-21   Down    
miR-210   Down    
miR-22   Down    
miR-221   Down  Down  
miR-222 Down Down Down  
miR-23a   Down    
miR-23b   Down    
miR-24   Down    
miR-25   Up    
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miRNA Xu Mattie Lin deVere White 
miR-26a   Up    
miR-27a   Down    
miR-27b   Down    
miR-28   Up    
miR-296-3p Down      
miR-29a   Down    
miR-29b     Down  
miR-301a Up Down    
miR-301b Up      
miR-30a Down Down    
miR-30a* Down Down    
miR-30c  Down   Down 
miR-30c-2* Down      
miR-30d  Down    
miR-31  Down    
miR-320  Down    
miR-342  Down    
miR-34a  Up    
miR-361    Up  
miR-362-5p Up      
miR-424   Up  
miR-629 Down      
miR-663   Down  
miR-664 Up      
miR-760 Down      
miR-92  Down    
miR-93  Up    
miR-96* Up      
miR-99a  Up    
miR-99b  Down    
 
Xu et al. (2010): Determined using next-generation sequencing.  Top 20 miRNAs differentially expressed 
between LNCaP and LNCaP-AI, all greater than 5-fold in either direction. 
Lin et al. (2008): Up- or down-regulated miRNAs in hormone refractory C4-2B/PC3 cells versus androgen-
dependent LNCaP/PC3-AR9 cells.  C4-2B are derived from LNCaP and possess the same mutant AR but have 
become androgen-independent and have lost parts of the downstream AR signalling pathway (Grossmann, 
Huang and Tindall, 2001).  PC3-AR possess all of the AR signalling components except the AR itself; transfection 
with the AR (PC3-AR9) results in restoration of the AR response (Litvinov et al., 2006).  
Mattie et al. (2006): miRNA differentially expressed between LNCaP and PC3. Up means higher in LNCaP 
versus PC3.  Of 200 miRNA present on the microarray, 51 were found to be differently expressed.   
DeVere White et al. (2009): 17 miRNA (10 up- and 7 down-regulated) identified as differentially expressed (3-
fold difference cut-off), of which five were confirmed by Northern blot (in table).  Comparison between LNCaP 
and LNCaP-cds (androgen insensitive).  Up means higher in LNCaP compared to LNCaP-cds. 
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7.2 Immunoblot reagents and recipes 
Table 7. 3 - Resolving gel recipe 
Reagent Acrylamide gel percentage % 
 6 8 10 12 15 
dH2O 7.8mL 6.5mL 5.1mL 4.0mL 2.0mL 
Resolving gel buffer 8.0mL 8.0mL 8.0mL 8.0mL 8.0mL 
30% Acrylamide/Bis-acrylamide 4.0mL 5.3mL 6.7mL 8.0mL 10mL 
10% APS 150µL 150µL 150µL 150µL 150µL 
TEMED 20µL 15µL 10µL 8.0µL 8.0µL 
Prepare fresh 10% APS (or use within one month).  Abbreviations: APS = ammonium persulphate solution; 
dH2O= deionised water; TEMED = tetramethylethylenediamide. 
 
Table 7. 4 - Stacking gel recipe 
Reagent  
dH2O 2.87mL     
Stacking gel buffer 1.25mL     
30% Acrylamide/Bis-acrylamide 0.83mL     
10% APS 100µL     
TEMED 5µL     
Prepare fresh 10% APS (or use within one month).  Abbreviations: APS = ammonium persulphate solution; 
dH2O= deionised water; TEMED = tetramethylethylenediamide. 
 
Resolving gel buffer 
91 g TRIS 
2 g SDS 
500 mL dH2O (deionised water) 
pH 8.8, autoclave and store at 4:C 
 
Stacking gel buffer 
30g TRIS 
2g SDS 
500 ml dH2O 
pH 6.8, autoclave and store at 4:C 
 
SDS-PAGE running buffer 
3g TRIS 
15g Glycine 
5g SDS 
1000 mL dH2O 
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Transfer buffer 
10x stock: 
30g TRIS 
140g Glycine 
1000 mL dH2O 
 
1x working solution: 
100 mL 10X stock 
700 mL dH2O 
200 mL methanol 
 
Wash buffer 
0.1% v/v TWEEN® 20 in dH2O  
 
Blocking buffer 
5% w/v semi-skimmed milk powder in wash buffer 
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7.3 PCA plots 
 
A – 4 hours 
  
 
 
B – 8 hours 
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C – 24 hours 
 
 
D – 120 hours 
 
 
Figure 7. 1 - Scores plots of samples at 4, 8, 24 and 120 hours 
Scores plot of a three component PCA model with pareto scaling.  Data is after ComBat adjustment and is 
coloured by treatment group and labelled by batch.  Principal components 1 and 2 (t[1] and t[2]) describe the 
greatest variation in the model.  Produced in SIMCA-P+ 12.2 by Dr James Ellis.  Abbreviations: b = bicalutamide; 
d = dihydrotestosterone; m = mibolerone; v = vehicle control.  
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"I have not failed 1,000 times. 
I have successfully discovered 1,000 ways that do not work, and I do not need to try them 
again."  
~ Thomas Edison ~ 
